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CHAPTER 1  
 
INTRODUCTION 
 
 
Environmental issues can be described as inherently complex and often involve the intersection of 
many different fields including Law, Science, Engineering, Medicine, Economics, and Philosophy.  
Science and Engineering hold the keys to technological development necessary to provide clean water and 
remove micropollutants from wastewater.  Many times regulations drive the development of new 
technology and the application of current technology to ensure that water remains clean for future 
generations.  Additionally, philosophy and economics provide impetus to further develop technology, and 
helps to determine whether technology gets implemented and provide impetus for new policy through the 
adoption of new doctrines and beliefs.  Therefore, when, how, and if environmental issues become 
addressed becomes a function of feasibility, the will to solve the problem at hand, and the economics of the 
solution chosen.   
For this thesis, the issue of micropollutants (such as pharmaceuticals and personal care products) 
will be examined through many of the lenses listed above.  In subsections below the motivation for 
removing micropollutants will be examined, along with philosophical arguments for addressing these 
substances in water, and finally the current state of the art in terms of science and engineering will be 
explored with a comprehensive literature review.   
1. Motivation 
 
Numerous countries around the world have recognized that water is becoming scarcer and as a 
result have begun to explore conservation methods including water recycling. Water is recognized as a 
critical resource for the future, and it has dramatic health consequences when it is not properly cared for.  In 
many regions around the world, drought has left 1.2 billion people without access to safe water and 2.6 
billion without access to sanitation [1].  In many regions, climate change has shifted the usual rain patterns 
making water scarce, resulting in the necessity for new policies and technologies [2].  Recycling water is 
becoming more common as advanced technologies such as Reverse Osmosis have developed to the extent 
of widespread commercialization [3, 4].  As an example, in San Diego California, in 2006 they received 
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only 24% of their normal rainfall during the rainy season [5].  As a result, it is proposed to expand their two 
recycled water facilities to help meet population growth in the region [5].  Another prime example is in 
southeast Australia which has been experiencing a drought for the past 10 years, resulting in large 
curtailing of water usage and conservation programs generating great interest in desalination and water 
recycling [6, 7, 8].  With increased interest in utilizing recycled water around the world, there are still 
concerns about this from both the consumer and technological standpoint.   
Keeping in mind water is a precious resource, it is necessary in many cases to recycle water for 
aquifer recharge, use in agriculture, or after proper treatment, as drinking water.  In countries such as 
Australia and on the West Coast of the United States, this process has already begun.  One primary concern 
is for the accumulation of low levels of pollutants, i.e., micropollutants in recycled waters.  These 
micropollutants include pharmaceuticals, pesticides, and other commercial/industrial organic compounds.  
Numerous researchers including the United States Geological Survey, USGS, recognize that many 
micropollutants are persistent in the environment, and in addition, carry potential risks to human and 
ecological health [9, 10, 11]. Many of these compounds pass through current treatment facilities and their 
fate and transport in the environment is not well understood [12].  If these compounds possess low 
biodegradability then they may persist in the environment indefinitely.  At the current time, the best method 
for purification is reverse osmosis, RO, but this is expensive and energy intensive [6].  While energy usage 
is outside the scope of this thesis, it does intricately link to exploring the fate and usage of other treatment 
process that compete with reverse osmosis to remove the micropollutants.  Additionally, it is important to 
try to prevent pharmaceuticals from reaching the environment through the development of “green 
pharmaceuticals” and through more effective recycling and disposal programs [13].   
It is crucial to understand whether chemical or biological processes are able to degrade some of 
these Personal Care Products and Pharmaceuticals, PCPPs, to prevent their accumulation within the 
environment and to allow for safe usage as drinking water augmentation, irrigation, or aquifer recharge.   
Even if the state of the art technology such as RO was utilized, there is still the problem of what to do with 
the waste products, i.e. the retentate [4, 6].  It is the treatment of this retentate via chemical adsorption, 
biological treatment or advanced processes, or application of biological, adsorption or advanced processes 
to WWTPs to prevent entry into the environment of PCPPs that is of great interest.   
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2. Precautionary principle  
 
One ethical and legal framework that has been applied to unknown hazards such as global 
warming is the precautionary principle, or:   
“The precautionary principle advises that lack of scientific evidence for 
a claim should not be taken as a reason for exercising a lack of caution 
when the risk is high.  When the risk is high, and we have some reason 
to think that immediate action is required to avoid catastrophe, the 
precautionary principle states we should take that action” [14].   
 
This approach seeks to protect the environment and public from excess risk in the face of a lack of 
scientific consensus and places the burden of proof rest with the parties advocating inaction [15] [16].  In 
Europe, this principle has become the dominate driver of regulation and policy within the environmental 
arena, since many of the problems faced in the environmental arena are wrought with uncertainty or are 
low probability events with drastic consequences [15] [16].  This principle has changed how environmental 
policy has been developed and instead of waiting for catastrophes to occur, seeks to prevent them.  While 
this principle is widely applied in international agreements and protocols, such as the Kyoto Protocol, the 
US has generally not changed its regulatory framework to utilize this principle.   
As PCPPs and their effects in the environment continue to be studied and better understood, it is 
likely in the future that they will become regulated under existing statutes,  or become the subject of new 
regulations, statutes, or guidance documents [15] [17] [18] [19].  The question becomes, whether the 
response to PCPPs in the environment and the resulting response will be governed by the precautionary 
principle or not.  In the case of PCPPs, there are numerous environmental impacts that can result from 
releasing these compounds in to the environment.  One such example is the increased incidence of fish 
downstream of wastewater treatment plants turning into females as a result of the estrogen at low 
concentrations in the water [20].  This finding is alarming, and, if as a society we wish to protect the 
environment, even if it is for our own selfish use in the future, then, we must attempt to rectify the 
situation, even in the absence of absolute proof [15] [16]. Additionally, as fresh water resources continued 
to be strained by climate change and population growth, the push for water recycling will be necessary to 
augment dwindling supplies [4].  Thus, with water recycling, there will be a potential for concentrating 
PCPPs, which would potentially present an increased health and environmental hazard.  In the end, the US 
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may choose to utilize the precautionary principle to guide its regulatory framework to protect human and 
environmental health.   
To understand how the precautionary principle might apply to regulating PCPPs, blood thinners 
such as aspirin, warfarin, and Plavix will be used a case study.  Blood thinners, like most pharmaceuticals, 
carry side-effects and potential hazards and thus must be viewed with caution.  For example, Warfarin was 
used as a rat poison, and while a very effective anticoagulant clinically, patients must be monitored closely 
to prevent excessive bleeding [21, 22].  In the case of water recycling, there is the potential for the 
concentration of these particular substances thereby increasing the risk associated with these water sources.  
If we apply the precautionary principle to recycled water and regulate blood thinners, then while there may 
not be ample scientific evidence available when the regulations are written, the regulations should be 
written with the intent to prevent harm from occurring to end-users.  This may result in a more strict 
regulation, but by the precautionary principle, it is better than waiting for scientific evidence to emerge 
before acting to regulate these substances.   
While utilizing the precautionary principle does potentially cost more than waiting for scientific 
consensus to form, it is unlikely (based on history) that the United States will change its model.  One of the 
most famous environmental disasters was Love Canal, and this site arguably helped to start the modern 
environmental movement [23, 24].  There were three different entities that dumped waste into the canal: 
first, Hooker Chemical disposed of approximately 21,800 tons of chemical waste in the trench between 
1942-1953, second, the US Army used the landfill to dispose of parts of the Manhattan project and 
potentially some chemical warfare compounds, and third, the city of Niagara Falls also used it for 
municipal waste [23, 24].  The landfill was closed in 1953, and sold to Niagara Falls Board of Education, 
who opened an elementary school in 1955 to accommodate the growing population [23].  Housing 
development began at the same time and continued into the mid-1970s despite that in the late 1950s, 
“residents began to complain about children being burnt, nauseous odors, and black sludge” [24].  Heavy 
rainfall in 1975-1976 caused ground water contamination and ponding of hazardous chemicals [23].  As a 
result of the chemicals at the site and heavy rainfall, birth defects, miscarriages, and chromosome damage 
was observed in residents [23, 24].  Evacuations began in 1978 and continued through 1980 until President 
Carter on 10/1/1980 ordered an evacuation of all residents of love Canal because of the emotional 
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disturbance [24].  Love Canal was not an application of the precautionary principle, while the evidence was 
still coming in, it would have been precautionary if action had been taken in the 50s.  On the whole, most 
superfund sites were cleaned up after hazards were already identified or after harm was observed.  In 
general, it is rare that sites were cleaned up before negative attributes were observed.  This will likely 
continue to be the method by which the United States operates and little or no action will occur prior to 
harm being scientifically observed.  Another prime example of the United States not implementing the 
precautionary principle is Climate Change.  Behind climate change now is a huge body of scientific 
literature with a consensus that global climate change is occurring [25, 26, 27].  Many International bodies 
agree that it needs to be addressed and the precautionary principle is often applied as a justification for 
action [25, 26, 27].  Despite this scientific evidence and international consensus, the US is not acting, along 
with the rest of the world, as quickly as may be required [25, 26, 27].  The potential consequences from 
CO2-induced climate change are massive, and while there is high uncertainty of the effects and in the 
modeled projections, the precautionary principle would argue that action must be taken to avert potential 
disasters.  Europe has embraced this theory, but the US to a large extent still considers inaction to be viable 
due to increased competition from developing nations like China.   
Both Love Canal and Climate Change were examples in which the United States has not utilized a 
precautionary principle framework for regulating, and it is not likely that PCPPs will be an exception to this 
behavior.  It is more likely that as new technologies develop, explored in Chapter 4 (page 83), PCPPs will 
be regulated only as hazards become identified rather than promulgated prior to the implementation of a 
viable technology.   
 
3. Technological pragmatism  
 
Many different ethical frameworks have been proposed to address environmental problems, but  
these frameworks mostly fail to account for the technological capabilities that constrain how a society can 
solve a current problem.   Technological pragmatism is a descendent of environmental pragmatism and 
environmental ethics [28].   It seeks to blend the constraints of Science and Engineering with moral 
philosophy.  When large issues such as sustainable water practices and sources of climate change seek to be 
addressed by traditional environmental ethics, all too often there are two schools of thought, 
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anthropocentric or human centered and non-anthropocentric or environmentally centered [19].  The 
problem with diametrically opposed frameworks is that there is little room for compromise and progress in 
terms of policy.  Therefore, ethicists seek to apply a pragmatic approach to solving the dilemmas presented 
in environmental issues.  The environmental pragmatist approach (compared to the non-anthropocentric 
ideal) addresses strong versus weak anthropocentrism (human felt preference versus human considered 
preferences) [18, 19].  It is the application of considered preferences where the moral argument for 
developing protection of the environment originates, even if it is an extension of ensuring continued use of 
the environment for future generations [18, 19, 29].  As a result, our degree of considered preferences, 
determines how we value of the environment and how much we will seek to protect it.  From this forms the 
basis of technological pragmatism which incorporates scientific progress and technological considerations 
into policy decisions, or “the purpose of blending science with moral philosophy is that one cannot make 
educated policy decisions without considering both” [28].   Technological pragmatism goes on to argue that 
there is a moral obligation for the development and application of technology [28].  While this ethical 
framework was originally proposed to address climate change and an ethical framework for preventing it, it 
can be applied to any problem that requires a balancing of ethics and science.  The regulation of 
micropollutants in the environment certainly qualifies within this framework.     
Once establishing that there is a desire to remove these micropollutants from water and wastewater 
to prevent environmental damage or to ensure safety for drinking water, it becomes necessary to consider 
how to approach removing PCPPs through the lens of technological pragmatism.  Currently, the removal of 
micropollutants is technologically limited and cost prohibitive due to their low concentration [30].   On the 
one hand people want their water to be pristine, accepting little to no contamination, but there is a 
technological limitation to getting water that clean in an economical fashion.  In order to remove 
micropollutants, the implementation of a new technology is likely required to accomplish this goal.  
Technological pragmatism dictates that if a new technology was to be applied, like RO, to remove PCPPs, 
then the impact on the environment in terms of the complete lifecycle must be considered and not just the 
anthropocentric benefits associated with access to clean water.  For example if RO was applied to 
wastewater effluents to remove carbamezipine, then there would need to be a consideration of whether the 
technology was sufficient to accomplish the job, what the general environmental benefits would be, and the 
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potential drawbacks of implementing the technology, as well as cost.  In this case there are benefits for 
humanity and the environment in preventing the intake of Carbamazepine and preventing accumulation of 
this compound in the environment over time.   On the other hand, implementation of RO necessitates a 
supply of more energy which is likely to come from fossil fuels, which would result in an increase in 
climate change impact.  Climate change has many different negative environmental impacts that are beyond 
the scope of this work (see [2] and [27] for further reading), but these must be taken into account.  In this 
case, technological pragmatism may argue that a current technology is not sufficient and rather would 
advocate for scientific development that would allow for the application of a cleaner technology.  If on the 
other hand, there exists a cleaner technology that decreases environmental harm and provides humanity 
with clean water, then as a society we have a moral obligation to implement that technology.  As to whether 
this technology exists yet from a scientific perspective, that question will be addressed within this work.   
Overall, seeking to remove PCPPs for environmental and anthropocentric reasons is in line with 
environmental pragmatism, and by applying technological pragmatism, an optimal technology can and will 
be able to reach this goal.  “Pragmatism embraces moral pluralism where there is no one correct practice or 
one set of practices to answer how we should proceed” [28, 29].  This is crucial, and while there are 
technologies currently available to remove these compounds, there is a limit to these technologies and 
hopefully within an open mind, scientists and engineers will continue to develop technology that will allow 
for these compounds to be successfully removed.  Pragmatism can be an ethical framework in which to 
operate for policy, regulatory, and technology implementation.  This viewpoint should be utilized as a 
framework to develop new regulations concerning PCPPs.  In the next section, the regulatory framework, 
current and future, will be explored.   
 
4. Relevant Laws Governing Water and Wastewater  
 
Law and regulation has evolved over the past forty years to help protect the environment in the 
wake of numerous environmental disasters, such as Love Canal and the valley of drums.  The modern 
environmental movement and the subsequent legislation were a response to these high profile events which 
had devastating impacts on communities.  Some of these laws have sought to regulate water and the two 
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pieces of legislation most relevant are the Safe Drinking Water Act (SDWA) and Clean Water Act (CWA) 
[16].  The first law to effectively address water quality and regulate discharges was the CWA.   
The CWA, was created to regulate discharges of pollutants and sets the standards that are 
applicable to Wastewater Treatment Plants, WWTPs.  Prior to the CWA, the primary means of prosecuting 
water pollution causation was Tort law [16].  Under this subdivision of law, a particular pollutant must be 
connected to a particular source to result in liability, which became almost impossible after industrialization 
due to the number of sources discharging into surface waters [16].  As a result, the CWA regulates effluent 
discharges, which come out of a specific point source thereby allowing for liability to be created.  The act, 
prohibits “all unpermitted discharges into navigable waters of the United States of pollutants from point 
sources, imposes effluent limitations on dischargers, and requires statewide planning for control of 
pollution from nonpoint sources” [16, p. 646].  There were three different types of pollutants that were 
regulated under the CWA: 1) conventional pollutants, which are pollutants amenable to biological 
treatment, 2) toxic pollutants, which “cause death, disease, behavioral abnormalities, cancer, genetic 
mutations, physiological malfunctions (including malfunctions in reproduction)” [31], and 3) Non-
conventional non-priority pollutants, which includes everything else like ammonium and heat [16].  A 
subset of contaminants of interest were referred to as Priority Pollutants, for which EPA has established 
applicable technology-based standards and were the first individual substances to be regulated.  Effluent 
limits also take into consideration: nutrients, pathogens, and sediment to maintain water quality in a given 
water body.  To maintain the integrity of a water body, the EPA mandates certain technology be utilized for 
certain pollutants (specified in the individual NPDES permit).   
The CWA was established as a technology forcing statute that required a specific technology to be 
utilized based of the type of contaminant being discharged.  After 1989, the standards that were applicable 
to each of the three categories of pollutants were: Conventional pollutants required BCT under 
§301(b)(2)(E), Non-Conventional non-toxic pollutants required BAT, new sources of conventional and 
non-conventional non-toxic pollutants require BADT/NSPS under §306, and Toxic pollutants required 
BAT after the Flannery Decree, which was added to §301 from the original act (Guidelines for priority 
pollutant can be found in §304(m) , whereas everything else is governed under the impaired water lists and 
ICS under §304(l)) [16].  While technology was utilized as one means of protecting a water body, 
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sometimes technology was not enough to maintain the integrity of a given navigable water.  When that 
occurred, the second mechanism of the act kicked in, which is known as Water Quality Standards.  There 
are two components that are necessary to form a water quality standard: 1) a designated use and 2) a water 
quality criteria meant to preserve that designated use [16].  Water quality standards are continually devised 
by the state and reviewed by EPA [16].   
 Unlike the CWA which regulates the discharges into a water body, the SDWA was created to 
regulate the contents of water intended for distribution.  The SDWA “regulates contaminants in drinking 
water supplied by public water systems, establishes a permit program regulating the underground injection 
of hazardous waste (to protect water supplies), and restricts activities that threaten sole-source aquifers” 
[16, p. 646].  Under this act, EPA set drinking water standards for public sources, but not private wells or 
bottled water [16].  There are two types of standards: 1) Maximum Contaminant Level Goals (MCLGs) 
which are non-enforceable and 2) Maximum Contaminant Levels (MCLs) which are enforceable [16].   
MCLGs were set at a level of no known or anticipated adverse health effects with an additional safety 
margin and the MCL was set as close to MCLGs as possible with the feasible  best treatment technology 
(cost is taken into account for large communities and was meant to be affordable) [16].  MCLs apply to any 
facility that supplies water for human consumption to at least 15 connections or approximately 25 people 
[16].   Currently there are more than 90 contaminants regulated, including disinfection byproducts, 
pathogens, and other chemicals [16].  The EPA has the ability under the act to consider adding 
contaminants to be regulated.  As a result, the latest scientific and technological breakthroughs allow for 
the continued protection of health without excess risk.   
It should be noted that no new environmental regulations have been passed through Congress in 
the past two decades and that most new applications or rulings issued by EPA have been accomplished 
through guidance.  Considering this set of circumstances, it is highly unlikely that there will be new 
regulations that govern the discharge of micropollutants under the CWA or SDWA, in the future.  With that 
said, it may become necessary to regulate these micropollutants via guidance issued by the EPA.   
As a case study, estrogenic compounds will be examined with respect to how they might be 
regulated and how they could end up as being controlled under the CWA and SDWA.  The CWA would 
govern discharges into the environment of estrogenic compounds whereas the SDWA would seek to protect 
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water destined for public water distribution.  The mechanisms and requirement that would result in 
successfully regulating PCPPs would depend not only upon the availability of successful water treatment 
technologies, but also evidence of harm or hazard to human health or the environment.   For the SDWA, 
there would likely be a recommended new technology applied to drinking water plants, and if water 
recycling were to become commonplace, then applicable MCLs and MCLGs for estrogenic compounds 
would be developed.  This would definitely increase the cost of drinking water treatment, but might be 
necessary as health information becomes available for these compounds.     
Many estrogenic compounds are recalcitrant and long-lived within the environment, making them 
likely to qualify under the CWA as a toxic pollutant [31].  Estrogenic compounds would likely qualify as a 
toxic pollutant, since numerous studies have shown that downstream of a WWTP, fish are largely female as 
a result of the increased estrogenic compounds in the water [20].  To regulate these compounds going into a 
specific body of water, first it must be known at what concentration fish begin to turn female.  Once 
ascertaining this threshold concentration, water quality standards could be devised for a given water body 
(based on fish species response).  After this, the relevant point sources discharging estrogenic compounds 
into the navigable water will need to be identified.  Let’s assume that there are two different dischargers, a 
WWTP and an industrial plant.  Once determining the Total Maximum Daily Load, TMDL, for that water 
body, allowances in the NPDES permits for each discharger can be devised that will protect the water body 
for the designated use.  This potential mechanism of regulation under the CWA would require the usage of 
“Best Available Technology,” BAT, to control the discharges of the WWTP and the industrial plant.  The 
allocations given to each of these would be dependent upon when each facility was built, how much each 
facility produces, and economic considerations such as the ability to pay for the required scale of treatment 
[16].  Regardless of which of the two dischargers will need to implement BAT and to what extent, the 
technology required to remove estrogenic compounds will likely be extremely costly and require advanced 
processes to prevent the compounds from reaching the water body.   
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Previous studies 
 
1. Overview 
 
Pharmaceuticals as they apply to agriculture, usage in agriculture, and potential health concerns 
have been a topic for many years, although methods of detection have been lagging.  One such example 
was published by Morgan et al. in 1987, where agricultural and veterinary journals publish articles on 
livestock medicine issues [32].  Many organizations were already starting to think about how these 
products may adversely impact public health [32].  This was the beginning of PCPPs in the literature and it 
was not for over a decade that methods of detection improved to the extent that major studies were able to 
be conducted.   
Previous authors have reported on the existence of PCPPs in the environment and the potential 
hazards associated with them.  One of the first reviews written was by Daughton et al., which presents a 
large synthesis article on the presence of PCPPs and examines the associated risks with these compounds in 
the aquatic environment [33].   In the same year, the National Research Council published its review on 
hormonally active substances in the environment.  This report demonstrated links with declining 
populations of some wildlife species, potential changes in structure and function relationships in wildlife, 
and a warning for observing human populations for signs of epidemiological changes and the incidence of 
“small penis size, abnormal testes in males, and abnormal ovaries in females” [20].  Hormonal compounds 
were not the only compounds of concern.  Buser et al. examined ibuprofen in depth and its presence in 
surface waters and WWTP samples [34].  This paper was one of the first to demonstrate that Ibuprofen 
appears to be degraded by the treatment process unlike other PCPPs, such as diclofenac and clofibric acid 
[34].  Some of the earliest work published has been performed in Europe.  Hirsch et al. focused on the 
presence of antibiotics in the environment and in wastewater effluents in Germany [35].  His group found 
that compounds from the antibiotic classes of acrolid antibiotics, sulfonamides, penicillins and tetracyclines 
were present in wastewater effluents and in streams, and did not appear to be easily degraded [35].  Also 
studying PCPPs in Germany, was Ternes in 1999, who’s paper was one of the first to demonstrate the link 
between WWTP effluent as the source contributing to the presence of these compounds in the environment 
[36].  Additionally, his findings demonstrated that many of the compounds that were not removed 
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effectively during treatment were acidic in nature, including: “lipid regulators bezafibrate, gemfibrozil, the 
antiphlogistics diclofenac, ibuprofen, indometacine, naproxen, phenazone and the metabolites clofibric 
acid, fenofibric acid and salicylic acid as well as neutral or weak basic drugs such as: the betablockers 
metoprolol, propranolol and the antiepileptic drug carbamazepine” [36].  These PCPPs “were found to be 
ubiquitously present in the rivers and streams” [36].  Therefore, these authors helped to develop some of 
the first studies on PCPPs and to bring awareness of a potential developing environmental health problem.   
One of the first comprehensive papers in the US that was written on the topic of PCPPs was by 
Koplin et al. and the USGS, which helped kicked off a major research efforts to characterize and address 
these compounds.  The major paper was published in Environmental Science &Technology in 2002 by 
Koplin et al. [37].  This paper was the first nationwide study of 95 PCPPs from 139 streams over 30 states, 
and it found that 82 out of the 95 PCPPs, were present in detectable amounts [37].  The most frequently 
detected compounds were: “coprostanol, cholesterol, N,N-diethyltoluamide, caffeine, triclosan, tri(2-
chloroetyl)phosphate, and 4-nonylphenol,” but these compounds were not necessarily present in the highest 
concentrations [37].  Part of the reason that it took until 1999 to develop adequate analytical methods 
capable of detecting PCPPs at very low concentrations, was the technological limitations associated with 
instrumentation [37].  With that said, even today, the methods that are available are still cumbersome and 
time consuming to perform, but the methods are capable of quantifying the presence of these compounds in 
water samples.   
The development of the methods that allowed for the detection of these compounds and continued 
evaluation of water samples have been spearheaded mainly by EPA and the USGS.  The main analytical 
methods for measuring PCPPs include: EPA method 1694 [38], USGS adapted methods from Koplin et al. 
[10].  Other methods require more adaptation and further development, as with Batt et al. [39].  These 
methods primarily rely on liquid chromatography coupled to three MS units [39].  Additionally, these 
methods require large prep time and often require concentrating samples several orders of magnitude to 
improve the sensitivity of the equipment used for detection [38].  Therefore, the currently available 
methods are time consuming to produce results, but they do offer the ability for reasonable recovery of the 
substances of interest.   
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2. Methods 
 
A comprehensive literature review was conducted and information was compiled into a series of 
tables.  A review of 140 articles including review articles was conducted for literature values and compiled 
into four different tables.  First, anytime an article mentioned a relevant WWTP influent, effluent, or 
environmental concentration it was added to Table 1.  The minimum and maximum values were then found 
for each PCPP until the literature review was finished.  Biodegradability, log Kow, and Solubility were 
taken from peer reviewed literature when available, and in its absence, were taken from EPA EPISUITES 
4.11 [40].  Additionally, as removal efficiencies were found for various treatment methods, this data was 
compiled into three different tables: Table 2 (Biological treatment methods), Table 3 (Chemical processes), 
and Table 4 (Physical processes).  The relevant concentrations that were utilized in these studies were also 
included for reference.  These tables will be further discussed in the next subsection.   
After compiling influent and effluent data in Table 1, a series of figures were constructed utilizing 
this data.  First, a figure was constructed by utilizing the minimum and maximum influent concentrations 
for each species and plotting them in a semi-log fashion.  The SDWA limit for phenol was used as a 
surrogate level for comparison with these compounds, since no limits currently exist for PCPPs.  Second, a 
figure was constructed by utilizing the minimum and maximum effluent concentrations after having been 
concentrated by seven times (as would be the case for an RO process for each species), and plotting them in 
a semi-log fashion [41, 42].  The SDWA limit for phenol was used as a surrogate level for these 
compounds since no limits currently exist for PCPPs.  Finally, six figures were created in total, one for the 
influent and one for the effluent, for a daily, monthly, and yearly sample mass flow of the PCPPs based on 
a total flow of 100 MGD as an example.  These values were then plotted in a semi-log fashion.   
After compilation of Log Kow data in Table 1, a final series of figures were constructed.  The data 
was grouped into three different groupings based on a hydrophobicity scheme by Rogers: log Kow less than 
2.5, log Kow between 2.5 and 4, and log Kow greater than 4 [43].  Plots were constructed of influent versus 
effluent for each set of compounds.  A linear trend line was applied to the data and compared to a line with 
a 1:1 slope (representing no removal of the compounds).  Compounds removed exhibit a ratio of effluent to 
influent concentrations less than 1.0.   
14 
 
3. Rationale for Tables and Figures from the literature  
 
In order to compress a comprehensive literature review into a short amount of space, tables and 
figures were chosen to summarize the information.  The 47 compounds that were explored in this study 
were chosen to provide a diversity of compound classes and were among some of the most prescribed 
drugs.  While many more papers have been written on the removal of PCPPs from water and wastewater, 
enough papers were reviewed to gain a wide breadth of knowledge while avoiding redundancy.   The 
information that was collected was then broken into four different tables.  The first overviews the chemical 
characteristics of the compounds of interest along with their influent, effluent, and environmental 
concentrations presented in literature.  The second, third, and fourth were organized into biological, 
chemical, and physical processes respectively.  All of these tables provide an excellent medium to quickly 
and comprehensively review literature values in a way that has not previously been published.   
  
Table 1: Concentration of PCPPs in the Environment (Note: all concentrations in µg/L unless stated otherwise)  
Drug 
WWTP influent 
concentration 
WWTP effluent 
concentration 
Environmental 
concentration 
Bio-
degradibility 
Log 
Kow Solubility References 
    
 Minimum Maximum Minimum Maximum Minimum Maximum 
    
Acetaminophen 0.015 150 0.028 1.48 0.1 10 No, weeksC 0.461a 1.4*10
4
 
mg/La [10,44-47] 
[44], 
[45], 
[46], 
[10] 
[47] 
ASA 0.001 7 0.015 1.51 0.05 0.34 Yes, weeks3 1.191a 4600 mg/La [43, 44, 45, 48, 49] 
[48], 
[49], 
[44], 
[45] 
[43] 
Acebutolol 0.335 1.04 0.01 0.255 0.8 8 Yes, weeks3 1.71 d 1.07*10
5
 
mg/La [44, 50-52] 
[50], 
[44], 
[51], 
[52] 
Amitriptyline 0.5 6.5 0.001 0.35 
     
[44] [44] 
Atenolol 0.03 25 0.01 70 1.1415 14.2 No, 
weeks/monthsc 0.161
a 1.33*104 
mg/La 
[44, 47, 50, 
52, 53] 
[50], 
[52], 
[47], 
[44], 
[53] 
Atrazine 0.032 0.87 0.049 0.87 2 2.01 No, monthsc 2.611a 34.7 mg/La [54, 55] [54], [55] 
Bezafibrate 0.05 28 0.008 5 30 30 Yes, monthsc 4.25 d 7.927 
mg/La [44, 50, 56] 
[50], 
[44], 
[56] 
Bisphenol A 0.088 11.8 0.006 4.09 0.0019 50 No, 
weeks/monthsc 3.32
a 120 mg/L [50, 57-59] [57], [50], [58], [59] 
Caffeine 3.69 118 0.174 12 0.081 71.9 Yes, weeksc -0.071a 
2.16*104 
mg/La 
[10, 43, 47, 
50] 
[50], 
[10] 
[47] 
[43] 
Carbamazepine 0.0819 22 0.042 2.44 0.11 2.3 No, 
weeks/monthsc 2.451
a 112 mg/L1 [44, 47, 49, 50, 52, 60, 61] 
[50], 
[52], 
[44], 
[49], 
[60], 
[61], 
[47] 
Celiprolol 0.44 0.44 0.28 0.28 - - No, 
weeks/monthsc 1.92
a 9401 mg/L1 [50] [50] 
Ciprofloxacin 0.09 15 0.007 5 0.02 0.03 No, monthsc 0.28a 3*10
4
 
mg/L1 
[10, 44, 50, 
52] 
[52], 
[50], 
[44], 
[10] 
Codeine 0.1 45 0.025 8 0.012 0.019 No, weeksc 1.19a 9000 mg/L1 [43, 44] [50], [44] [43] 
Diclofenac 0.03 13 0.04 10.5 0.25 0.75 No, 
weeks/monthsc 4.51
a 2.37 mg/L1 [44, 50, 62] [50], [44], [62] 
Doxycyclin 0.0025 2.48 0.023 1.09 ND ND No, monthsc -0.02a 630 mg/La [10, 44, 50] [50], [44], [10] 
Venlafaxine (Effexor 
XR) 0.015 0.93 0.057 2.4 0.4 1.4 No, months
c
 3.28 d 1422 mg/Lb [63-65] [63], [64], [65] 
Erythromycin 0.1 10 0.008 6.5 0.01 12 No, 
recalcitrantc 3.06
a 1*106 
mg/Lb 
[10, 43, 44, 
48, 50] 
[50], 
[44], 
[10], 
[48] 
[43] 
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17α-estradiol 0.003 3.1 0.0002 0.055 0.03 0.074 Yes, weeksc 2.45d 558 mg/Lb [10, 44] [44] , [10] 
17β-estradiol 0.0001 0.01 0.0002 0.055 0.0001 0.16 Yes, weeksc 2.45d 558 mg/Lb [10, 44, 59, 66] 
[44], 
[10], 
[59], 
[66] 
Estrone 0.0001 0.7 0.0002 0.01 0.0001 0.11 No, 
weeks/monthsc 3.131
a 30 mg/La 10, 44, 47, 55, 66, 67] 
[55], 
[47], 
[67] 
[44], 
[10], 
[66] 
Fenofibric Acid 0.079 0.42 0.078 70 0.012 0.012 Yes, monthsc 5.19d 0.832 
mg/Lb [10, 44, 50] 
[50], 
[44], 
[10] 
Gemfibrozil 0.03 18 0.003 5.5 0.048 0.79 No, 
weeks/monthsc 4.77
d
 8.42 mg/Lb [10, 44, 47, 50, 68] 
[50], 
[10], 
[47], 
[68], 
[44] 
Hydrochlorothiazide 0.6 10 1.7 12 0.00053 0.256 
   
[44, 50, 69] [44], [50], [69] 
Ibuprofen 0.0143 300 0.03 45 0.05 3.87 Yes, weeksc 3.97a 21 mg/La [10, 43-45, 47, 50, 67] 
[50], 
[10], 
[47], 
[67], 
[44], 
[45] 
[43] 
Iopromide 0.01 9.205 0.01 9 0.011 0.91 No, monthsc -2.05a 3.35*10
5
 
mg/Lb [44, 50, 70] 
[50], 
[44], 
[70] 
Iomeprol 6.05 6.05 1.606 1.606 0.01 0.89 No, monthsc -2.79a 1*10
6
 
mg/Lb [50] 
[50] 
Iohexol 6.7 6.7 2.706 2.706 - - No, monthsc -3.05a 1*10
6
 
mg/Lb [50, 70] 
[50], 
[70] 
Iopamidol 2.3 2.3 1.9 1.9 0.17 2.8 No, monthsc -2.42a 1.04*10
5
 
mg/Lb [50, 70] 
[50], 
[70] 
Lipitor 0.025 0.55 0.01 0.575 0.324 0.448 No, monthsc 6.361a 0.013531 
mg/Lb [54, 71, 72] 
[71], 
[72], 
[54] 
Meprobamate  0.0082 0.073 0.0057 0.0059 0.043 0.043 No, 
weeks/monthsc 0.701
a
 4700 mg/La [43, 48, 54, 63] 
[63], 
[54], 
[48] 
[43] 
Metformin  18 105 1.3 26 0.11 0.15 
   
[10, 73] [73], [10] 
Metoprolol 0.01 2.29 0.018 4.9 0.145 0.145 Yes, weeksc 1.88 a 1.69*10
4
 
mg/La 
[44, 50, 52, 
74, 75] 
[50], 
[44], 
[52], 
[74], 
[75] 
Naproxen 0.04 70 0.001 2.62 0.0021 0.145 No, weeksc 3.181a 15.9 mg/La [43-45, 50, 58, 67] 
[50], 
[58], 
[67], 
[44], 
[45] 
[43] 
Norfloxacin 0.018 0.96 0.007 0.33 0.12 0.12 No, monthsc -1.03a 4.02*10
4
 
mg/Lb 
[10, 44, 50, 
52] 
[52],  
[44], 
[50], 
[10] 
Ofloxacin 0.007 35 0.007 1.75 0.0081 0.634 No, 
recalcitrantc -0.39
a 6.87*103 
mg/Lb 
[10, 44, 50, 
52] 
[52],  
[50], 
[44], 
[75] 
Paraxanthin 26.732 26.732 0.836 0.836 - - Yes, weeksc -0.39
a
 
(est)2 
2.2*105 
mg/Lb [50] 
[50] 
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Progesterone 0.0022 0.00031 0.00058 0.00058 0.11 0.199 No, 
weeks/monthsc 3.87
a 8.81 mg/La [10, 54] [10], [54] 
Propranol 0.036 0.51 0.03 0.18 - - Yes, weeksc 3.48a 61.7 mg/La [50] [50] 
Roxithromycin 0.01 18 0.008 5 0.03 0.35 No, 
recalcitrantc 2.75
d
 
4.74*105 
mg/Lb [44, 50, 75] 
[50], 
[44], 
[75] 
Sotalol 0.37 3.28 0.13 1.12 - - No, 
weeks/monthsc 0.24
a 1.41*104 
mg/Lb [50, 52] 
[50], 
[52] 
Sulfamethoxazole 0.003 10 0.003 5 0.066 2 No, 
weeks/monthsc 0.891
a
 610 mg/La [10, 43, 44, 47, 50, 60, 67] 
[50], 
[60], 
[47], 
[67], 
[44], 
[10] 
[43] 
Testosterone 0.0011 0.0012 - - 0.116 0.214 No, 
weeks/monthsc 3.32
d 23.4 mg/Lb [10, 54] [10], [54] 
Triclosan  0.15 1.93 0.012 0.219 0.029 2.3 No, monthsc 4.76a 10 mg/La [10, 44, 50, 58] 
[44], 
[50], 
[58], 
[10] 
Trimethoprim 0.005 10 0.04 1.34 0.15 0.71 No, days/weeksc 0.911
a
 400 mg/La [10, 44, 50] [44], [50], [10] 
Warfarin - - - - ND ND No, 
weeks/monthsc 2.701
a
 17 mg/La [10, 76] [10], [76] 
Zocor 0.004 0.004 0.002 0.002 - - No, 
weeks/monthsc 4.681
a
 0.03 mg/La [50] [50] 
Sertralie (Zoloft) - - - - 0.00029 0.00029 No, monthsc 1.67d 0.63763 
mg/Lb [63] 
[63] 
a. Log Kow and solubility data was obtained from the EPA EPISUITE 4.11, downloaded in December 2012 to ensure accuracy and was up to date [40].   
b. Estimated solubility data from EPA EPISUITE 4.11 [40].   
c. Estimated Bio-degradability of compounds was obtained from the EPA EPISUITE 4.11 with BIOWIN model [40] 
d. Estimated Log Kow data was obtained from the EPA EPISUITE 4.11, downloaded in December 2012 to ensure accuracy and was up to date [40].   
 
  
Table 2: Summary of previous findings on removal efficiencies for selected PCPPs using biological based 
treatment. 
PCPPs Removal Rate 
ASPe 
Removal Rate 
MBRe 
Influent 
Concentration  
Reference 
Acetaminophen  98.4%-99.9%d 99.6%-99.9%d  [77] 
 
 -66%b .1505 µg/L [78] 
 
100%d  37-130 µg/L [79] 
 
100%d  1.571-23.2  µg/L [80] 
 
>99%d  28.79-94.58 µg/L [81] 
 
96%-100%d  1-26 µg/L [82] 
 
 99.82%-99.91%d 11.5  µg/L [83] 
 
100%d  1.571-37.458  µg/L [84] 
ASA 95%-99%d  12.6-31.7 µg/L [85] 
 
82%-99%d  1-7 µg/L [82] 
Acebutolol 38%-60%d  .04-1.040  µg/L [52] 
 
58.2%d  0.355 µg/L [50] 
 
-10%-95%d  0.810-9.867  µg/L [86] 
 
54.9%-79.5%d  0.39-0.51 µg/L [51] 
Amitriptyline     
Atenolol 37%-77%d  0.350-1.71  µg/L [52] 
 
56.7%d  0.03-1.197 µg/L [50] 
 
 5%b 0.2006 µg/L [78] 
 
5%-95%d  0.99-8.384 µg/L [86] 
 
31.5%-62.6%d  0.72-0.91 µg/L [87] 
 
14.4%d  0.66-2.432 µg/L [80] 
 
82%-93%d  0.916-2.44 µg/L [88] 
 
20%-97%d  0.05-3 µg/L [82] 
 
84%d  0.3-4.3 µg/L [89] 
 
45%-92.2%d  0.51-0.8 µg/L [51] 
Atrazine     
Bezafibrate 60.8%d  0.05-4.9 µg/L [50] 
 
9.1%d  0.048-0.361 µg/L [80] 
 
23%-99%d  0.04-2 µg/L [82] 
 
97%d  0.8-9 µg/L [89] 
 
36.8%-99.5%d 77.3%-96.4%d 0.01-7.6 µg/L [90] 
Bisphenol A 60%-100%b  120-1600 µg/L [57] 
 75.8%-85%d 74.2%b 1.94-2.19 µg/L [91] 
 71%d  0.088-11.8 µg/L [50] 
 10.5%-98.7%d 92.7%-99.3%d 0.035-2.025 µg/L [90] 
Caffeine 96.9%d  3.69-118 µg/L [50] 
 
100%d  54-120 µg/L [79] 
 
94.9%d  5.01-65.625 µg/L [80] 
 
0%-100%d  0.44-3.28 µg/L [85] 
 
>99%d  29.09-53.32 µg/L [81] 
 
 98.83%-99%d 9.68 µg/L [83] 
Carbamazepine -22% to -193%d  0.160-.820 µg/L [52] 
 
-5.7%d  0.0819-1.68 µg/L [50] 
 
 -42%b 0.2013 µg/L [78] 
 
-81.8%-10.8%d  0.66-1.0 µg/L [87] 
 
-40%-18%d  0.130-0.40 µg/L [79] 
 
9.5%d  0.106-0.173 µg/L [80] 
 
0%-95%d  0.07-0.97 µg/L [85] 
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41%d  0.084-0.136 µg/L [81] 
 
37.8%-64.9%d  0.064-0.099 µg/L [88] 
 
 0%-10%b 0.1-0.775 µg/L [92] 
 
0%d  0.7-3.3 µg/L [89] 
 
 -9.5% to -4.55%d 0.042 µg/L [83] 
 
0%d  0.18-2 µg/L [93] 
 
-43.1%-13.8%d -12.8%-12.5%d 0.01-1.85 µg/L [90] 
 
-28.6%-34.5%d -7.1%-30.9%b 0.7-2.25 µg/L [94] 
 
-43.1% to -17.5%d  0.31-0.4 µg/L [51] 
Celiprolol 36.4%d  0.44 µg/L [50] 
 
-60%-75%d  0.10-0.16 µg/L [87] 
 
36%d  0.1-0.78 µg/L [89] 
Ciprofloxacin 79%-96%d  0-4.230 µg/L [52] 
 
62.3%d  0.09-5.524 µg/L [50] 
 
52%-90%d  0.43-1.10 µg/L [79] 
 
57%d  0.16-13.625 µg/L [80] 
 
37%-99%d  0.04-2 µg/L [82] 
 
80%-95.5%d  0.42-0.65µg/L [51] 
Codeine 32.5%d  2.8605 µg/L [50] 
 
79.2%-86.25%d  0.12-0.16 µg/L [87] 
 
69.3%d  0.15-2.087 µg/L [80] 
 
86.7%-91.8%d  0.055-0.338 µg/L [88] 
Diclofenac 34.6%d  0.16-3.1 µg/L [50] 
 
 5%b 0.1412 µg/L [78] 
 
58%-78%d  0.14-0.28 µg/L [79] 
 
5%d  0.232-0.561 µg/L [80] 
 
0%-70%d  0.099-0.72 µg/L [85] 
 
30%-100%d  0.25-0.9 µg/L [82] 
 
33%d  0.5-3.5 µg/L [89] 
 
 -150% to -120%d 0.01 µg/L [83] 
 
49.9%-88.4%d  0.901-1.036 µg/L [95] 
 
33.3%d  0.85-2 µg/L [93] 
 
7.1%-62.7%d -6.6%-50.6%d 1.4-4.114 µg/L [90] 
 
40%-59%d 55%-120%b 3.1-4.9 µg/L [94] 
Doxycyclin 35.4%d  0.067-2.48 µg/L [50] 
 
50%d  0.181-1.295 µg/L [81] 
Venlafaxine (Effexor 
XR) 
    
Erythromycin 48.8%d  0.346-0.83 µg/L [50] 
 
-38%-73%d  0.140-0.480 µg/L [79] 
 
4.3%d  0.346-2.31 µg/L [80] 
 
72%-89.8%d  0.032-0.08 µg/L [88] 
 
41%-52.4%b 82.2%-98.6%b 0.354-1.514 µg/L [96] 
 
25%d  0.56-1.1 µg/L [89] 
 
 4.55%-9.09%d 0.044 µg/L [83] 
 
-128% to -33.3%d  0.071-0.141 µg/L [95] 
17α-estradiol 80%d  0.0008-.0103 µg/L [86] 
 
0%-95%d  0.067-0.18 µg/L [85] 
17β-estradiol 60%-100%d  0.0035-0.0499 µg/L [86] 
 
0%-95%d  0.145-0.19 µg/L [85] 
 
83%-98%b  0.011-0.068  µg/L [97] 
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0%-99%d  0.01-0.162 µg/L [98] 
Estrone 30%-100%d  0.0058-0.012 µg/L [86] 
 
-21%-68%b  0.021-0.068 µg/L [97] 
 
33.3%-89%d  0.01-0.833 µg/L [98] 
 
97.14%d  0.005-0.01  µg/L [93] 
Fenofibric Acid -148.1%d  0.079 µg/L [50] 
 
1.3%d  0.079-0.117 µg/L [80] 
Gemfibrozil 51.5%d  0.453-3.525 µg/L [50] 
 
76%d  0.415-17.055 µg/L [80] 
 
30%-99%d  0.05-3 µg/L [82] 
Hydrochlorothiazide 53.2%d  2.514 µg/L [50] 
 
53.2%d  0.617-10.018 µg/L [80] 
Ibuprofen  0%b,c  0.4 µg/L  [57] 
 
52%-99.7%d 89%-99.8%b  [77] 
 
74.2%d  .0143-22.7 µg/L [50] 
 
100%d  3.9-15 µg/L [79] 
 
95%d  2.687-4.113 µg/L [80] 
 
0%-98%d  12.9-50.6 µg/L [85] 
 
65%-100%d  1-26 µg/L [82] 
 
96%d  1.7-5.1 µg/L [89] 
 
 98.3%-99%d 5.32 µg/L [83] 
 
-13.3%-53.3%d  7.741-33.764 µg/L [95] 
 
62.5d  1.1-3.5 µg/L [93] 
 
-4.2%-99.2%d 97.2%-99.2%d 0.01-2.448 µg/L [90] 
Iopromide 78.1%d  9.205 µg/L [50] 
 
83%d  12-24 µg/L [89] 
 
70%d  0.0001-7.5 µg/L [93] 
 
-862% to -32%d  0.026-3.84 µg/L [90] 
Iomeprol 73.5%d  6.05 µg/L [50] 
 
89%d  6-14 µg/L [89] 
Iohexol 59.6%d  6.7 µg/L [50] 
 
89%d  7-11 µg/L [89] 
Iopamidol 17.4%d  2.3 µg/L [50] 
 
17%d  0.7-3.9 µg/L [89] 
Lipitor (atorvastatin) 40%-80%d  0.04-2 µg/L [82] 
Meprobamate      
Metformin      
Metoprolol 2%-34%d  0.460-1.460 µg/L [52] 
 
55.8%d  0.02-4.9 µg/L [50] 
 
-35%-46.7%d  0.81-1.2 µg/L [87] 
 
-50%-90%d  0.0046-0.473 µg/L [86] 
 
6.5%d  0.02-0.052 µg/L [80] 
 
64%-78.3%d  0.033-0.076 µg/L [88] 
 
65%d  1.5-8.3 µg/L [89] 
 
-1.9%-26.7%d  1.05-1.35 µg/L [51] 
Naproxen 81.6%d  0.206-23.21 µg/L [50] 
 
 80%b 0.1386 µg/L [78] 
 
60.9%d  1.196-5.228 µg/L [80] 
 
0%-95%d  2.54-4.09 µg/L [85] 
 
60%-100%d  0.025-7 µg/L [82] 
 
 35.9%-41.22%d 0.262 µg/L [83] 
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73.08%d  0.6-2 µg/L [93] 
Norfloxacin >90%d  0-0.96 µg/L [52] 
 
54.3%d  0.066-0.25 µg/L [50] 
 
30%-98%d  0.04-2 µg/L [82] 
 
69.2%-86.7%d  0.078-0.18 µg/L [51] 
Ofloxacin 75%-88%d  0-.350 µg/L [52] 
 
64.5%d  0.007-2.275 µg/L [50] 
 
64.1%d  0.848-5.286 µg/L [80] 
 
0%d  0.0021-1.14 µg/L [88] 
 
20%-99%d  0.04-2 µg/L [82] 
 
80%-92.3%d  0.01-0.13 µg/L [51] 
Paraxanthine 96.9%d  26.722 µg/L [50] 
 
96.9%d  4.547-98.5 µg/L [80] 
Progesterone 0%d  0.01-0.02 µg/L [98] 
Propranol 48.5%d  0.036-0.51 µg/L [50] 
 
-48%-45.2%d  0.04-0.073 µg/L [87] 
 
-55%-80%d  0.0144-0.703 µg/L [86] 
 
1%d  0.012-0.061 µg/L [80] 
 
0%-60%d  0.2-0.39 µg/L [85] 
 
59.2%-74.7%d  0.072-0.309 µg/L [88] 
 
65%d  0.16-0.86 µg/L [89] 
 
-590% to -235%d  0.06-0.119 µg/L [95] 
Roxithromycin 39.5%d  0.0272-1.5 µg/L [50] 
 
54.4%-79.2%b 81.8%-97.2%b 0.279-1.39 µg/L [96] 
 
33%d  0.39-1.23 µg/L [89] 
 
8.7%d  0.012-0.05 µg/L [93] 
 
-80%-43.8%d 34.4%-73.5%d 0.036-0.078 µg/L [90] 
Sotalol 54%-71%d  0.370-3.28 µg/L [52] 
 
52.6%d  1.667 µg/L [50] 
 
-60%-60%d  0.129-3.2 µg/L [86] 
 
-31.5%-45.4%d  0.87-1.3 µg/L [87] 
 
56.5%-83.2%d  0.04-0.222 µg/L [88] 
 
48%d  1.2-3.8 µg/L [89] 
 
59.4%-75%d  0.03-0.130 µg/L [51] 
Sulfamethoxazole 17.5%d  0.02-0.674 µg/L [50] 
 
 20%b 0.088 µg/L [78] 
 
 57%-71%b 0.2-0.85 µg/L [92] 
 
43%-95%d  1.2-3.4 µg/L [79] 
 
17.3%d  0.162-0.53 µg/L [80] 
 
63%-68%d  0.984-2.148 µg/L [81] 
 
62.7%-76.9%d  0.02-0.268 µg/L [88] 
 
30%-92%d  0.04-2 µg/L [82] 
 
9.1%-49.7%b 62.3%-76.9%b 0.206-0.391 µg/L [96] 
 
24%d  0.59-1.05 µg/L [89] 
 
 63.9%-70.1%d 0.194 µg/L [83] 
 
25%d  0.07-0.6 µg/L [93] 
 
-279%-65.5%d 61.4%d 0.024-0.145 µg/L [90] 
Testosterone 50%-99%d  0.001-0.02 µg/L [98] 
 
 83.33%d 0.06 µg/L [83] 
Triclosan  65%-75%b   [57] 
 
76.8%d  0.3-1.93 µg/L [50] 
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92%-98%d  0.17-0.82 µg/L [79] 
 
74.5%d  0.86-2.417 µg/L [80] 
 
 96.6%-97.3%d 0.74 µg/L [83] 
Trimethoprim 1.4%d  0.0535-1.3 µg/L [50] 
 
-21%-92%d  0.39-0.77 µg/L [79] 
 
5.1%d  0.078-0.197 µg/L [80] 
 
39.2%-70.6%b 92%-100%b 0.0053-0.0597 µg/L [96] 
 
69%d  0.84-1.36 µg/L [89] 
 
 -47.6 to -33.3%d 0.021 µg/L [83] 
 
-94.4% to -35%d  0.213-0.3 µg/L [95] 
a. Lab conditions, single substrate 
b. Multiple substrates, lab conditions 
c. Higher than field-like concentrations, lab conditions 
d. Field-like concentrations and species  
e. ASP (Activated Sludge Process), MBR (Membrane Bioreactor)  
  
Table 3: Summary of previous studies’ findings on removal efficiencies for selected PCPPs using chemical processes.  
PCPPs RRe – Chemical 
Oxidation   
RRe – Wet-air 
oxidation  
RRe – Electro-
chemical  
RRe – Ozone or 
Ozone H2O2 
Concentration in 
influent  
Author 
Acetaminophen    100%  7.8-3.74  µg/L [42] 
 
 
 
    
ASA       
Acebutolol    86%d 0.810-9.867  µg/L [86] 
Amitriptyline       
Atenolol    97%d 0.72-0.91 µg/L [87] 
 
   28.1%-97.4%d 0.911  µg/L [84] 
Atrazine   10%-98%  7.8-3.74  µg/L [42] 
Bezafibrate    37.4%-96.5%d 0.115 µg/L [84] 
Bisphenol A    68%-95%d 0.20-0.43 µg/L [91] 
 
   >99%d 0.242 µg/L [99] 
Caffeine   55%-100%  7.8-3.74  µg/L [42] 
 
   -33%-100%d 54-120 µg/L [79] 
Carbamazepine   23%-100%  7.8-3.74  µg/L [42] 
 
   88%-100%d 0.130-0.40 µg/L [79] 
 
   85.2%->98%d 0.106 µg/L [84] 
Celiprolol       
Ciprofloxacin    45%-100%d 0.43-1.10 µg/L [79] 
 
   36%->95%d 0.522 µg/L [84] 
Codeine    >98.7%d 0.378 µg/L [84] 
Diclofenac   90%-100%  7.8-3.74  µg/L [42] 
 
   >99.8%d 0.433 µg/L [84] 
Doxycyclin       
Venlafaxine (Effexor 
XR) 
  55%-100%  7.8-3.74  µg/L [42] 
 
   29.1%->96.6%d 0.179 µg/L [84] 
Erythromycin    45%-100%d 0.140-0.480 µg/L [79] 
 
   77.8%->86.1%d 0.072µg/L [84] 
17α-estradiol       
17β-estradiol       
Estrone       
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Fenofibric Acid       
Gemfibrozil   70%-100%  7.8-3.74  µg/L [42] 
 
   84.9%-95.5%d 0.332 µg/L [84] 
Hydrochlorothiazide   30%-100%  7.8-3.74  µg/L [42] 
 
   34.8%->99.9%d 0.707 µg/L [84] 
Ibuprofen  0%b,c    0.4 µg/L  [57] 
 
52%-99.7%d 89%-99.8%d    [77] 
 
  25%-75%  7.8-3.74  µg/L [42] 
 
74.2%d    .0143-22.7 µg/L [50] 
Iopromide       
Iomeprol       
Iohexol       
Iopamidol       
Lipitor       
Meprobamate        
Metformin        
Metoprolol   60%-100%  7.8-3.74  µg/L [42] 
 
   97%d 0.0046-0.473 µg/L [86] 
 
 1.2%-25.8%a   0.10 µg/L [100] 
 
   37%->88.9%d 0.027 µg/L [84] 
Naproxen  1.7%-28.8%a 
23.0%-86%d 
  0.10 µg/L [100] 
 
   >89%d 0.109 µg/L [84] 
Norfloxacin   85%-100%  7.8-3.74  µg/L [42] 
 
   -47%->78.9%d 0.038µg/L [84] 
Ofloxacin    92.3%-99.7%d 3.594 µg/L [84] 
Paraxanthin       
Progesterone       
Propranol    100%d 0.0144-0.703 µg/L [86] 
 
   78.1%->93.75%d 0.032 µg/L [84] 
Roxithromycin   40%-100%  7.8-3.74  µg/L [42] 
Sotalol    100%d 0.87-1.3 µg/L [87] 
Sulfamethoxazole    65%-92%d 1.2-3.4 µg/L [79] 
 
   58.9%->91.6%d 0.095 µg/L [84] 
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Table 4: Summary of previous studies’ findings on removal efficiencies for selected PCPPs using physical separation processes. 
Testosterone       
Triclosan     67.9%-78.5%d 0.246 µg/L [84] 
 
   78%-83%d 0.246-1.486 µg/L [99] 
Trimethoprim   83%-100%  7.8-3.74  µg/L [42] 
 
   100%d 0.39-0.77 µg/L [79] 
 
   90.4%->97.3%d 0.073 µg/L [84] 
Sertralie (Zoloft)       
a. Lab conditions, single substrate 
b. Multiple substrates, lab conditions 
c. Higher than field-like concentrations, lab conditions 
d. Field-like concentrations and species  
e. RR (Removal Rate) 
PCPPs RR – NF or 
UFe  
RR – MAR 
or 
WTLNDe 
RR – ROe RR – UVe  TiO2/UV Adsorption – GACe Concentration  Author 
Acetaminophen    97%-
100%D 
   1.6-8 µg/L [101] 
 
91%B      0.0908 µg/L [78] 
ASA 86%-90%C      25  µg/L [102] 
 
  100%D    10.25-38 µg/L [101] 
 
 95%-100%B     0.132-5.448 µg/L [103] 
Acebutolol -4%D  62%-82%D 7%D   0.810-9.867  µg/L [86] 
Amitriptyline  70%-100%B     0.341-6.711 µg/L [103] 
Atenolol 85%B      0.2006 µg/L [78] 
 
5%D  89%-99%D 30%D   0.72-0.91 µg/L [87] 
 
  >99%D    0.13-0.33 µg/L [88] 
 
 70%-95%B     3.09-33.106 µg/L [103] 
Atrazine         
Bezafibrate  95%-100%D      [104] 
 
 50%-81%B     0.135-1.391 µg/L [103] 
Bisphenol A   95%-
100%D 
  66%C 0.579 µg/L [99] 
 
      6.1-23 µg/L [101] 
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Caffeine      -10%-80%D 54-120 µg/L [79] 
 
82%-84%C      25  µg/L [102] 
 
     
155.6		1		 !"  10000-15000  µg/L [105] 
 
     93%C 1.519 µg/L [99] 
Carbamazepine 93%B      0.2013 µg/L [78] 
 
     55%-90%D 0.130-0.40 µg/L [79] 
 
24%-28%C      25  µg/L [102] 
 
  >99%D    0.029-0.052 µg/L [88] 
 
  95%-99%D    1.6-2.5 µg/L [101] 
 
     71%-93%B 0.65-0.9 µg/L [92] 
 
 -50%-60%B     0.104-3.11 µg/L [103] 
Celiprolol         
Ciprofloxacin      55%-100%D 0.43-1.10 µg/L [79] 
Codeine   >99%D    0.014-0.02 µg/L [88] 
Diclofenac 97%B      0.1412 µg/L [78] 
 
 60%-95%D      [104] 
 
     75%-100%D 0.14-0.28 µg/L [79] 
 
24%-44%C      25  µg/L [102] 
 
     
63.7		1		 !" 	 10000  µg/L [105] 
 
  100%D    0.125-0.8 µg/L [101] 
 
 -48%-43%B     0.026-1.161 µg/L [103] 
 
   -141%-
35.7%D 
  0.12-0.5 µg/L [95] 
Doxycyclin         
Venlafaxine (Effexor 
XR) 
        
Erythromycin      78%-90%D 0.140-0.480 µg/L [79] 
 
  >99%D    0.005-0.013 µg/L [88] 
 
 -100%-
99%B 
    0.144-10.025 µg/L [103] 
 
 
 
65.4%-79%B  98.6%-    0.135-0.368 µg/L [96] 
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100%B 
 
   6.3%-
45.4%D 
  0.153-0.258 µg/L [95] 
17α-estradiol         
17β-estradiol         
Estrone         
Fenofibric Acid  70%D      [104] 
Gemfibrozil   96%-
100%D 
   0.425-4.1 µg/L [101] 
Hydrochlorothiazide         
Ibuprofen   80%-100%D      [104] 
 
     75%-100%D 3.9-15 µg/L [79] 
 
 52%-72%C     25  µg/L [102] 
 
  97%-
100%D 
   2.5-10.1 µg/L [101] 
 
 85%-98%B     0.968-6.328 µg/L [103] 
 
   51.7%-
87.5%D 
  8.77-15.78 µg/L [95] 
Iopromide  65%-100%D      [104] 
Iomeprol  80%D      [104] 
Iohexol  80%D      [104] 
Iopamidol  25%-80%D      [104] 
Lipitor         
Meprobamate          
Metformin          
Metoprolol 10%D  95%-97%D 15%D   0.0046-0.473 µg/L [86] 
 
  >99%D    0.011-0.018 µg/L [88] 
 
 -5%-65%B     0.039-0.146 µg/L [103] 
Naproxen 78%B      0.1386 µg/L [78] 
 
 70%-95%D      [104] 
 
52%-93%C      25  µg/L [102] 
 
  99%-
100%D 
   1.25-8 µg/L [101] 
 
 58%-90%B     0.4-3.504 µg/L [103] 
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Norfloxacin         
Ofloxacin   >99%D    0.605 µg/L [88] 
Paraxanthine         
Progesterone         
Propranol -28%D  96%D -10%D   0.0144-0.703 µg/L [86] 
 
  >99%D    0.046-0.075 µg/L [88] 
 
 -20%-95%B
 
    -20%-95% µg/L [103] 
 
   6.3%-
45.4%D 
  0.357-0.414 µg/L [95] 
Roxithromycin  85%-98%D      [104] 
 
71.3%-
91.5%B 
 99.2%-
100%B 
   0.134-0.359 µg/L [96] 
Sotalol -4%D  -4%-88%D 11%D   0.87-1.3 µg/L [87] 
 
  >99%D    0.0198-0.051 µg/L [88] 
Sulfamethoxazole 90%B      0.088 µg/L [78] 
 
 5%-98%D      [104] 
 
  >99%D    0.024-0.038 µg/L [88] 
 
     77%-107%B 0.6-0.9 µg/L [92] 
 
 -20%-97%B     0.003-0.274 µg/L [103] 
 
38.6%-82%B  95.2%-
100%B 
   0.085-0.266 µg/L [96] 
Testosterone         
Triclosan       95%C 2.0232 µg/L [99] 
Trimethoprim  80%-90%D      [104] 
 
 40%-80%B     0.46-6.79 µg/L [103] 
 
   D  90%-100%D 0.39-0.77 µg/L [79] 
 
   22.2%-
46.3%D 
  0.388-0.414 µg/L [95] 
 
45.9%-
86.9%B 
 86.4%-
100%B 
   0.015-0.02 µg/L [96] 
a. Lab conditions, single substrate 
b. Multiple substrates, lab conditions 
c. Higher than field-like concentrations, lab conditions 
d. Field-like concentrations and species  
e. RR (Removal Rate), NF (Nano-filtration), UF (Ultra-Filtration), MAR (Managed Aquifer Recharge), WTLND (Wetland), RO (Reverse Osmosis), GAC 
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Figure 1: Comparison of WWTP influent concentrations for all micropollutants.  Note, only 12 compounds exceed the 18ppb limit for phenol as a competitive 
substance.   
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Figure 2: Comparison of RO retentate concentration after 7x concentration of wastewater effluent.  Note, only 18 compounds exceed the 18ppb limit for phenol.     
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Figure 3: Daily influent flow of PCPPs entering a WWTP using 100 MGD Capacity as an example (Mass, lb/d=(Concentration, µg/L)*0.835). 
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Figure 4: Monthly influent mass flow of PCPPs entering a WWTP using 100 MGD Capacity as an example (Mass, lb/month=(Concentration, µg/L)*28.05; 
assuming 30 days per month). 
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Figure 5: Yearly influent mass flow of PCPPs entering a WWTP using 100 MGD Capacity as an example (Mass, lb/year=(Concentration, µg/L)*304.8) 
34 
 
 
Figure 6: Daily effluent mass flow of PCPPs exiting a WWTP using a 100 MGD Capacity as an example (Mass, lb/d=(Concentration, µg/L)*0.835). 
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Figure 7: Monthly effluent mass flow of PCPPs exiting a WWTP using a 100 MGD Capacity as an example (Mass, lb/month=(Concentration, µg/L)*28.05). 
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Figure 8: Yearly effluent mass flow of PCPPs exiting a WWTP using a 100 MGD Capacity as an example (Mass, lb/year=(Concentration, µg/L)*304.8). 
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Figure 9: Influent versus Effluent concentration for Log Kow less than 2.5.  The dashed line is a 1:1 relationship which would indicate that  
what flows into the plant is flowing out of the plant without treatment.  Since the linear trend line demonstrates a slope of 0.1303, there is a clear removal of 
compounds by some process within the plant.   
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Figure 10: Influent versus Effluent concentration for Log Kow between 2.5 and 4.  The dashed line is a 1:1 relationship which would  
indicate that what flows into the plant is flowing out of the plant without treatment.  Since the linear trend line demonstrates a slope of 0.1456,  
there is a clear removal of compounds by some process within the plant.   
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Figure 11: Influent versus Effluent concentration for Log Kow greater than 4.  The dashed line is a 1:1 relationship which would indicate  
that what flows into the plant is flowing out of the plant without treatment.  Since the linear trend line demonstrates a slope of 0.3109, which  
is less than one, there is a clear removal of compounds by some process within the plant.   
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Conclusions 
 
1. Interpretation of previous study results  
 
Previous studies concerning treatment methods for removing PCPPs and the concentrations found 
in conventional WWTPs and the environment revealed that many compounds were recalcitrant.  Generally, 
47 compounds were studied from various classes to gain general insights into the drugs that exist.  First, it 
was examined what was going into the environment from wastewater effluents (see Table 1) and it was 
found that many of the 47 compounds going to the environment were not readily biodegradable.  The 
average concentration in the effluent was around 1.8ppb, so in general the compounds were exiting the 
WWTP at extremely low concentrations.  Many compounds like Atenolol, 17ß-Estradiol, Atrazine, 
Fenofibric Acid, Lipitor Carbamazepine were not very amenable to biological treatment.  Knowing that 
these compounds were not extremely biodegradable, the treatment removal efficiencies of different 
treatment processes were examined.  Many compounds like Atenolol, 17ß-Estradiol, Atrazine, Fenofibric 
Acid, Lipitor Carbamazepine, Ethromycin, Ibuprofen, Metoprolol, Ofloxacin, Propranol, roxithromycin, 
Sulfamethoxazole, and Trimethoprim have been observed to be recalcitrant (see Table 2).  Generally, 
antibiotics, beta-blockers, and psychoactive compounds tend to be poorly removed with conventional 
biological treatment and in some instances further removal can be obtained via MBR processes.  Many of 
the PCPP compounds were poorly removed by biological processes, but were removed with physical or 
chemical processes (see Table 3 and Table 4).  Chemical processes in general were effective for removing 
PCPPs, with the exception of some antibiotics did not respond well to ozone oxidation, and metoprolol was 
not removed by Wet Air Oxidation.  Finally, the physical separation processes appear to be dependent upon 
the concentration added and the properties of the molecules.  For example, beta-blockers such as 
Metaprolol and Sotalol were poorly removed in any membrane process, adsorption, or UV process.   This 
was likely due to the lack of favorable interactions between either the membrane surface or the activated 
carbon surface groups.  Therefore, many of the compounds that were not very biodegradable can be treated 
with physical or chemical processes.  While these methods appear to be effective, many of the studies were 
conducted under laboratory conditions with synthetic waste samples at higher concentrations than would 
normally be found in the effluent.   
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Many of the PCPPs that were present in the WWTP influent and effluent have concentrations in 
the ppt to ppb range, and therefore seem inconsequential in terms of a mass load.  To better understand the 
mass of compounds that on average pass through a plant and the role that concentration can have on the 
potential removal of these compounds, Figures 1-8 were constructed.  Using a readily biodegradable 
compound, phenol, as a comparison, it became apparent that many of these compounds will have a hard 
time competing with other compounds entering a WWTP.  Of the 47 compounds studied, only 12 met or 
exceeded the NPDES or SDWA phenol limit prior to concentration, whereas 18 met or exceeded the phenol 
limit with concentration after RO (see Figure 1and Figure 2).  Higher concentration of these compounds 
provides a higher probability that the compounds will undergo biological degradation.  To provide context 
for the mass flows of compounds of interest, the daily, monthly, and yearly mass flows for each of the 47 
compounds was shown in Figure 3, Figure 4, and Figure 5.  The daily mass load ranged approximately 
from 0.0009 pounds per day for Estrone and 17β-Estradiol to 150 pounds per day for Iomeprol (based on 
100 MGD plant flows).  While the lower end of these values does not seem to constitute a substantial 
contribution, compounding these values yields startling results.  The yearly mass load ranged 
approximately from 0.3285 pounds a year for Estrone and 17β-Estradiol to 54,000 pounds a year for 
Iomeprol.   If compounds were not recalcitrant to biological treatment, then the mass flows to the 
environment should be lower than the influent mass flows.  To provide context for the mass flows of 
compounds of interest, the daily, monthly, and yearly mass flows for each of the 47 compounds was shown 
in Figure 6, Figure 7, and Figure 8.  The daily mass load ranged approximately from 0.0002 pounds per day 
for Estrone, 17α-Estradiol, and 17β-Estradiol to 60 pounds per day for Atenolol and Fenofibric acid.  When 
these values were scaled to a year, significant contributions could be seen.  The yearly mass load ranged 
approximately from 0.07 pounds per year for Estrone, 17α-Estradiol, and 17β-Estradiol to 22,000 pounds 
per year for Atenolol and Fenofibric acid.   Comparing the mass flows on a given day to the effluent mass 
flows, it became evident that compounds are being removed during wastewater treatment.  With all of this 
said, the concentrations that these compounds were entering and exiting the plant (see Table 1) were in the 
ppb to ppt range, but still constitute a sizeable mass flow due to the volumes encountered in WWTPs.  As a 
result, even though the public and policymakers may perceive these compounds as being trace compounds, 
they must still be taken seriously.  Finally, considering that the numbers presented apply to a single 100 
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MGD treatment plant, the mass load of these compounds when averaged across the country becomes 
substantial and helps to explain observed effects such as fish becoming all female downstream of a WWTP 
[20].   
There is a 
fundamental relationship 
between Log Kow and 
solubility, which plays a 
role in PCPPs in a 
WWTP.  Generally, as the 
Log Kow increases, the 
solubility of a compound 
decreases and it becomes more likely that the compound will partition to a solid or surface phase, for 
example sludge solids in a WWTP [106, 107].  Looking at Figure 9, Figure 10, Figure 11, in general PCPPs 
were removed by the conventional WWTP processes.  Table 5 summarizes the removal or concentration of 
compounds as a function of Log Kow.  There were few exceptions to the removal of PCPPs during 
biological wastewater treatment and these exceptions include: Atenolol (Log Kow = 0.161, Effluent:Influent 
ratio (EI) = 2.797), 17ß-Estradiol (Log Kow = 2.45, EI = 5.465), Atrazine (Log Kow = 2.611, EI = 1.019), 
Fenofibric Acid (Log Kow = 5.19, EI = 104.44), and Lipitor (Log Kow = 6.361, EI = 1.017).  These 
compounds become more concentrated rather than being removed during biological treatment.  The 
mechanism by which these compounds become more concentrated in the effluent than in the influent is not 
well understood, but adsorption processes associated with sludge and reversible desorption in a cyclic 
fashion could occur [108, 109].  Additionally, as the Log Kow increased, there was a larger amount of 
chemicals coming out compared to lower Log Kow values (Log Kow<2.5: EI=0.1303, 2.5<Log Kow<4: 
EI=0.1456, Log Kow>4: EI=0.4634).  Therefore, as the Log Kow increases and the molecules become less 
soluble and more hydrophobic, there will generally be a higher concentration of the compound in the 
effluent and the fractional removal will be less.  While the list of PCPPs in this thesis is not exhaustive, Log 
Kow was predictive of the concentration in the effluent and thus, if the Log Kow was known for any PCPP, it 
likely would follow the same general trend as shown in Figure 9, Figure 10, and Figure 11.  As a result, the 
Table 5: Summary of Removal properties based of EI ratio 
 Log Kow <2.5 Log Kow 2.5-4 Log Kow 
>4.0 
Number 
Concentrated 
4 15.4% 1 10.0% 1 12.5% 
Number Removed 20 76.9% 8 80.0% 5 62.5% 
Neither removed or 
Concentrated 
2 7.7% 1 10.0% 2 25.0% 
Note: Concentration occurs when EI>1.2, Removal occurs when EI < 0.8, and 
neither removal or concentration occurs when 0.8 ≤ EI ≤ 1.2  
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larger the Log Kow was the higher likelihood the pollutant will be found in the effluent.  Potential 
mechanisms underlying the removal of these compounds will be explored in subsequent chapters, although 
potential removal processes include: sludge adsorption (irreversible or reversible), biological degradation, 
and biological transformation.   
 
2. Preview and Hypotheses  
 
 This thesis will seek to answer key questions related to biological treatment, adsorption processes, 
the viability of advance treatment processes, and business considerations to remove PCPPs from water.  
The hypotheses are: How does the concentration of these micropollutants affect their ability to be treated? 
How are carbon adsorption and biological treatment affected by competition of other substrates? To what 
extent will current technology allow for their safe removal from discharge sources?  
The remainder of this work will explore methods of removal of PCPPs in depth.  In chapter two, 
biological treatment will be analyzed with and without competitive effects to see if further biological 
treatment will be fruitful.  In chapter three, chemical adsorption will be analyzed with a Freundlich 
isotherm model to determine how its application could aid in the removal of PCPPs.  Finally, in chapter 
four, advanced processes with special consideration for cost will be analyzed to assess their feasibility for 
removal of PCPPs.     
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CHAPTER 2  
 
THE ROLE OF CONCENTRATION ON BIODEGRADATION 
 
Introduction 
 
1. Overview 
Wastewater treatment plants are typically biological based treatment processes.  Wastewater 
treatment seeks to: “reduce BOD, reduce toxics or carcinogens, remove metals, N, and P, and remove 
pathogens” [110].  Biological treatment is a bacteria based processes where the bacteria utilize the 
compounds as substrates for catabolism [106].  In other words, the bacteria feed on organic chemicals that 
make up BOD and reduce it over time [111].  The biological activity occurs via an activated sludge 
process.  ASP involves the oxidation of organic matter, which results in conversion to new cell mass and 
then gravity sedimentation of the bacterial flocks, which separates the biomass from the effluent [110].  In 
the context of a WWTP, ASP constitutes only a portion of the treatment process.   
 WWTPs operate in four definable phases: Screening, Primary treatment, Secondary treatment, and 
Tertiary/Advanced treatment.  First, the screening step occurs at the intake to the plant and its purpose is to 
remove debris that would otherwise disrupt plant operation [106, 110].  Next, primary treatment occurs via 
gravity sedimentation, which removes solids (organic and inorganic) on the basis of size and density [110].  
Afterward, secondary treatment via biological treatment usually consists of an ASP and nutrient removal 
[110].  Disinfection may occur by death of the infectious agents in the ASP and/or post disinfection 
(usually by chlorination [110].  Finally, Tertiary/Advanced (see chapter 4), includes chemical processes 
such as ozonation, advanced oxidation, etc. [110].   
 Within WWTP, authors have reported substantial variation in the removal efficiencies of PCPPs.   
The PCPPs in the influent of WWTPs include: analgesics, antibiotics, anticonvulsants, psychoactive drugs, 
cholesterol-lowering agents, imaging contrast media, and estrogenic compounds [110].  Many of the 
concentrations of these compounds in the influent can easily exceed 1 µg/L, thereby exceeding trace 
amounts, but not enough to make it a dominant species [110].  The removal is a function of secondary 
treatment, filtration, and disinfection, and solid retention time [111].  The effect of this variation on 
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removal efficiency results in many of the effluents containing recalcitrant compounds that are persistent in 
water supplies and potentially contaminate finished drinking water even after treatment [110].  
Additionally, water bodies during dry spells can contain significant contributions of effluent (50-90%) and 
therefore become contaminated with PCPPs [110].   Therefore, the PCPPs enter into the environment, and 
if they are recalcitrant, will be immune to ASP and accumulate in the environment.   
 
2. Literature review  
 
Numerous authors have written about the existence of PCPPs in WWTP influent and effluents, 
along with the subsequent concentrations that are found in the environment see Table 1, page 15).  The 
influent range of PCPPs was between 0.0001 and 70 µg/L, indicating that there is a substantial variation in 
the load of chemicals entering a WWTP.  On the other hand, the WWTP effluents demonstrated a range 
between 0.0002 and 70 µg/L showing that removal was to some degree occurring, but this trend did not 
necessarily hold for every chemical studied.  This effluent discharge results in a mass flow to the 
environment, which, then depending on the characteristics of the compounds, will have an excellent 
reflection in the concentrations found in the environment.  The environmental concentrations observed in 
various studies exhibited a concentration range between 0.0001 to 71. 9 µg/L.   Finally, the removal 
efficiencies for ASP WWTPs and MBR WWTPs are shown in Table 2 (see page 18).  These tables 
demonstrate that many compounds are recalcitrant to conventional ASP WWTPs.  On the other hand, many 
of the compounds that are biologically recalcitrant demonstrate potential for removal in MBR plants.   
Methods 
1. Literature Values and Previous studies 
 
A comprehensive survey of the literature was conducted to ascertain the concentrations of PCPPs 
of interest and their treatability.  140 journal articles were compiled with values for influent, effluent, and 
environmental concentrations (see Table 1).   Of these 140 journal articles, 10 were comprehensive review 
articles that formed the basis of producing the final list of PCPPs.  Minimum and maximum values were 
compiled with measurements being taken within the United States being given preference and non-US data 
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being utilized when US data was not available.  Additionally physical and chemical data concerning 
biodegradiblity, log Kow, and solubility data was estimated in EPISUITES 4.1 [40].    
Additionally, a literature search was also conducted to ascertain the effectiveness of different 
treatment methods currently employed in either lab-scale or in the field.  140 journal articles were compiled 
to determine the minimum and maximum values for each PCPP in a given process (see Table 2, Table 3, 
and Table 4).  By assessing the current practices in the field, it became possible to estimate the removal 
efficiencies for each of the various treatment methods.   
 
2. Probability Plots and Distribution Determination 
 
Probability plots were constructed to determine the distributions of influent, effluent, and 
environmental concentrations; as well, averages of the literature values.  All probability plots were 
constructed in Excel® under the same procedure.  First, the concentrations of interest were rank ordered 
from smallest to largest.  Then a probability was computed by using the formula:  % = '(#	*+	,	*	'(-., 
and taking the normsinv(p) and loginv(p). The obtained values were then plotted with probability (as 
number of standard deviations from the mean) versus concentration (S with two standard deviations from 
the mean), on log normal and normal scales to determine the distribution for each parameter of interest 
(based on curvature and R2 value).   
 
3. Monte Carlo Simulation  
 
In order to study the role of concentration on biodegradation, a Monte Carlo simulation was 
conducted for CSTR and Batch reactors with and without competitive effects due to other substrates.  The 
Monte Carlo simulation was conducted in Microsoft Excel® 2010.  The simulation utilized 1000 trials and 
all variables were subject to the appropriate distributions.  In order to roll the dice for each trial, the 
random() function in Excel® was utilized to generate a probability between 0 and 1 for each of the 
variables.  The dice roll was separate for each of the variables of interest, Km, kd, Y, k, and S2.  To generate 
values for each of these, the normsinv(p) and loginv(p) functions were used with the dice roll for each 
variable in the trial, with the relevant mean and standard deviation (shown in Table 6).  For Km, kd, Y, and 
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k, the values for phenol were used as a surrogated for the compounds of interest due to the wide availability 
of data, and the fact that Phenol is the a relatively biodegradable compound that is frequently found in 
industry and medicine.  Phenol is also well regulated within the current regulatory scheme and as such 
provides an excellent model.  The means and standard deviations were compiled from Magbuana et al., 
which provided an excellent sampling of experimental data and literature values [112].   
Table 6: Constants used in Monte Carlo Simulation for Biodegradation [113] [106] [112]  
 
After extracting the parameters for each of the trials, the competitive and non-competitive trials 
were completed.  The dice were re-rolled for 1000 trials for each of the cases (CSTR and Batch with and 
without competitive effects).  Utilizing the values from the pertinent distributions, values for each of the 
scenarios were found.  First, equation 3k was solved for batch with a non-competitive single substrate 
(phenol).  Then a CSTR was solved with a non-competitive single substrate with / of 1, 2, 5, 8, 10, 12, 14, 
16, 18, and 20 days.  After completing the calculations for the non-competitive cases, the calculations were 
redone to account for competitive effects by solving equations 7j and 8i.  For each of the four scenarios, 
averages and standard deviations were obtained across the 1000 runs, and the average was plotted with two 
standard deviations indicated.     
 
4. Results Analysis 
 
The final results were plotted as a percent of the compound that was removed by biological degradation.  It 
was assumed that the influent, effluent, and environment inputs contained 45, 44, and 38 compounds 
respectively.   
 
 
Constants  mg VSS/ mg Phenol kd, d-1 k, d-1 KM, mg/L S2 mg/L 
Mean 0.85 0.03 4.86 0.63 0.001889* 
Standard Deviation 0.20 0.01 1.94 0.86 0.015625* 
Distribution Normal Normal Log Log Log 
*Values obtained by averaging and standard deviation of all the influent concentrations found 
in Table 1. The 45 pharmaceuticals of interest, therefore form a distribution with a mean and 
standard deviation.  This distribution was log-normal.   
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Biodegradation: Minimum Achievable Substrate Concentration 
 
1. Introduction 
 
When organic compounds biodegrade, a portion of the compound is used for energy to drive 
metabolism of the bacteria; while the other portion is used for growth as a carbon source [113] [106].  That 
is exhibited schematically in Figure 12.   
 
Figure 12: utilization of organic compounds.   
Then, any model of biodegradation must include both substrate utilization and microbial growth.  
Simple first-order biodegradation models without considering active microorganisms is incomplete and will 
yield erroneous results, especially when low substrate concentrations are considered [113].  With respect to 
low concentrations of substrates , a minimum achievable substrate concentration, Smin, is reached when the 
microorganisms can no longer grow faster than they die off, or the growth rate = the death rate (endogenous 
decay) [113].  The values of Smin will depend on the reaction conditions (flow regime) and therefore differ 
between batch or plug flow conditions and continuously stirred conditions (CSTRs).  The equations for 
Smin, can be constructed for each case and are considered in the subsequent sub-sections.   
 
2. Batch Reactor  
 
Beginning with the Monod Model of microbial metabolism and separate rate equations for substrate 
utilization and net microbial growth [113]:  
 
Substrate utilization: 
 
0102 = − 4516 + 1 (1) 
Net Microbial Growth: 
 
0502 = 8 9−0102: − 4;5 = 8 4516 + 1 − 4;5 
                                                      Growth      Death  
(2) 
 
Organic 
Compounds
New Cells 
(growth)
Energy
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Where, X is microbial biomass, Y is the microbial yield coefficient, S is the substrate concentration, k is  
 
the specific substrate uptake rate, kd is the endogenous decay coefficient, and Km is the half saturation  
 
constant.  In order for microorganisms to grow or at least maintain a level of subsistence,  TU2ℎ ≥
2ℎ, or   
 
 84516 + 1 ≥ 4;5 (3a) 
 
And, dividing by X (microbial biomass):  
 
 8416 + 1 ≥ 4; (3b) 
 
Now we can solve for the concentration of substrate needed to support microbial growth, Smin or:  
 
 841,'6 + 1,' = 4; (3c) 
 
Then, rearranging and finally solving for Smin:  
 
 1XYZ 	N84 − 4;Q = 4;6 (3d) 
 [\]^ = _`a\b_− _` (3e) 
 
Also, the batch reactor situation is assumed to be representive of a plug-flow continuous reactor.  
 
 
3. CSTR with Recycle  
For ASPs, the system can be broken down into the aeration basin and clarifation (used to 
segregated/concentrate and recycle biomass).  This leads to several separate considerations in solving for 
the constituents in completely mixed processes.  This is indicated in Figure 13 as the three distinct mass 
balance envelopes that can be considered:  
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Figure 13: CSTR with Recycle.  Three envelopes for mass balance analysis: A) around the aeration basin, 
B) around the secondary clarifier, and C) around the entire system.  Q is flow rate, X is microorganism 
concentration, S is substrate concentration.  Subscripts i indicate influent, r indicates the recycle loop, w is 
the waste biomass and e is effluent.   
Starting with the Aerator (Envelope A),  
 
 c 0502 = d5,' − d5 + de5f + c 84516 + 1 − c4;5 (4a) 
 
Then assuming Xin=0 and dividing by V yields:  
 
 
0502 = −dc 5 +dc e5f + 84516 + 1 − 4;5 (4b) 
 
Assuming steady state conditions (;g; = 0), the equation becomes:  
 
 0 = −dc 5 + dc e5f + 84516 + 1 − 4;5 (4c) 
 
Then, around the entire system (Envelope C), the equation becomes:  
 
 c 0502 = d5, − d5 − di5i + c 84516 + 1 − c4;5	 (4d) 
 
Assuming that Xi and Xe are equal to zero, the equation becomes:  
 
 c 0502 = −di5i + c 84516 + 1 − c4;5	 (4e) 
 
Dividing through by VX and assuming steady state (;j; = 0) yields the equation: 
  
 0 = −di5ic5 + 8416 + 1 − 4; (4f) 
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Where gklgl = /, which is the biomass residence time (amount of time a bacterial cell (the biomass)  
 
resides in the system, on average)  and substituting, then:  
 
 0 = −1/ +
8416 + 1 − 4; (4g) 
 
Rearranging the equation and solving for Smin yields:  
 
 
1/ + 4; =
841,'6 + 1,' (4h) 
 9 1/ + 4;: N6 + 1,'Q = 841,' (4i) 
 841,' = 6 9 1/ + 4;: + 1,' 9
1/ + 4;: (4j) 
 841,' − 1,' 9 1/ + 4;: = 6 9
1/ + 4;: (4k) 
 1,' m84 − 9 1/ + 4;:n = 6 9
1/ + 4;: (4l) 
 
And, finally solving for Smin, 
[\]^ = a\ o
pq + _`r
sb_ − o pq + _`rt
 (4n) 
 
Note, for systems without recycle, such as maybe assumed for a lake, / =  (hydraulic residence time).   
 
 
4. Multiple Substrate competition 
 
Some bacteria utilize more than one substrate in a competitive fashion in order to grow.  The result of this 
is that the previous set of equations must be modified to incorporate the effects of multiple substrates in 
solution [113].  For two substrates, the substrate rate equation may be modified as follows:  
 
 
01.02 = −451.6,. + 1. + 6,.6,v1v (5a) 
 
This may be written as a summation for n-substrates [113] (look for additional reference): 
 
 
01.02 = −451.6,. + 1. + 6,. ∗ Σ,yv' N6,,1,Q (5b) 
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Then, the biomass growth equation may be rewritten, or :  
 
 
05.02 = −8 ∗ 0102  (5c) 
 
05.02 = 8451.6,. + 1. + 6,. ∗ Σ,yv' N6,,1,Q (5d) 
 
 
This equation is then substituted into the equations for batch reactors and CSTRs to derive a multiple 
substrate competitive Monod model.  The Smin values for multiple substrates can be found in a similar 
manner to a single substrate.  This was done using equation 5d by considering S1 as our primary substrate.   
 
5. Multiple Substrate Competition Batch Reactor  
 
In order for microorganisms to grow or at least maintain a level of subsistence,  TU2ℎ ≥ 02ℎ:  
 
 
8451.6,. + 1. + 6N,.Q ∗ Σ,yv' N6,,1,Q ≥ 4;5 (6a) 
 
And dividing by X (microbial biomass),  
 
 
841.6,. + 1. + 6N,.Q ∗ Σ,yv' N6,,1,Q ≥ 4; (6b) 
 
Now we can solve for Smin, or:   
 
841.6,. + 1. + 6N,.Q ∗ Σ,yv' N6,,1,Q = 4; (6c) 
 
Collect S1 on each side:  
 
 841.,,' − 4;1.,,' = 4;6,. + 4; ∗ 6,. ∗ Σ,yv' z6,,1,{ (6d) 
 
Finally, rearranging and solving for S1,min:  
 
 
[p,\]^ = a\,p +a\,p ∗ |]y}^ za\,][]{b__` − p
 (6e) 
 
 
6. Multiple Substrate Competition CSTR with recycle 
 
Beginning with the same configuration in Figure 13, the analysis begins with the aeration basin (A),  
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c 0502 = d5,' − d5 + de5f + c 8451.6,. + 1. + 6N,.Q ∗ Σ,yv' N6,,1,Q − c4;5 (7a) 
 
Then assuming Xin=0 and dividing by V yields:  
 
 
0502 = −dc 5 + dc e5f + 8451.6,. + 1. + 6N,.Q ∗ Σ,yv' N6,,1,Q − 4~5 (7b) 
 
Assuming steady state conditions (;j; = 0), the equation becomes: 
 
 
0 = −dc 5 + dc e5f + 8451.6,. + 1. +6N,.Q ∗ Σ,yv' N6,,1,Q − 4~5 (7c) 
 
Then, around the entire system (C), the equation becomes:  
 
 
c 0502 = d5, − d5 − di5i + c 8451.6,. + 1. + 6N,.Q ∗ Σ,yv' N6,,1,Q − c4;5	 (7d) 
 
Assuming that Xi and Xe are equal to zero, the equation becomes:  
 
 
c 0502 = −di5i + c 8451.6,. + 1. + 6N,.Q ∗ Σ,yv' N6,,1,Q − c4;5 (7e) 
 
Dividing through by VX and assuming steady state (;j; = 0) yields the equation: 
 
 
0 = −di5ic5 + 841.6,. + 1. + 6N,.Q ∗ Σ,yv' N6,,1,Q − 4; (7f) 
 
Where gklgl = /, which is the mean cell residence time (amount of time a bacteria resides in the system,  
 
on average)  and substituting, then: 
  
 
0 = −1/ +
841.6,. + 1. + 6N,.Q ∗ Σ,yv' N6,,1,Q − 4; (7g) 
 
Rearranging the equation and solving for S1,min yields:  
 
 
1/ + 4; =
841.6,. + 1. +6N,.Q ∗ Σ,yv' z6,,1,{ (7h) 
 841. = 9 1/ + 4;: ∗ o6,. + 1. +6N,.Q ∗ Σ,yv' z6,,1,{r (7i) 
 841. = 9 1/ + 4;: ∗ 6,. + 9
1/ + 4;: ∗ 1. + 9
1/ + 4;: ∗ o6N,.Q ∗ Σ,yv' z6,,1,{r (7j) 
 841. − 9 1/ + 4;: ∗ 1. = 9
1/ + 4;: ∗ 6,. + 9
1/ + 4;: ∗ o6N,.Q ∗ Σ,yv' z6,,1,{r (7k) 
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 1. ∗ 984 − 1/ − 4;: = 9
1/ + 4;: ∗ 6,. + 9
1/ + 4;: ∗ o6N,.Q ∗ Σ,yv' z6,,1,{r (7l) 
 1.,XYZ = o
1/ + 4;r ∗ 6,. + o 1/ + 4;r ∗ o6N,.Q ∗ Σ,yv' z6,,1,{r
84 − 1/ − 4;
 
(7m) 
 [p, = a\,p ∗ o
pq + _`r ∗ op + |]y}^ za\,][]{r
b_ − pq − _`
 
(7n) 
 
Note, for systems without recycle, such as maybe assumed for a lake, / =  (hydraulic residence time).   
 
A summary of the equations derived for the minimum substrate concentrations is presented in Table 7.   
 
Table 7: Summary of derived minimum substrate equations for various reactor types 
Type of 
Reactor Smin w/o competition Smin with competitive effects 
Batch 1,',
 = . (eq. 3e) 1.,,' =
,-∗ z,	{.
 (eq. 6e) 
CSTR with 
recycle 1,',
 = o
-(r(o -(r
 (eq. 4n) 1.,XYZ = ,∗o -(r∗o.- z,	{r( (  (eq. 7n) 
CSTR 
without 
recycle 
Eq. 4n;  = θ Eq. 7n;  = θ 
Results 
Utilizing Monod kinetics and accounting for competitive effects during Monte Carlo simulation, 
the results are presented in the sections which follow.  The first set of results obtained examined the 
distribution of results obtained in batch, CSTR, and literature review data to determine the underlying 
distributions of values.  These values were crucial to the modeling exercise, since utilizing competitive 
effects creates a dependence on the concentration of the other substrates in solution.  Therefore, this 
concentration and distribution must be determined in order to proceed.   
Probability Plots 
 Utilizing data that was compiled from the literature search, probability plots for the influent, 
effluent, environmental, and average concentrations of PCPPs were compiled (see Figure 14, Figure 15, 
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Figure 16, and Figure 17 respectively).  The average and the minimum and maximum concentration for the 
compounds examined demonstrated that log-normal distributions were reasonable fits for influent, effluent, 
and environmental concentrations with R2 values of 0.8884, 0.9655, and 0.917 respectively.  As a result, 
the influent case (Figure 14), was utilized as the basis of the competitive average and standard deviation 
values, and was assumed to be log normal.     
 Once the Monte Carlo simulation results were obtained, probability plots of the Smin for both batch 
and CSTR (see Figure 18, Figure 19), with and without competition, revealed log-normal distributions were 
a reasonable fit (visual linearity and R2 > 0.9).  This was expected, since most of the inputs were log-
normally distributed.   
 
Figure 14: Influent probability plot demonstrates generally a log-normal distribution for all three sets of 
data, i.e. minimum, average, and maximum concentrations detected (data from a variety of sources, see 
Table 1).   
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Figure 15: Effluent probability plot demonstrates generally a log-normal distribution for all three sets of 
data, i.e. minimum, average, and maximum concentrations detected (data from a variety of sources, see 
Table 1).   
 
Figure 16: Environmental concentration probability plot demonstrates generally a log-normal distribution 
for all three sets of data, i.e. minimum, average, and maximum concentrations detected (data from a variety 
of sources, see Table 1).   
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Figure 17: Average probability plot demonstrates log-normal distributions for the averaged values for the 
influent, effluent, and environmental concentrations compiled from a literature search.   
 
Figure 18: Smin batch reactor probability plot demonstrates log-normal distributions for the values obtained 
by 1000 trials for both competitive and non-competitive cases.     
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Figure 19: Smin CSTR reactor with a  of 5 days probability plot demonstrates log-normal distributions 
for the values obtained by 1000 trials for both competitive and non-competitive cases.     
 
Non-Competitive Kinetics  
 
When competitive effects are disregarded, an idealized case is modeled where a single substrate is 
being consumed by a bacterial species without regard to the other organic and inorganic compounds that 
would be present in the influent of a WWTP.  The results displayed in Figure 20, represent the most 
optimal case for determining the substrate concentration necessary for the rate of bacterial growth to equal 
the bacterial death rate.  If this concentration is not exceeded, then the bacterial counts will dwindle and 
further utilization of the substrate will cease.   
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Figure 20: Minimum substrate concentrations Smin, for batch and CSTR reactors without competition.  
Non-competitive phenol degradation demonstrates a substantially lower minimum concentration for plug 
flow reactors than CSTR reactors.  The range of operating parameters in a WWTP shows that the minimum 
necessary concentration for a substrate decreases with increasing MCRT (based on Monte Carlo simulation 
of equations 3e and 4n, using phenol as a surrogate substrate, and parameters listed in Table 6).  Note: the 
shaded region of this figure is one standard deviation from the average.   
 In terms of a typical WWTP, MCRT is one of the dominant variables that can be controlled by the 
operators of the plant.  This parameter has a drastic effect on the minimum substrate concentration 
necessary to sustain bacterial growth.  Utilizing the range of MCRTs that are typical for WWTP operations 
(5 to 20 days), demonstrates that the minimum concentration necessary to maintain bacterial counts varies 
between 37 ppb to 13 ppb for MCRTs of five and twenty days respectively. This means that in order for a 
PCPP to be potentially biodegraded, it must exceed this level in the influent.  On the other hand, the plug 
flow reactor demonstrates a small range of Smin with an average of 4.47 ppb with a standard deviation of 
2.23 ppb.  One might also note that the batch or plug-flow results appear to be the limit for the CSTR 
(CSTR→PF as Ɵc → ∞).  There is no dependence on the MCRT in the plug flow case, but it is interesting 
to note that the Smin is substantially lower than in the CSTR case.  The significance of this is that a few 
more compounds than in the CSTR case maybe biodegraded due to the lower minimum concentrations.  
Very few of the compounds included in this study have influent concentrations that exceed the Smin values 
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predicted in Figure 20.  As a result, within most WWTPs, biological degradation is not expected to a large 
extent.  If these compounds were concentrated to sufficient levels to maintain bacterial growth, they could 
then be potentially biodegraded and would become an attractive substrate for the bacteria.  Additionally, 
the US EPA priority pollutant limit intersects the average CSTR minimum concentration with a mean cell 
residence time of 13 days for CSTR and the minimum for the batch reactors are always lower than the limit 
for phenol.  The implications of this is that the effluent that is leaving most facilities regulated by NPDES 
permits will not  exceed the median MCRT for CSTRs and as a result, will most likely not undergo any 
further biological degradation.  Also, any species in the influent that are below Smin will tend to be 
outcompeted by the higher concentration substrates. This helps to explain the phenomena of some PCPPs 
that are in the ppt range that simply pass through the plant.   
Unfortunately, real world conditions do not involve a single substrate with a single bacterial 
species.  Waste streams entering a typical WWTP are complex mixtures of compounds and bacteria, 
necessitating that competition will occur and the highest concentration substrates will be preferentially 
degraded.   
Competitive Kinetics 
When competitive effects are taken into account, a more realistic case is modeled where multiple 
substrates are competing to be consumed a bacterial species. This competition would occur due to the 
complex nature of the organic compounds that are present in the influent of a WWTP.  Therefore, the 
results obtained in Figure 21, represent a more realistic case for determining the bacterial concentration 
necessary for the degradation of a single substrate of minimal concentration to occur.  If this minimum 
concentration is not met, then the bacterial counts will dwindle and biodegradation will cease.   
 In terms of a typical WWTP, the MCRT is one of the dominant variables that can be controlled by 
the operators of the plant.  This parameter has a drastic effect on the minimum concentration necessary to 
sustain bacterial growth.  Utilizing the range of MCRTs that are typical for WWTP operation, modeling 
demonstrates that the minimum concentration necessary to maintain bacterial counts varies between 65 ppb 
to 13 ppb for MCRTs of five and twenty days respectively. Additionally, the US EPA priority pollutant 
limit never intersects the CSTR range.  On the other hand, the plug flow reactor demonstrates a small range 
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of Smin with an average of 7.58 ppb with a standard deviation of 2.36 ppb.  There is no dependence on the 
MCRT in the plug flow case, but it is interesting to note that the Smin is substantially lower than in the 
CSTR case.  The implications of this is that the effluent that is leaving most facilities regulated by NPDES 
permits will not  exceed the median MCRT for CSTRs and as a result, will most likely not undergo any 
further biological degradation.  Also, any species in the influent that are below Smin to begin with will tend 
to be outcompeted by the higher concentration species. This helps to explain the phenomena of some 
PCPPs that are in the ppt range that simply pass through the plant.   
 
Figure 21: Minimum substrate concentrations, Smin, for batch and CSTR reactions with competitive 
substrate effects.  Competitive degradation demonstrates a substantially lower minimum concentration for 
plug flow reactors than batch reactors.  The range of operating parameters in a WWTP shows that the 
minimum necessary concentration for a substrate decreases with increasing MCRT (based on Monte Carlo 
simulation of equations 6e and 7n, using phenol as a surrogate substrate, and parameters listed in Table 6).   
Discussion 
 Biological degradation of any organic molecule is a function not only of the type and amount of 
bacteria present within the culture, but also, the concentration and number of chemical substrates that are 
present within the wastewater.   Within WWTP influents, there are thousands of compounds that will 
eventually be competing for different bacteria that will specifically digest them.  While a single bacteria 
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species will not digest all of these compounds, there will be multiple compounds that are most likely 
competing to be the substrate of choice for that particular bacterial species.  As a result, the modeling 
exercise demonstrates that adding just one more competitive substrate means that the minimum 
concentration necessary for degradation must increase and almost double (equal concentrations or equally 
competing substances).  This means that only compounds that are present in the highest concentrations will 
be effectively degraded biologically.  Therefore, in order for a PCPP to be potentially biodegraded, it must 
be present in the influent at a sufficient level to be preferentially degraded.   
Accounting for competitive effects amongst species increased the necessary minimum 
concentration substantially by adding one competitive substrate into the reactor.  It is important to note that 
these concentrations with two substrates competing results in approximately a 75% increase in the 
minimum concentration of that substrate for a CSTR and a 70% approximate increase for batch/plug flow 
reactors. This indicates that as more substrates are considered to be competing for the same bacterial 
species (a more realistic scenario); there will be a further increase in the minimum concentration of the 
compounds to allow bacterial colonies to be maintained.  In the context of WWTP influent, there will be 
scenarios where there are more than two substrates competing for a bacterial species, which would produce 
an underestimation of the minimum concentration by the model.  Additionally, different kinetic parameters 
(Km, k, and kd) for each substrate will affect the relative contribution of that substrate to raising 
competitively the overall minimum concentration for another substrate.  This will become crucial as not all 
substrates will have to meet the same minimum concentration, and will instead be based upon what other 
substrates are present and competing for that bacterial species.   
 If the 45 compounds that were considered for this study are considered at their influent 
concentrations, less than 10% of those compounds would be even potentially biologically degraded (see 
Figure 22).  This assumes that the maximum concentration of that compound is present and that the 
minimum substrate concentration is utilized to produce the most optimal result.  This will not necessarily 
be the case for a WWTP where more than two substrates maybe competing for the same bacterial species.  
The general result shows that as more species are added, the minimum concentration necessary for 
biological degradation increases. As a result, due to the complex nature of the waste stream entering a 
WWTP, there will rarely be an optimistic case where a single substrate is interacting with a single bacterial 
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species.  Even if the most optimistic case is assumed, a compound would need to be present within the 
influent waste stream above the Smin (13-37 ppb depending on MCRT).  Very few of the compounds in this 
study fit within those parameters (less than 20%).  Then, either the biokinetic parameters are more 
favorable than those used as a surrogate, i.e., k > kphenol or Km < Km,phenol, or for many PCPPs there must be 
other processes occurring within the treatment plant that remove these compounds.     
 
Figure 22: Utilizing the best case scenario of non-competitive kinetics; most WWTPs behaves as a CSTR 
and very few of the compounds of interest are present in the influent at a sufficient concentration to 
undergo further biodegradation.  Removal of the 45 selected compounds of analysis demonstrates that in 
terms of a CSTR less than 18% of the 45 will be removed, while in the batch case fewer than 55% will be 
removed.  This finding is crucial, since it demonstrates that removal of any species is very dependent upon 
the concentration of that species present in the inflow.  As a result, at best less than 18% of the PCPPs 
would be removed if only two species were in competition with one another.   
Membrane Biological Reactor, MBRs 
It should be noted that MBRs are a special class of bioreactors, operated as a CSTR with a 
membrane to restrict the flow of solids (biomass) in the final effluent.  This implies that MBRs can operate 
at higher MCRTs, and then, the results for MBRs would be more similar to batch reactors (MCRT > 20 
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days).  Data from the literature (see Table 2, page ) entirely supports this view, showing lower effluent 
concentrations of PCPPs than CSTRs for many substrates of interest.    
Conclusions 
Biological degradation can only account for a small portion of the removal that is witnessed within 
a WWTP.  Potential removal mechanisms for substrates that are substantially lower than the minimum 
substrate concentrations modeled are sludge adsorption (either reversible or irreversible) [114], chemical 
transformation as a result of the employed treatment process, hydrolysis, or photolysis [115].  While there 
may be other processes occurring within the WWTP, further studies must be conducted to ascertain the 
exact fate and transformation of these PCPPs.  However under normal circumstances, it is unlikely that the 
fate can be readily understood and quantified due to the difficulty and expense of measuring these 
compounds and their reaction byproducts within the plant.   
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CHAPTER 3  
 
THE ROLE OF CONCENTRATION ON ADSOPRTION PROCESSES 
 
 
Introduction 
 
1. Adsorption Overview 
 
There are two different types of sorption processes that can occur, either as as reversible or 
irreversible reactions.  First, absorption is defined by, the substance being drawn in, and is integrated into 
the absorbent [106, 116, 117].  Conceptually, this process can be demonstrated with a sponge that is 
compressed and then immersed in water, and when the sponge is released, the water becomes a part of the 
sponge.  The second process is adsorption and occurs when the sorbate binds to the surface of the absorbent 
[106, 116, 117].  Conceptually, any chemical that could bind to the surface of the sponge and not enter the 
matrix space would be considered to be adsorbed (e.g. grease).  For the purposes of this study, adsorption is 
of interest and is the driving force governing the potential removal of pollutants.  There are two different 
types of processes that govern adsorption process: 1) physisorption which occurs as a result of Van der 
Walls forces or other weak attractive forces between the adsorbent and the sorbate and 2) chemisorption 
which occurs as a result of chemical bonding or reaction between the adsorbent and the sorbate [106, 116, 
117].   Physisorption, or physical adsorption, is reversible whereas, chemisorption is the irreversible 
transformation of solute catalyzed by the surface of the adsorbent [106, 116, 117].   
Reversible processes are characterized by “adsorption isotherms” and numerous models have been 
developed to describe the behavior of the adsorbent and adsorbate.  Isotherms are a graph of the amount of 
adsorbate that has adsorbed onto the adsorbent as a function of the gas pressure or concentration of the 
adsorbate at a constant temperature [106, 116, 117].  The shape of the isotherm led to the development of 
different models to describe the empirical data.  The primary isotherm models are linear, Langmuir (BET is 
a generalization of this model), and Freundlich [106, 116, 117].  The shapes of each of these models vary: 
the linear model does not reach a maximum whereas the Langmuir model eventually reaches a maximum 
value (noting that this is rarely observed in the lab unless high concentrations are utilized [106, 116, 117].  
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The Freundlich model’s shape is depended on the sorbate concentration to some power, n, where: if it is 
equal to one produces a linear graph, if it is less than one resembles an inverse exponential curve shape, and 
if n is greater than one, resembles an exponential curve shape [106, 116, 117].  Selection of a model is 
dependent upon inherent assumptions for each model, but for PCPPs and micropollutants, the most 
common model applied is the Freundlich.   
There are numerous types of adsorbents each with different applications and properties with the 
most common being activated carbon.  Good adsorbents have a large exposed surface area and the more 
surface area exposed, the better the adsorbent [118].  Commonly encountered adsorbents are shown in 
Table 8 below.   
Table 8: Common Adsorbents Utilized in Industrial, Chemical, Commercial, and WWTP Processes  
Natural  
Peat Adsorbs more than lignite…compaction in the earth from Peat->Lignite->Coal 
decreases surface area, thereby decreasing the adsorption capacity  
Lignite Formed by decaying of biological material via biochemical and geochemical 
processes 
Fuller’s Earth Sedimentary clay or clay like material  
Bentonite Impure clay composed mainly of montmorillonite.  Many different types, but 
named after predominate element (K, Na, Ca, or Al) 
Synthetic and 
Chemically Modified  
 
Activated Carbon Carbon chemically processed to increase surface area   
Bone Char Produced by charring bone, have lower surface area than AC 
Activated 
Alumina 
Manufactured from aluminum hydroxide  
Silica Gel Granular and porous form of SO2 made from silicate 
Bauxite Aluminum ore that can be chemically modified into an adsorbent  
Molecular Sieves Zeolite metal aluminosilicates - Composed of porous aluminosilicate 
frameworks of SiO4 and AlO4 
Chitosan  Made by chemically treating shrimp and other crustacean shells 
Ion Exchange 
Resins  
Synthetic organic polymer substrates that are formed into a bead matrix.  Four 
different functional groups: 1) strongly acid, 2) strongly basic, 3) weakly acidic, 
and 4) weakly basic 
Source: [118] 
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One of the most utilized adsorbents in industrial and chemical processes is activated carbon.  It is 
composed of a graphite lattice and can be produced relatively inexpensively [118, 119].  Activated carbon 
can come from any carbon containing substances, but it commonly is derived from: coal, peat, wood, or 
coconut shells [118, 119].  Also during the production process, the surface of the adsorbent can readily be 
modified in many instances to allow for adsorption in the desired application.  Finally, activated carbon has 
been shown to effectively adsorb organic substances and non-polar substances making it suitable as a 
potential treatment technology for micropollutants [118, 119].   
 
2. Derivation of Freundlich Model  
 
The Freundlich Isotherm model was first proposed in 1909 as an empirical equation that fits a 
curve of adsorption density (sorbate/sorbent) to the concentration of solute in the liquid or gas pressure at 
equilibrium.   Traditionally, the equation has been treated as an empirical equation, but Weber 
demonstrates that the Freundlich model is a special case of Gibbs Surface Energy [117, 120, 121].    
Beginning with Γ, Gibbs surface excess,  
 Γ =  = − "e 0
°
0" (2a) 
or, 		 = "e
° − d°
00" (2b) 
 
Where:  is amount of sorbate absorbed to the adsorbent surface, "  is the solution equilibrium 
concentration, ° is the initial surface tension of the pure solvent, and ° is the surface free energy.  The 
surface free energy is given by:  
 
 ° = °z1 − ° { + 	°°  (2c) 
 
Where is ° the fractional surface coverage.  Integrating the previous equations yields: 
 
 lnNQ = ed°° −  lnN"Q + ln6 (2d) 
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Which reduces to the Freundlich equation if,  = fk°°, or:  
 
   = a¡ p^ (2e) 
or,   = a¡ ^  (2f) 
 
One limitation of the derivation shown above is that the surface excess being equal to the , is only valid 
when there are “high surface concentrations and low residual concentrations of solute in solution” [117, 
120, 121].  Equation 2e can be further modified by substituting   = ¢¢~  and taking the log of both sides 
yielding:  
 £¤¥ 9¦ − §¦ : = £¤¥za¡{ +
p^ £¤¥N Q	 (2f) 
 
 
3. Derivation of Competitive Freundlich Model 
 
The Freundlich isotherm, derived in the previous section, was a useful tool when a single 
component was of interest, but this was rarely the case in situations outside of the laboratory setting.  
Therefore, a multicomponent isotherm model was required to understand the effects of competitive 
substances in solution and how they affect one each other’s ability to adsorb.  A multicomponent isotherm 
was proposed by Sheindorf and Rebhun in 1981 and has become known as the SRS equation [122].  In 
order to derive a multicomponent isotherm, each component must be assumed to follow the Freundlich 
isotherm.  The SRS equation can be derived by starting with an exponential distribution of adsorption 
energies,  
 ,¨NdQ = ©,'kf  (3a) 
  = 1,… , 4 (3b) 
 
Where, Ni(Q) is the number of sites having adsorption energy Q.  To be able to arrive at a Freundlich 
model, a competitive Langmuir model can be utilized as a starting point.  Then, the surface coverage at 
every energy level can be described by, 
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, = «,",,1 + Σ¬y.( «¬",¬ (3c) 
 «, = «, kf (3d) 
 
Where, bi is the adsorption coefficient, which varies with the adsorption energy for that particular 
component.  From here, if there is an incremental increase dQ in Q, then it becomes possible to find 
fraction of the total sites that have that range of adsorption energy, or:  
 0Θ,NdQ = Θ,NdQ ,¨NdQ0d (3e) 
 
Integrating equation 3e from negative infinity to positive infinity, allows for the total coverage by sorbate i 
to be found: 
 
Θ, = ® «,
kf",,
1 + Σ¬y.( «¬ kf",¬
∗ ©,'kf 0¯¯  (3f) 
 Θ, = ©,e«,, 	"+zΣ¬y.( «¬"¬{
'.
 
(3g) 
Simplifying where, 6°,, = ©,e«,' and ©,¬ = ±, which is the competition coefficient.   The final form of 
the multicomponent isotherm is given by,  
 ] = a²,]] 	o|³yp_ z´]³³{r^]p (3h) 
 
And solving for one of the components in a bi-solute solution yields,  
 
 p = a²,ppNp + ´p}}Q^pp (3i) 
 
This model does collapse down to the original Freundlich monocomponent isotherm equation if, C2=0,  
 
 . = 6°,.". ∗ N". + ©.v ∗ 0Q'. (3j) 
 . = 6°,."..-'. = a²,pp^ (3k) 
 
 The multicomponent isotherm was useful for describing the behavior of numerous sorbates in solution but 
does presuppose that the competition coefficient can be found for each species interacting with one another.   
When competition occurs under isothermal conditions, the competition coefficient approaches unity and if 
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they compete equally with one another, then ©.,v = 1.  In this study, it will be assumed that any mixed 
sorbates will be equally competitive.   
 
4. Literature Review  
 
 Generally, adsorption of organic substances like PCPPs, has been previously reviewed and has 
demonstrated good removal of many of these compounds.   Removal efficiencies were compiled during a 
comprehensive literature review conducted in the first chapter of this work (See Table 4, page 25).  The 
papers reviewed were restricted to GAC, however, the type of GAC differed in most cases.  These authors 
demonstrated a wide variation in removal efficiencies of compounds with a few general trends observed.  
First, when higher than field like conditions (ppb concentrations) were utilized, substantially better removal 
was observed  than when field like conditions were utilized, removal in many cases was dependent upon 
what else was in the samples and whether or not the compound was readily removed.   For example, many 
studies utilized field-like conditions and showed excellent removal, but conducted their experiments in 
distilled water instead of wastewater or synthetic wastewater.  As a result, the competition effects that 
would be present in synthetic wastewater and wastewater were not evaluated.  Second, the papers 
demonstrate a potential for removal of certain PCPPs while a substance like caffeine, exhibited a wide 
range of removal from -10% to 80% [99].  Adsorption processes appear to be mediated by the presence or 
lack of hydrophobic interactions with the surface of the adsorbent [123].  While this explains a portion of 
the behavior, the surface groups of activated carbons may also undergo electrostatic interactions to adsorb 
the sorbate [123].  While both of these explanations are common in literature, the exact mechanism of 
adsorption of PCPPs is still not well understood and will require further research to explain the phenomena 
described in peer-reviewed literature.   
Adsorption has been well addressed by various authors but studies tend to be restricted to one to a 
few compounds in solution.  Some of the most important PCPPs to be removed due to their potential are 
estrogenic compounds.  Novel materials have been utilized for the adsorption of Bisphenol A and 17α-
Ethinyl Estradiol with single-walled carbon nanotubes (SWCNT), which demonstrated a high adsorption 
capacity and hysteresis for both compounds [124].  Another estrogen derivative, 17-ß Estradiol, was tritium 
labeled (able to detect down to 1.36 ng/L) and demonstrated removal efficiencies of 95% from pure water 
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and raw water samples [125].  While some estrogenic compounds are absorbable, another estrogenic 
compound nonylphenol was poorly adsorbed due to high log Kow [126].  Like estrogenic compounds, 
Naproxen and carbamazepine removal appears to be a function of hydrophobicity and as log Kow increased, 
the compounds became less and less adsorbed [126].  Additionally, caffeine was adsorbed in a dose 
dependent fashion, whereas diclofenac was not efficiently adsorbed [105].  Therefore, at least for 
estrogenic and other pharmaceutically active compounds, one predictor of adsorption density of a particular 
compound is log Kow.  Another set of compounds of interest are antibiotics.  Unlike estrogenic and other 
pharmaceutically active compounds, one of the most important factors in the removal of antibiotics is pH.  
For trimethoprim, the Toth isotherm describes the adsorption behavior better than the Freundlich isotherm 
and adsorption capacity appears to increase with decreasing pH [127].   Sorption is dependent upon pH, and 
at acidic pHs the surface charge of the sorbents and ionization of sorbate help to drive the adsorption 
process [128].  While activated carbon is a useful adsorbent, adsorption of nalidixic acid onto resin is vastly 
superior.  This is due to the fact that the aromatic ring forms key bonds with neutral and anion-exchange 
polymers to allow adsorption to occur [129].  Additionally, below the pKa of the nalidixic acid, neutral 
aromatic polymer matrices are better suited to removing the compound [129].  Therefore, for antibiotics, 
pH appears to be the dominant variable controlling absorption.   
While numerous authors have published papers on the adsorption of phenolic compounds, there is 
not a wide body of literature available with constants for modeling and predicting the behavior of PCPPs.  
As a result, the adsorption of phenolic compounds were used as a surrogate for PCPPs. Phenolic 
compounds are among the most well characterized compounds in the literature.  Additionally, there is a 
large body of literature available that allow for the collection of a broad range of constants with a high 
degree of certainty that their values are accurate.  The values from various studies are shown in Appendix I 
(see page 117).  Numerous types of adsorbents have been examined, but activated carbons are the most 
common, along with bentonite.  Phenolic compounds are well studied and the parameters for Freundlich 
isotherms can have large variations: Phenol (Kf: 0.008-89.43, n: 0.037-3.84615) [130, 131, 132, 133, 134, 
135, 136, 137, 138, 139], 2-Chlorophenol (Kf: 0.566-169.2, n: 0.286-28.57143) [132, 140, 141, 137], 4-
Chlorophenol (Kf: 0.03458-101.504, n: 1.873-3.737) [132, 142, 137], Dichlorophenol (Kf: 1.75-220.9557, 
n: 0.144-3.925) [132, 136, 137], Trichlorophenol (Kf: 2.965-588.7, n: 0.1512-6.821) [132, 143, 136, 137], 
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Pentachlorophenol (Kf: 14.12-31.33, n: 2.132-3.236) [132], and P-Nitrophenol (Kf: 0.0302-166.5, n: 
0.1494-4.235) [141, 142, 136].  This wide degree of variation demonstrates that a single set of values 
cannot be utilized.     
Methods 
1. Literature Values and Previous Studies 
 
A comprehensive survey of the literature was conducted to ascertain the concentrations of PCPPs 
of interest and their treatability.  140 journal articles were compiled with values for influent, effluent, and 
environmental concentrations (see Table 1).   Of these 140 journal articles, 10 were comprehensive review 
articles that formed the basis of producing the final list of PCPPs.  Minimum and maximum values were 
compiled with measurements being taken within the United States being given preference and non-US data 
being utilized when US data was not available.  Additionally physical and chemical data concerning 
biodegradiblity, log Kow, and solubility data was calculated in EPISUITES 4.1 when citations were not 
available in EPISUITES 4.1 [40].   From this data, probability plots were constructed to determine standard 
deviations for use as parameters for modeling.   
Additionally, a second literature search was conducted with respect to Freundlich models for the 
removal of Phenol by Activated Carbon adsorption.  This literature search revealed 45 articles and these 
values were compiled.  All of these papers were selected to have GAC as their adsorbent, although there 
was some variation on the type of GAC across these papers.  In order to compare the values obtained from 
these papers, the units of Kf were converted to a single set of unified units (see Appendix I, page 115).    
Finally, Phenol was chosen as a surrogate for the removal of PCPPs, since it is the most studied 
environmental contaminant, has similar properties to the PCPPs of interest, and represents a compound that 
readily participates in the adsorption process.   
 
2. Probability Plots, Statistical Analysis, and Distribution Analysis  
 
All distribution fitting was conducted with EasyFitXL Professional 5.5, produced by Mathwave 
Data Analysis and Simulations (http://www.mathwave.com/en/home.html).  This program is able to test the 
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fit of 55 different probability distributions (see Appendix II, page 120) and provides recommendations on 
the best fit to utilize the data provided.  In order to recommend the best distributions that fit the inputted 
data, EasyFitXL utilizes three goodness of fit models (Komogorov Smirnov, Anderson Darling, and Chi-
Squared).  With each distribution, and goodness of fit test, the program determines whether the distribution 
fits given a significance value (©) of 0.2, 0.1, 0.05, 0.02, and 0.01.  In the event that the best distribution fit 
does not have significance at any of the values, the top distribution is still assumed to be acceptable if it is a 
visual fit.   Finally, all statistical analysis such as mean, standard deviations, and p-values were found with 
the built in functions specific to the distribution selected.  The final output for choosing distributions for 
each set of data can be found in Appendix III (see page 121).   
 
3. Modeling Exercise 
 
In order to accomplish the modeling portion of the exercise, Matlab R2012a was utilized to 
construct an algorithm based on Freundlich adsorption (eqn. 2f).   The program was created to solve 
equation 2f, where: C is the equilibrium concentration, C0 is the initial concentration, D0 is the carbon dose, 
1/n and Kf are constants from the adsorption isotherm graph [116, 117].  The final program is shown in 
Appendix IV (see page 151).  It should be noted that the initial version of this program decoupled n and Kf 
and generated separate distributions for these variables, but this was not statistically valid.  The program 
was run for the 10%, 50%, and 90 percentiles for the influent concentration to the adsorption process.  For 
each one of these concentrations, 45 different runs were performed corresponding to each paired set of n 
and Kf values from the literature.  These values were also run at one specific carbon dosage and the process 
was repeated for carbon doses of 0.01, 0.1, 0.2, 0.5, 1, 2, 4, 6, 8, 10 g/L.  To plot each data point, the 
distribution for a certain carbon dose at a specific influent percentile was evaluated in EasyFitXL with the 
same procedure as described in the previous section.  After each distribution was found, the mean and 
standard deviation for that specific set of runs (n=45), allowed for one data point to be plotted.  This 
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process was then repeated for the next carbon dose at a specific influent concentration.  After modeling was 
completed, these points were then connected to create a relationship between carbon dose and the influent 
concentration.  It should be noted that the original model decoupled Kf and n values and created random 
distributions for each that were not statistically appropriate.  To have any significant results, Kf and n must 
be coupled together.  Finally, probability plots were all constructed with Matlab’s built in statistical tool 
box with the distributions found for each set of points.    
 
4. Competitive Freundlich Isotherm  
 
In order to study the role of competitive effects on adsorption density, a Monte Carlo simulation 
was conducted for a multicomponent isotherm.  The Monte Carlo simulation was conducted in Microsoft 
Excel® 2010.  The simulation utilized 1000 trials and only KF was varied according to the distribution of 
literature values.  In order to roll the dice for each trial, the random() function in Excel® was utilized to 
generate a probability between 0 and 1 for the variables of interest.  To generate a Kf value, the loginv(p) 
function was used with the dice roll for each variable in the trial, with the mean and standard deviation for 
Kf (µ=1.4561, σ=2.673).  After the inverse, the closest of the paired n and Kf values were utilized for that 
particular dice role.   For Kf and n, the values for phenol were used as a surrogated for the compounds of 
interest due to the wide availability of data, and the fact that it is a fairly absorbable compound that is 
frequently found in industry and medicine.  Phenol is also well regulated within the current regulatory 
scheme and as such provides an excellent model.  The means and standard deviations were compiled from 
a comprehensive literature review for Freundlich constants (see Appendix I, pg.115).  Each trial was 
completed for a different set of competitive phenol concentrations, Cephenol of 0, 1, 2, 5, 8, 11, 14, and 18 
ppb.  Equation 3i was solved for each trial for a given Cephenol, and equilibrium concentrations of PCPPs of 
0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, and 10 
ppb.  At each relevant concentration of PCPPs, the 1000 trials were averaged to obtain a single adsorption 
density value for a given equilibrium concentration of Cephenol and CePCPP.  The final results were plotted as 
Adsorption density versus the equilibrium concentration of PCPPs.    
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5. Results Analysis  
 
The final results were plotted as a percent of the compound that was removed by adsorption.  It 
was assumed that the influent, effluent, and environment inputs contained 45, 44, and 38 compounds 
respectively.  The plotting of results in this fashion allows for trends to be extracted.   
Results 
 
 Utilizing Freundlich isotherms and accounting for multicomponent systems during Monte Carlo 
simulation, the results are presented in the sections 
which follow.  The first set of results obtained examined 
the effect of carbon dose and the underlying 
distributions behind the n and KF literature values.  
These values were crucial to the modeling exercise, 
since utilizing competitive effects depends on the 
concentration of the other substrate in solution.  For the 
final set of modeling results, a competitive isotherm was 
utilized to examine the role of competition on the 
removal of PCPPs.  Therefore, for the competitive 
isotherms to be calculated, it was necessary to first find 
the distributions associated with various constants. 
 
 
1. Distribution Analysis   
Freundlich isotherm constants, n and KF were 
first determined by distribution fitting in order to 
successfully be applied to Monte Carlo modeling.  The 
Table 9: An example ranking of probability 
distributions for the individual Freundlich 
Parameters.   
Rank n Kf 
1 Cauchy Weibull 
2 Log-Logistic Log-Pearson 3 
3 Dagum Burr 
4 Dagum (4p)  Log-Logistic 
(3p) 
5 Kumaraswamy Dagum 
6 Exponential (2p)  Weibull (3p) 
7 Weibull Lognormal 
(3p) 
8 Frechet (3p) Gen. Gamma 
(4p) 
9 Exponential Lognormal  
10 Log-Pearson 3 Pearson 6 
11 Fatigue Life (3p) Burr (4p) 
12 Weibull (3p) Fatigue Life 
(3P) 
13 Gen. Gamma (4p) Log-Logistic  
14 Burr Frechet(3p) 
15 Inv. Gaussian 
(3p) 
Dagum (4p) 
16 Burr (4p) Pareto 2 
17 Gen. Extreme 
Value 
Pearson 6 (4p) 
18 Pearson 6 Gen. Gamma  
19 Lognromal (3P) Gen. Gamma 
(3p) 
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end result was that a log normal distribution was selected as the best visual fit for each of these (see Table 
9).  Although this was not the best fit, a log normal was selected to keep the values coupled, so that each 
followed the same distribution.   An Anderson-Darling test for n revealed that at α=0.01 and 0.02 a log 
normal distribution could not be rejected, while at all  α values in the Kolmogorov-Smirnov test, the 
distribution was rejected.  Ultimately for n, a visual inspection of a log normal fit, demonstrated a 
reasonable fit and in combination with the Anderson-Darling test, allowed for the lognormal distribution to 
be selected.  As for Kf, an Anderson-Darling and Kolmogorov-Smirnov test was performed and revealed 
that at all significance levels (α=0.01,0.02, 0.05, 0.1, and 0.2) the log normal distribution could not be 
rejected.  Furthermore, the distribution provided a good visual fit to the data.  Therefore, the reasonable 
visual fit and the results of the Anderson-Darling and Kolmogorov-Smirnov tests allowed for a log normal 
distribution to be selected.  The mean and standard deviation of the lognormal distribution for Kf and n 
were: Kf (µ=1.4561, σ=2.673) and n (µ=0.37267, σ=1.2159).   
The average influent concentration was utilized for PCPPs to arrive at a range of values for 
modeling.  The previous results on a distribution analysis were presented in Shown in Figure 14 (page 55).  
This figure demonstrates that the data follows a log normal distribution reasonably well with a fitted trend 
line of R2 = 0.8884.  Additionally, Kolmogorov-Smirnov, Anderson-Darling, and Chi-Squared tests were 
performed to ascertain whether a log-normal distribution was a reasonable fit.  For the Anderson-Darling 
and Kolmogorov-Smirnov tests, revealed that at all significance levels (α=0.01,0.02, 0.05, 0.1, and 0.2) the 
log normal distribution could not be rejected while for the Chi-Squared test all significance levels except 
for α=0.2 stated that the log normal distribution could not be rejected.  Therefore, while EasyFit XL ranked 
the lognormal distribution as 17th, the results of the Chi-Squared, Anderson-Darling, and Kolmogorov-
Smirnov tests, along with visual fitting allow for the lognormal distribution to be confirmed for the average 
influent values. 
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2. Non-Competitive Adsorption 
 
When competitive effects are 
disregarded, an idealized case is modeled where 
a single substrate is being adsorbed onto the 
activated carbon surface without regard to other 
organic and non-organic compounds that would 
be present in a WWTP.  The results are 
displayed in Figure 23 and represent the most 
optimal case for adsorption of PCPPs.  Carbon 
dose will play a crucial role in how much 
removal occurs of a given single substrate.   
 In terms of an activated carbon 
process, carbon dose is one of the dominant 
variables that can be controlled by plant 
operators.  This parameter has a large effect at 
lower doses on removing PCPPs, but eventually 
the benefit of adding more activated carbon 
does not have a substantial effect.  This 
asymptote occurs around 2 g/L of activated 
carbon for the 33rd and 50th percentiles, and at 
around 4 g/L for the 67th percentiles (see Table 10).  The largest response seems to occur between 0.001 to 
0.5 g/L of carbon.  For removal efficiencies, at 2 g/L PCPPs were 77.6%, 78%, and 78.4% removed for the 
33rd, 50th, and 67th percentiles respectively.  There was little additional response going to 10 g/L, which 
resulted in 83.2%, 84.2%, and  85.4% removal for the 33rd, 50th, and 67th percentiles respectively 
percentiles (see Table 10).  While there is a difference between a carbon dosage of 10 g/L and 2 g/L in 
terms of raw percentages, it should be noted that other factors such as cost may drive operator decisions as 
to how large of a dose to add.  It should also be noted that there is more of a dose response to those PCPPs 
that were present at concentrations above the average value and it would be expected that as the 
Table 10: Summary of Non-Competitive Adsorption 
results as a function of Carbon Dose 
 
Carbon 
Dose 
(g/L) 
Initial 
Concentration 
(ppb) 
Projected 
PCPP final 
concentration 
(ppb) 
% 
Removal 
0.1 0.0859 0.0235 72.6% 
1.6242 0.5218 67.9% 
30.6950 13.1954 57.0% 
0.2 0.0859 0.0231 73.2% 
1.6242 0.4804 70.4% 
30.6950 11.2601 63.3% 
0.5 0.0859 0.0228 73.4% 
1.6242 0.4440 72.7% 
30.6950 9.6441 68.6% 
1 0.0859 0.0228 73.5% 
1.6242 0.4312 73.5% 
30.6950 8.8925 71.0% 
2 0.0859 0.0227 73.5% 
1.6242 0.4175 74.3% 
30.6950 8.2321 73.2% 
4 0.0859 0.0227 73.6% 
1.6242 0.4239 73.9% 
30.6950 7.6527 75.1% 
6 0.0859 0.0226 73.7% 
1.6242 0.4133 74.6% 
30.6950 7.4245 75.8% 
8 0.0859 0.0226 73.8% 
1.6242 0.4101 74.7% 
30.6950 7.3034 76.2% 
10 0.0859 0.0225 73.8% 
1.6242 0.4075 74.9% 
30.6950 7.2219 76.5% 
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equilibrium concentration continues to increase toward the far extreme of the distribution, that the dose 
response will become more extreme.    
 
Figure 23: Removal of PCPPs at influent concentrations of the 33rd, 50th, and 66th percentiles (mean 
±standard deviation) demonstrates a carbon dose dependent removal, with a high degree of response even 
at low dosages.  Note: the last data point is the initial concentration of an average PCPP, which were 0.086 
ppb, 1.624ppb, and 30.695ppb for the 33rd, 50th, and 66th percentiles respectively.   
 
 Unfortunately, real world conditions do not involve a single substrate being adsorbed onto 
activated carbon.  Waste streams within a WWTP are complex mixtures of organic, inorganic, and 
biological materials, necessitating that competition will occur and that this competition will have an 
inhibitory effect on the lower concentration substances.   
 
3. Competitive Adsorption  
 
When competitive effects are taken into account, a more realistic case is modeled where multiple 
substrates are being adsorbed onto a single activated carbon surface.  This competition would occur due to 
the other organic and non-organic compounds that would be present in a WWTP.  Therefore, the results 
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that are displayed in Figure 24, represent a more realistic case for determining the adsorption density of 
PCPPs in the presence of a competitor.     
 
Figure 24: Two component competitive degradation of PCPPs is modeled and demonstrates that as the 
concentration of the competitive species increases, the adsorption density decreases.  The range of PCPPs 
was 0.1 to 10 ppb and was modeled with equation 3i, using phenol parameters for Kf and n, and phenol as 
the dominant competitive species.   
 In terms of an activated carbon process, carbon dose and competitive species concentration are 
some of the dominant factors that will affect the adsorption density.  As competitive species are added to 
form a multicomponent adsorption process, the species with the highest concentration with dominate the 
adsorption density if they are adsorbed equally.  As the equilibrium concentration of phenol increased from 
zero, to one, to two, to eighteen ppb, the resulting adsorption density being approximately 18.8, 7.8, 2.4, 
and 0.75 ppb respectively for PCPPs.   It was important to note that the addition of one competitor at one 
ppb at the average PCPP concentration of 1.6ppb, the decrease in adsorption density was over 50% 
indicating that isothermal equally competitive sorbates will have a significant impact on how much of a 
single substrate will be adsorbed.  Therefore, this helps to explain some of the literature values where lower 
concentrations of compounds tend to not undergo adsorption and remain untreated.   
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Discussion and Conclusions 
 
 Adsorption onto activated carbon is not only a function of the carbon dose, but also the 
concentration and number of chemical substrates that are present within wastewater.  Within the WWTP 
influent, there are thousands of compounds that will be in competition with one another for the sites on the 
activated carbon surface.  As a result, the compounds that are present in the highest concentrations, as long 
as they allow for favorable surface interactions, will be preferentially adsorbed and will decrease the 
adsorption density of the lower concentration sorbates, i.e., PCPPs.  This implies that the concentration of 
compounds like PCPPs need to be much higher than currently present in order to become competitive with 
the dominant species.  Therefore, in order for any one given PCPP to be adsorbed, it must either increase in 
concentration relative to the dominant species, or must have more favorable surface interactions with the 
activated carbon surface groups to become more competitive.  Additionally, the amount of carbon that is 
added will have an effect on the amount of removal that occurs.  While only a monocomponent system was 
analyzed in this work, it is likely that there would also be a dose response in a competitive situation.  As the 
amount of carbon added to the system increased, there would be more surface area available for adsorption.  
The result of this would be that there would still be preferential adsorption of the highest concentration 
compounds, until their concentrations became competitive with the other species.  Then there would be 
increased competition for the remaining spots.   
 Competitive species in water and wastewater treatment plants will have an effect on whether or 
not a given species will adsorb onto the activated carbon.  With only one competitive species under 
isothermal conditions, the adsorption density of PCPPs decreased by more than half.  This effect of 
decreasing adsorption density will be compounded by the complex nature of water and wastewater.  The 
net result will be a drastic decrease in adsorption density for lower concentration PCPP compounds, which 
are not in a position to outcompete other compounds.  Typical domestic wastewater influent concentrations 
are characterized as shown [106]:  
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COD-430 mg/L,  
Alkalinity-200 mg/L,  
BOD-190 mg/L,  
TSS-210 mg/L,  
VSS-160 mg/L,  
TKN-40 mg/L,  
NH4-N-25 mg/L,  
Phosphorous-7 mg/L.   
 
Given that the average PCPP compound is present in the influent at 0.0016 mg/L, these other compounds 
that can be adsorbed are present at much higher concentrations in the influent and will most likely be 
preferentially adsorbed.  The only other means of overcoming the difference in concentration would be that 
the competition coefficients would be substantially more favorable for the PCPPs than for the other major 
constituents of the wastewater effluent.  To accomplish this, the competition coefficient can partially 
compensate for a large concentration coefficient, but there is a practical limit on how large this coefficient 
can become.  The competition coefficients reported by Sheintuch, state that a coefficient of 10 is usually 
expected as a maximum [122, 134].  Therefore, it is highly unlikely that PCPPs will be preferentially 
adsorbed before the other major constituents of wastewater.  In the context of WWTP effluent, there will be 
scenarios where there are more than two substrates competing for the same adsorption site, and depending 
on the competition coefficients and Freundlich constants that may change over time, the model may 
underestimate the impact of additional species being present in the water.  Therefore, the competition 
coefficients amongst the sorbates will play a key role in determining how much of a given substance will 
be adsorbed successfully and if another substance is more preferentially adsorbed, then that will have an 
impact on the ultimate amount adsorbed of the lower concentration substance.   
 While activated carbon adsorption has been the focus of this chapter, sludge sorption (adsorption 
onto the biomass grown on wastewater constituents) has been posited as a removal mechanism for some 
PCPPs.  Sorption can occur via either adsorption or absorption [123].  Adsorption occurs by “hydrophobic 
interaction of the aliphatic and aromatic groups of a compound with the lipophilic cell membrane of the 
microorganisms and the fat fractions of the sludge” and absorption occurs by “electrostatic interactions of 
positively charged groups with the negatively charged surfaces of the microorganisms” [123].  With that 
said, these sorption processes appear to only apply to PCPPs that are not highly polarized, which for these 
highly polarized substance sorption onto sludge is essentially negligible [123].  On the other hand, specific 
interactions have been reported for flurochinolones and tetracyclines [123].   Some authors have observed 
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sorption for 17-α Estradiol between 10-30% and that the variability can be explain by “sorbent-specific 
characteristics such as organic carbon content, particle size, pH, salinity, and ion content that varies from 
plant to plant” [144].  Therefore, some adsorption of certain PCPPs may occur onto the biomass.  This 
helps to explain the removal efficiencies observed in Table 4 (see page 25) and further research must be 
conducted to determine the extent to which sorption processes occur under wastewater influent conditions 
with extreme competition for the removal of PCPPs.   
 Therefore, adsorption by activated carbon may be a useful process for the removal of PCPPs as a 
tertiary treatment in a WWTP as long as there is a lack of high concentration competitors to impede the 
process.  Future research must address: 1) the isotherm constants for competitive adsorption for PCPPs, 2) 
the mechanism of removal for activated carbon adsorption of PCPPs in the presence of higher 
concentration adsorbents, 3) further materials research for novel adsorbents that will be more selective for 
PCPPs, 4) development of better models to predict the behavior of new pharmaceuticals in adsorption 
processes, and 5) decreased cost for regeneration of activated carbon to allow for more wide usage.   It 
should be noted however that under normal circumstances, the determination of constants and 
concentrations is extremely difficult due to the difficulty and expense in measuring these compounds.  
Therefore, improved instrumentation will become necessary to allow for proper quantification of many of 
the research goals enumerated above.     
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CHAPTER 4  
 
ALTERNATIVE TREATMENT METHODOLOGY, COST ANALYSIS, AND 
CONCLUSIONS 
 
Introduction 
 
1. Reverse Osmosis  
Reverse Osmosis (RO) is a commonly applied process for the removal of undesired solutes and 
has been applied for the production of fresh water from seawater.  Like microfiltration, ultrafiltration, and 
nanofiltration, RO is characterized by the pore size that dictates its rejection of solutes [41, 145].  As the 
pore size decreases, the membrane becomes increasingly more selective and allows fewer and fewer solutes 
to pass through the membrane.  The primary function of this technology has been its application of water 
desalting [41, 145].  The driving force for the RO process is pressure, and there is resistance due to the 
buildup of ionic compounds in the rejection stream [41, 145].  As a result, osmosis is partially a passive 
process, and equilibrium occurs when the osmotic pressure prevents the passage of a solvent across the 
membrane [41, 145].  Therefore, if more solute is to be driven across the membrane, then a pressure 
gradient will be needed.  Osmosis, by definition, is the diffusion of a solvent from one side of a semi-
permeable membrane to a more concentrated solute side in order to equalize the concentration of the two 
sides [41, 145].  There are three different osmotic pressure situations that can exist.  The first circumstance 
is a hypotonic situation, which donates water across a membrane to dilute the hypertonic side, causing the 
concentration of hypotonic side to increase [41, 145].  On the other hand, the hypertonic side causes water 
to move across a membrane to dilute the hypertonic side (higher concentration of solute) [41, 145].  
Finally, if there are equal concentrations on both sides, the sides are balanced and are referred to as isotonic 
[41, 145].  These traditional definitions are for osmosis processes, and RO operates in reverse.  The reject 
stream contains all of the concentration, while what crosses the membrane to the other side is pure water 
[41, 145].  Therefore, to drive the water from the concentrated to the diluted side a pressure gradient must 
be utilized to drive water against its natural grad
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Depending on the application of RO, different materials are better suited to certain conditions.  
The first category of membranes are seawater membranes, which operate with water that contains salt on a 
3-5% by weight basis and requires a pressure differential of 800-1000 psi to operate [41, 145].  These 
membranes tend to be utilized for desalinization of seawater for generation of freshwater.  The second 
category of membranes are brackish water membranes, which operate with water that contains salt 
concentrations of 2000 to 10,000 ppm and requires less pressure at 200-400 psi [41, 145].  The drop in 
operating pressure as compared to seawater, is due to the drop in osmotic pressure that must be overcome 
in order to drive clean water across the membrane.  Finally, low-pressure nanofiltration operates at 100-150 
psi at salt concentrations of 200-500 ppm [41, 145].  Therefore, as the amount of ionic substances decrease 
in concentration, the osmotic pressure decreases, and the necessary pressure to create clean water 
decreases, thereby decreasing overall energy requirements.  Membranes can be composed of different 
materials, and these materials have different efficiencies associated with them.  In order of development 
and efficiency, the common materials are: 1) Cellulose Acetate, 2) Polymers, and 3) Composites [41, 145].  
Therefore, a choice of membrane is usually a tradeoff between flux and rejection, so as the flux increases, 
the pore size decreases and as does the rejection of solutes.   
 RO treatment has numerous pros and cons associated with its usage that must be considered to 
determine whether or not to apply the technology.  RO advantages include: generation of high quality water 
output; effective removal of organic compounds, salts, natural minerals, and micropollutants; removal of 
95-99% of TDS; removal of chemicals such as asbestos, arsenic, some pesticides, fluoride, lead, mercury, 
and radium; low installation cost; and commercially available membrane modules with low installation 
time [41, 145, 116, 146, 147, 148, 149].  RO disadvantages include: increased membrane fouling and 
operating costs, high quality inflow requirements (lots of a pretreatment), high maintenance costs and 
membranes costs, dangerous molecules are still able to snake through the membrane, since rejection is not 
100%, removes healthy minerals in water that have to be added back in (trace elements key in biology), and 
limited treatment per square foot of membrane compared to alternatives and slow process [41, 145, 116, 
146, 148, 149].  Therefore, depending on the application and value of the water being produced, the 
advantages can outweigh the disadvantages, allowing for RO to be effectively utilized.   
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A comprehensive literature review demonstrates that RO generally removes many biologically 
recalcitrant PCPPs.  RO literature review can be found in Table 4 on page 25.   
 
2. Filtration 
Filtration has many different applications and is principally characterized by pore size and 
operating pressures needed for filtration to occur.  Ultrafiltration, microfiltration, and nanofiltration are not 
fundamentally different and are differentiated by the size of the molecule that is rejected [116, 150].  
Microfiltration (MF) has pore sizes between 0.03-15µm; nanofiltration (NF) has pore sizes between 
0.0005-0.02µm; and ultrafiltration (UF) has pore sizes between 0.002-10µm [116, 150].  These membranes 
work by discriminating on the basis of molecule size, shape, and flexibility, and the filtration process is 
powered by pressure (except microfiltration does not necessarily have to be) [116, 150].  Unlike RO, which 
requires high pressures to overcome the osmotic pressure, UF, NF, and MF are not affected by osmotic 
pressure, and these membranes operate at low-pressure differences, 5-100 psi [116, 150].  Typical 
operating parameters, which allow these membranes to be operated economically, are a pressure difference 
of 10-50 psi and a water flux of 20-50 µ+;¶ [116, 150].  Overall, UF, NF, and MF are currently used 
commonly due to their lower cost compared to an RO system, but they do not remove nearly as many 
compounds as a RO system due to larger pore sizes.   
Membrane filtration treatment has 
numerous pros and cons associated with its usage 
that must be considered to determine whether or 
not to apply the technology.  The advantages of 
utilizing filtration over other technologies are its 
proven track record in industrial, chemical, and 
biomedical applications, and it is cost effective 
when the value of the recovered product is greater 
than the process cost [41, 116, 145].  On the other 
hand, filtration has disadvantages associated with 
 
Figure 25: A gel layer is formed where rejected 
solutes need to back diffuse to the main stream.  
Reproduced from: [41].   
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it including: become increasingly energy intensive as pore size decreases (i.e. microfiltration-
>ultrafitlration-> nanofiltration), high incidence of membrane fowling and gel layer formation like RO, 
prohibitive cost, and decreased membrane fluxes with decreasing pore size, thereby decreasing the potential 
volume that can be treated at one given time [41, 116, 145].  The formation of a gel layer formation is a 
natural part of the membrane operation process and is depicted in Figure 25.  As the membrane runs and 
pressure is applied to the membrane, a gel layer will form thereby decreasing performance [41, 116, 145].  
This gel layer will become consolidated with an increasing applied pressure gradient, thereby creating an 
inverse relationship between pressure and the formation of a gel layer [41, 116, 145].  The gel layer is 
where rejected solute collect and must back diffuse into the mainstream.  As a result, resistance will form to 
a purified solution crossing the membrane [41, 116, 145].  At high-enough pressures, this gel resistance 
controls the flux across the membrane, and membrane resistance begins to play a smaller role [41, 116, 
145].  Therefore, careful attention must be paid when selecting an operating pressure for these membranes, 
since the gel layer can have major effects on the flux across the membrane.   
A comprehensive literature review demonstrates that UF, NF, and MF are generally effective at 
removing many biologically recalcitrant PCPPs.  UF, NF, and MF literature reviews can be found in Table 
4 on page 25.   
 
3. Advanced Oxidation  
Advanced Oxidation Processes (AOPs) are 
utilized to (fully or partially) degrade biologically 
recalcitrant compounds.  In general, AOPs generate a 
hydroxyl radical to oxidize compounds [106, 151].  
Hydroxyl radicals can be produced from Ozone or 
Ozone/UV process as well as hydrogen 
peroxide/ozone or hydrogen peroxide/UV processes 
[106, 151].  All of these processes produce hydroxyl 
radicals, which have the ability to attack organic 
compounds of interest.  There are other compounds that can be utilized to oxidize compounds (see in Table 
Table 11: Oxidation potential of various 
compounds 
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11), but they have similar mechanisms of actions to one another [106, 151].  When conventional oxidants, 
such as ozone, oxygen, and chlorine, fail to remove organic compounds, then the use of AOPs may be 
considered [106, 151].  If a hydroxyl radical attacks organic matter, it will result in ·v¸, "¸v, and salts if 
taken to completion [106, 151].  As a compound is degraded, there are various amounts of completion that 
occur: 1) Primary, where there are structural change in parent compound; 2) Acceptable, where there are 
structural changes reducing toxicity; 3) Ultimate, which converts organic carbon to "¸v; and 4)  
Unacceptable, where the structural changes increase toxicity [106, 151].  If positive reactions (1-3) occur, 
then hydroxyl radicals will interact with the organic compound and will begin to degrade the compound.  In 
order for this to occur, there must be a production of hydroxyl radicals, or an equivalent molecule.  The 
oxidizer chemistry with key reactions is outlined below [106, 151, 152]:  
 
Many of the starter substances above produce hydroxyl radicals (with the exception of potassium 
permanganate), but each of these substances can then interact by a hydroxyl-like attack to lead to ultimate 
degradation.    
The mechanism by which compounds are degraded is oxidation, of which, there are four primary 
means by which hydroxyl attack can occur.  Hydroxyl radicals are used to oxidize trace amounts of 
refractory organic molecules and are not used for disinfection due to their short half-life [106].  The first 
mechanism of attack is radical addition, which is characterized by the chemical reaction: e + ·¸∙ → e¸· 
[106].  The second mechanism of attack is hydrogen abstraction, which is characterized by the chemical 
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reaction: e + ·¸∙ → e∙ +·v¸ [106].  The third mechanism of attack is electron transfer, which is 
characterized by the chemical reaction: e' +·¸∙ → e'. + ¸· [106].  The final mechanism of attack is 
radical combination, which is characterized by the chemical reaction: ·¸∙ +·¸∙ → ·v¸v [106].  Each of 
these mechanisms has potential byproducts of reactions of aldehydes and carboxylic acids, as intermediate 
products of the degradation of an organic pollutant [106].  As a result, these intermediates can present new 
pollutants that must be remediated.  Therefore, the attack of hydroxyl radicals can occur in multiple ways.   
Advanced oxidation has numerous pros and cons associated with its usage that must be considered 
to determine whether or not to apply the technology.  The most prominent advantage of advanced oxidation 
over alternative technologies is that oxidation is a destruction process.  Thus, if taken to completion, there 
is only ·v¸,  "¸v, and salts [106, 151, 152, 153].  Additionally, AOPs are more effective than conventional 
oxidants, due to the high oxidation potential of hydroxyl ions, and AOPs effectively remove many 
recalcitrant organic compounds [106, 151, 152, 153].  On the other hand, AOPs have numerous 
disadvantages including: carbonate and bicarbonate in some wastewaters can neutralize the hydroxyl 
radical produced by AOPs; natural organic matter and reduced metal ions interact with hydroxyl radicals, 
and kill the reaction; and AOPs are sensitive to pH, suspended materials, residual TOC [106, 151, 152, 
153].  Furthermore, the chemicals and equipment needed for AOPs tend to be expensive, and generally 
there are increased maintenance costs over traditional oxidation with chlorine or ozone [106, 151, 152, 
153].  Finally, if a UV process is added, turbidity can affect the effectiveness of the radiation to produce 
hydroxyl radicals.  Therefore, in the proper application, oxidation can be a useful method for complete 
removal of recalcitrant compounds.   
A comprehensive literature review demonstrates that AOPs are generally effective at removing 
many biologically recalcitrant PCPPs.  A literature review can be found in Table 3, on page 23.   
 
4. Ozonation  
Ozone is a highly reactive molecule that in the lower stratosphere serves to block UVB light from 
the sun, but its properties as an oxidant are extremely useful for the treatment of various molecules.  Ozone, 
¸», is a highly unstable gas that can be utilized to oxidize molecules, and it works by rupturing an 
organism’s cell wall [106, 154].  This mechanism of cell wall rupture is extremely useful in drinking water 
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disinfection and provides an excellent alternative to chlorine disinfection.  Ozone is produced in the 
atmosphere by UV light and lightening during a thunder storm [106, 154].  Its properties are quite distinct 
and include, a blue color at 25°C, distinct odor, explosive quality when above 20% by weight in air, 
solubility governed by Henry’s Law (1940-5980 atm/mole [0-30°C]), and greater stability in air than water, 
but short half-life [106, 154].  Ozone has four distinct decomposition reactions that govern its behavior: 1) 
¸» + ·v¸ → ·¸»- + ¸·, 2) ·¸»- + ¸· → 2·¸v, 3) ¸» + ·¸v → ·¸ + 2¸v, and 4) ·¸ + ·¸v →
·v¸ + ¸v [106, 154].  Therefore, in order for these reactions to occur and degrade organic compounds, 
ozone must be successfully generated.   
Ozone generation is a multistep process and can occur by various different processes.  These 
generators can either work by cold electrical discharge or UV light, where UV lamps emitting 185nm light 
split oxygen gas into ¸, which binds to ¸v to stabilize, forming ¸» [106].  The UV process is a 
substantially less-energy intensive process compared to cold electrical discharge, where this process 
mimics the atmospheric lightening that is responsible for generating natural ozone in the environment.   
Due to its short half-life, ozone must be generated onsite, and it can present a health hazard to workers 
[106].  Air or pure oxygen can be utilized as an input for the generation of ozone and will result in different 
amounts of ozone produced.  First, air that has been dried can produce 1-3% ozone by weight or the air can 
be enriched with oxygen resulting in a higher yield of ozone [106].  Second, pure oxygen can be utilized 
and will produce 3-10% ozone by weight, making it an ideal source for producing ozone and allowing for 
more economical treatment [106].  Therefore, the production of ozone, while expensive, can be 
accomplished with relatively low cost inputs.   
Ozone has numerous pros and cons associated with its usage that must be considered to determine 
whether or not to apply the technology.  As mentioned above, ozone can be utilized to generate hydroxyl 
radicals, but it can also be an excellent oxidant on its own.  Ozone has numerous advantages of its usage 
including: effective odor elimination, decreased oxygen demand, since one of the decomposition reactions 
produces oxygen; thereby increasing dissolved oxygen, removal of the bulk of colors, phenolic, and 
cyanide compounds, and requires a short contact time, 10-30 minutes, for degradation [106, 155, 156, 157, 
158].  Furthermore, unlike chlorine, ozone does not form chlorinated disinfection byproducts, non-
brominated disinfection byproducts can be removed with biological active filter or carbon column, and 
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ozone intermediates form are usually short lived [106, 155, 156, 157, 158].  It is crucial that these products 
can be relatively easily removed, since chlorinated disinfection products are quite resilient and as a result, 
can be expensive to remove [106, 155, 156, 157, 158].  On the other hand, ozone has numerous 
disadvantages including: high capital and treatment costs, high demand for electric power for ozone 
generation, high corrosiveness (steel, iron, and neoprene), high transfer efficiency (>90%) is required for 
ozone, in order for it to be economical, and high hazard potential from off-gas presents a worker hazard and 
must be destroyed [106, 155, 156, 157, 158].  Moreover, ozone treatment produces numerous undesirable 
byproducts including Formaldehyde, Acetaldehyde, Glyoxal, Methyl glyoxal, Acetic acid, Formic acid, 
Oxalic acid, Succinic acid, Pyruvic acids, Bromate ion, Bromoform, Brominated acetic acids, Bromopicrin, 
Brominated Acetonitriles, Cyanogen bromide, and hydrogen peroxide [106, 155, 156, 157, 158].  Some of 
these byproducts are desirable such as hydrogen peroxide, which can serve as an additional oxidant and can 
help to drive reactions to their completion.  Therefore, ozone can be an excellent tertiary treatment for 
removing difficult compounds.   
Improving on traditional ozone treatment 
methods is the addition of UV light, which 
improves overall treatment of wastes and allows for 
enhanced efficiency in the treatment of organic 
compounds.  Combining UV with ozone allows for 
the advantages of both compounds to be utilized 
with ozone as a chemical oxidant, and UV radiation 
able to damage proteins, DNA, and RNA [106, 
159].  This combination allows for chemicals to be 
treated that might otherwise be resistant to 
conventional ozone treatment.  UV radiation can 
break many covalent bonds including those in PCBs, dioxins, polyaromatic compounds, and BTEX, where 
ozone oxidation fails to oxidize those compounds [106, 159].  UV radiation has a synergistic effect on the 
chemical oxidation effects of ozone, and the mechanism is unknown, but further efficiency can be gained 
by treating with a peroxide module [106, 159].  Few of these systems have been implemented, but they 
Table 12: Pros and Cons of adding UV to Ozone 
Treatment 
 
Source: [106].   
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have shown great promise in research settings and in some commercial settings.  The pros and cons of the 
addition of UV are shown in Table 12.   
A comprehensive literature review demonstrates that Ozone is generally effective at removing 
many biologically recalcitrant PCPPs.  A literature review can be found on Table 3, on page 23.   
 
5. Wet air oxidation  
Wet Air Oxidation (WAO) is used in high organic content wastewater, and, particularly for toxic 
or for refractory organic (non-biodegradable) wastewater.  WAO operates at 125-320°C and 0.5-20 MPa, 
where increased temperature and pressure allows for increased oxygen solubility in water and the increased 
pressure keeps water in liquid form [152, 160].  By utilizing high temperature and pressure, oxidation of 
organic contaminants is more complete and has the added benefit of little waste product as long as organic 
material is present to oxidize [152, 160].  If there is inorganic material present, these compounds will be 
mostly left in solution [152, 160].  WAO results in carbon oxidized to "¸v, nitrogen oxidized to ¨·», and 
sulfur and halogens converted to inorganic halides and sulfides [152, 160].  The degree of oxidation is a 
function of temperature, oxygen partial pressure, and reaction rates of pollutants in the waste stream [152, 
160].  As a result, there are many operating parameters that can be controlled or optimized to ensure proper 
degradation of organic compounds.   
Currently, there is only one commercially 
available WAO processes, the Zimpro® process.  By 
1996, 200 units were installed, with greater than 50% 
of these utilized for sludge treatment [161, 162].  
Sludge contains high amounts of organic waste that is 
not amenable to conventional treatment methods and 
usually is treated by incineration or landfill disposal [161, 162].  The alternative to this is the Zimpro® 
process, where the main reactor tends to be a vertical bubble with or without internal baffling, which 
operates under the following parameters: 1) operating temperatures tend to be 150-320°C, 2) operating 
pressure is variable and used to control water evaporation, and 3) optimal retention time of 1 hour, but 
ranges between 20 minutes and 4 hours [161, 162].  One limitation of utilizing this column design is non-
 
Figure 26: Process schematic of the Zimpro® 
process. Source: [161].   
92 
 
uniform mixing and residence time, resulting in non-uniform treatment [161, 162].  Therefore, the 
treatment stream must be examined after treatment to ensure that the degree of treatment achieved is 
adequate, and if not, further treatment within the reactor maybe necessary.  The process diagram for the 
Zimpro® process is shown in Figure 26.  The process is relatively simple and requires an air compressor, 
heat exchanger, reactor (where oxidation occurs and an exothermic oxidation reaction occurs), feed 
exchanger, and pressure control valve [161, 162].  The separator is crucial where the effluent is separated 
into vapor (vented) and liquid effluent, sent for traditional biological treatment as needed [161, 162].  
Therefore, the process has two different outputs, each of which can be a highly oxidized waste stream that 
is substantially less toxic than the original influent.   This process is owned by Siemens® Water and has 
been thoroughly tested and implemented around the world despite some of the disadvantages of this 
technology.   
Wet Air Oxidation has numerous pros and cons associated with its usage that must be considered 
to determine whether or not to apply the technology.  Some advantages of this technology include, a variety 
of compounds can be treated simultaneously, an effective pre-treatment for high concentration wastewater 
resulting in biodegradable organics, a potentially large elimination in toxicity and reactivity and COD, and 
an ability to recycle and/or recover process liquor [161, 162, 163, 164].  Moreover, unlike incineration, the 
wastes are destroyed in the liquid phase and do not have to be dried out first, which is an extremely energy 
intensive process [161, 162, 163, 164].   In terms of COD, which can be used to help measure how much 
energy maybe required to make a process sustainable, WAO requires greater than 20,000 mg/L to be 
sustainable, whereas incineration requires substantially more at CODs greater than 300,000-400,000 mg/L 
[161, 162, 163, 164].  Additionally, the WAO process does not produce NOXs and does not contribute 
significantly to air pollution like incineration does [161, 162, 163, 164].  Therefore, WAO has many 
advantages over incineration as a treatment method, but it also has many drawbacks.  These disadvantages 
include, high capital costs, waste must be in the liquid phase (excludes solid wastes unless they are 
dissolvable), treatment is limited to oxidizable wastewater with organic and inorganic compounds (will not 
work on PCBs for example), and there are safety implications from operating at high temperature and 
pressure [161, 162, 163, 164].  Therefore, depending on the content of the waste and the air quality 
requirements, WAO may provide an excellent treatment option.   
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While WAO has many positives, there are wastes that are not treated easily with WAO and instead 
are better suited to Supercritical Water Oxidation (SCWO) [152, 165].  Unlike WAO, SCWO operates 
under supercritical conditions, which occur above 374°C and 22.3 MPa [152, 165].  The supercritical 
condition allows for a more rapid oxidation over WAO [152, 165].  The removal rate is a temperature 
dependent process, so for example, at 400-450°C, 99-99.9% conversion in 5 minutes, whereas at 600-
650°C, 99.9999% conversion in less than 1 minute [152, 165].  Therefore, depending on how much energy 
will be invested to raising the temperature in the reactor, will dictate the rates of oxidation reaction within 
water.  Water provides an excellent medium for oxidation since it can dissolve both organic compounds 
and gases, and the peak efficiency for SCWO is when organics are 1-20% of the waste stream by weight 
[152, 165].  SCWO works by injecting supercritical wastewater into a reactor and then adding ¸v, which 
results in oxidation of the organics until essentially none remains [152, 165].  Typical wastewaters that are 
treated with SCWO are pesticide waste, petrochemical processing waste, cyanide containing metal 
finishing wastes, spent caustic wastewaters, and organic chemical production wastewater [152, 165].  
Therefore, as a treatment method for hard-to-treat wastes, SCWO carries the exact same advantages of 
WAO, and does not contribute to SOX and NOX emissions [152, 165].  These are highly favorable 
characteristics for the removal of difficult to treat organic wastes, but there are drawbacks to the usage of 
this technology.  The primary drawback of SCWO is corrosion, which is a large problem that must be 
considered in weighing whether to build a plant or not [152, 165].  Few plants have been built and 
implemented due to this corrosion issue, and as a result, SCWO remains a virtually untested industrial 
process.   
A comprehensive literature review demonstrates that SCWO is generally effective at removing 
many biologically recalcitrant PCPPs.  A literature review can be found in Table 3, on page 23.   
 
6. Plasma Arc Waste Disposal 
 
Plasma Arc waste disposal is an extremely effective method for reducing all types of waste to 
basic components and energy.  Pyrolysis, which is the underlying mechanism of Plasma Arc waste 
disposal, occurs in an oxygen-depleted environment and unlike combustion that is exothermic; it is an 
endothermic process requiring the heat input of hot plasma [166].  Hot plasma is formed by ionized gas in a 
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strong electrical arc with a power of 2-20 MW producing 2000-6000°C plasma [167].  The plasma is 
formed by a plasma torch, which is two electrodes, with a carrier gas in between them, which then transfers 
energy to waste [166].  When waste comes in contact with the plasma, inorganic compounds are melted to 
form non-toxic dross while the organic components are dissociated into simpler gases of H2, CO, and CO2 
[167, 166].  The simpler gases, H2 and CO, form syngas after reaction with water and oxygen, which after 
purification can be used to generate heat and run a turbine for electrical energy generation [167, 166].  
Also, metals can be recovered from the dissociation process and resold, helping to offset cost, while the 
remaining dross can be used as a construction additive [167].  The dross is essentially vitrified by the 
process and is non-leachable making it exceptionally useful for hazardous waste that may not be 
completely destroyed in the process or elements that are toxic in the environment [166].   Therefore, this 
process is very attractive in situations where lots of waste is generated, metal recovery is attractive, or 
where environmental concerns over placing materials in a land fill become paramount.  This technology 
has been implemented on smaller scale in the US at Hurlburt Air Force Base in Florida, processing about 
10 tons/day and in Arlington, Oregon by InEnTec processing 25 tons/day as a test system [168].  The 
largest operating systems abroad are found in Utashinai, Japan, which utilizes a 150 tons/day, and a plant 
just opened last summer in Morcenx, France is processing industrial waste and wood chips [168].  These 
plants pale in comparison to the planned GeoPlasma facility in St. Lucie County, which would have burned 
600 tons/day and produced approximately 220 MW for the grid, but the downturn in the economy, crippled 
this project [169].  Finally, loans issued for Fulcrum BioEnergy to build a 400 ton/day plant outside Reno, 
NV to open in 2014, which will stand as the largest plant to date [168].  As more plants are built and more 
hours are successfully logged, it is clear that the technology has great potential and that financing will be 
the largest hurdle to successful implementation.   
The Plasma Arc waste disposal process is a relatively simple system with four main components.  
First, the waste feeder, the design of which varies depending on the waste being fed into the system, but 
typically there is a sealed portion that is pushing the waste into the reactor [166, 170].  Second, is the 
process chamber or reactor where both AC joule-heating zone and DC arc plasma zone are utilized [166, 
170].  The DC plasma arc is created with a potential difference across the electrodes with one being 
positive and the other being negative, while AC potential is applied directly to glass [167].  By constantly 
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applying current to the glass, it becomes possible to separate out the components.  There are then two mass 
streams out of the reactor, a solid and a syngas stream.  Third, the process gas cleaning is where Syngas is 
taken from the reactor through a heat recovery steam generator, where steam is then used to drive a turbine 
[166, 170].  At the same time, as the steam goes to a turn, the syngas goes through a series of filters (three 
stages: 1) hot particulate removal, 2) wet scrubber removes additional particulates and acid gases, and 3) 
carbon filter to remove trace elements) to a boiler to produce additional steam to drive a turbine [166, 170].  
From the turbine, electrical energy is generated to help power the plant and any remaining energy can be 
sent to the grid [166, 170].  Finally, the solid mass stream exiting the reactor is where glass and metal 
recovery occurs.  Separate streams are formed for the glass products and metals, which can then be 
recovered and either sold or used as a construction aggregate [166, 170].   
Plasma Arc waste disposal has numerous pros and cons associated with its usage that must be 
considered to determine whether or not to apply the technology.  Plasma Arc waste disposal has many 
advantages over traditional incineration plants: the quick cooling of produced syngas prevents the 
formation of dioxins and furans, which are normally a combustion byproduct of incineration; no toxic ash-
like incineration to dispose of;  <50% of NOX and 5% of SOX and Mercury emissions compared to 
traditional incinerator; and 300:1 volume reduction as compared to 5:1 for incineration due to ash 
production [168, 167].  Also, this technology allows for the destruction of hazardous, municipal, medical, 
and ash wastes including being able to destroy electronics waste, which has no treatment method currently 
[168, 167].  Additional benefits of Plasma Arc waste disposal include, the filtered Syngas that is produced 
is as clean as natural gas; clean energy is produced by the process; burning of municipal waste decreases 
landfill requirements; and the stripping process produces HCl and NaHSO4, which can be resold for 
industrial purposes [168, 167].  Many of the drawbacks associated with Plasma Arc waste disposal are 
economically based: high cost since there is a reliance on electrical power and huge upfront capital cost and 
a lack of willingness to finance these projects (analogous to the capital needed for building a nuclear plant) 
[168].  Additionally, many critics of this technology point to a perceived lack of reliability [168].  
Furthermore, there are concerns about syngas release, which could affect climate change, have public 
health implications, and potential failure of the liners creating a safety issue.   
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Methods - Cost Analysis 
A cost analysis of potential treatment methods for PCPPs was conducted to ascertain, which of the 
many technological approaches would be the most cost effective.  Modeling was undertaken in Excel® 
2010.  In order to conduct the modeling, two primary sources of data were utilized including acquiring cost 
information from the manufacturers when it was available and in the absence of available data, a 
comprehensive literature review was conducted.   For the literature review, two or more sources were 
utilized to generate high, low, and average costs in order to generate a viable range of values for the 
modeling exercise.    
  In order to compare the costs of various treatment methods, cost curves must be constructed for 
each of the methods for removing PCPPs from wastewater effluents.  For this analysis, the treatment 
methods considered include, filtration (NF and µF), RO, UV, GAC, biological processes, chemical 
oxidation, ozone, Wet Air Oxidation, and plasma arc waste disposal.  The range of flow rates considered 
include, 10 MGD, 50 MGD, 75 MGD, and 100 MGD to 1.6 BGD of wastewater.  These values were 
selected to represent a range of treatment plant sizes, as well as to reflect the 90% waste volume reduction 
that would occur as a result of the RO process.  The upper range of values is important for processes, like 
RO, that potentially must treat the entire volume of waste from a WWTP.  Three different scenarios were 
considered for each of the treatment systems, low, average, and high cost scenarios.  It was assumed that an 
interest rate of 10% was applied to any capital costs that had to be finance by loans within calculations of 
the total cost per unit of treatment. Total costs were assumed to include operations, capital, and 
maintenance costs when available.  Finally, graphs of cost curves were plotted for each of the resulting 
scenarios with bands to demonstrate the range of potential costs. 
Results 
A rudimentary cost analysis was performed to compare RO, GAC, Biological, and WAO 
treatments.  The results are shown in Figures 27-29.   These results demonstrate that ozone treatment is 
consistently one of the most expensive treatment options for large volumes of wastewater, whereas 
conventional biological treatment has been the most cost effective.   These results do not include Plasma 
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Arc Waste Disposal, which is considered separately and has a cost that ranges between $60-$86 per ton of 
treated municipal solid waste (MSW).   These costs must then be applied to the mass content of the 
wastewater flow in order to determine how much operations would cost.   Utilizing this back-of-the-
envelope method for calculating costs, a set of cost estimates can be obtained for Plasma Arc Waste 
Disposal and is presented in Table 13.  The costs estimates that were obtained provide a wide range of 
values and are highly dependent on the water content of the waste.  This water content can have the effect 
of adding 1000 times the cost to the treatment of the wastewater treatment stream.   
 
Figure 27: Lowest projected total costs associated with various treatment methods on a daily basis.  
NOTE: these estimates allow for relative comparisons to be made. Sources: [41, 152, 171, 172].  
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Figure 28: Average projected total costs associated with various treatment methods on a daily basis.  
NOTE: these estimates allow for relative comparisons to be made. Sources: [41, 152, 171, 172].  
 
Figure 29: Highest projected total costs associated with various treatment methods on a daily basis.  
NOTE: these estimates allow for relative comparisons to be made. Sources: [41, 152, 171, 172]. 
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Table 13: Daily cost estimate of Plasma Arc Waste Disposal Treatment including Capital, Operations,  
and Maintenance costs.  NOTE: that water content in this rough analysis is assumed to be either 0% or 
100% and thus the additional weight would be responsible for adding cost.  Source: [173, 174].   
MGD  1 10 100 
Low Cost (with water) $  320,000 $  3,207,000 $  32,068,000 
High Cost (with water) $  360,000 $  3,591,000 $  35,910,000 
Low Cost (without water) $          420 $          4,230 $          42,300 
Low Cost (without water) $          475 $          4,740 $          47,370 
Discussion of Practicality 
Several trends and limitations can be noted about the cost analysis that was conducted above.  
First, limited data was available for the cost analysis, and therefore, there is a need for increased data 
availability to hone in on the actual costs.  In addition, full lifecycle cost estimates are largely unavailable.  
The implications of this lack of data availability are that the results must be used with caution and should 
not be used as absolute values.  Therefore, further research is necessary to develop a fuller picture of the 
costs associated with these treatment methods.  This could be accomplished if corporations would be 
willing to aggregate their processes into a database, which could mask the individual corporation’s 
proprietary processes.  Several trends with implications were noted from the modeling exercise, which can 
be used to make decisions on which type of technology should ultimately be applied for the removal of 
PCPPs from wastewater.  Firstly, biological is always the cheapest, and ozone is always the most expensive 
treatment process.  Secondly, Wet Air Oxidation, which is considered to be an expensive process, is 
surprisingly more cost effective than is perceived in the industry.  Thirdly, activated carbon is also an 
expensive process, and as was shown in the previous chapter, susceptible to competitive effects of the 
dominant species, and is dependent upon the dose of carbon added.  As the carbon dose increases, the cost 
increases.  Finally, as the volume of waste to be treated increases, the slope decreases eventually coming to 
a sort of plateau in cost.  This reflects the economies of scale principle, where the cost to add a unit of 
output decreases, thereby making larger scale plants more cost-effective than their smaller scale 
counterparts.  Hence, Wet Air Oxidation in terms of a cost-benefit analysis is the most favorable, and 
generally as all of the plant types get larger, they become more cost effective.   
In terms of cost-effective treatment, the methods discussed in this chapter are not likely to be 
cheap enough for widespread application.  From a practicality standpoint, more research must be conducted 
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on Plasma Arc Waste Disposal.  It is unlikely that this technology will be applied directly to a wastewater 
treatment stream due to its cost, but rather, it may be utilized to generate electricity from MSW.  
Furthermore, as discussed previously, biological and GAC processes will not be likely to treat PCPPs on 
the scale of a WWTP.  Therefore, the highest potential for direct application to wastewater stream would be 
Wet Air Oxidation, which has numerous technological and environmental advantages with its 
implementation.    
Conclusions 
1. Implications of research: ethical, moral, legal  
 
The combination of ethics, morality, and legal arguments will provide a potential impetus for 
action.  For example, when considering climate change, water is becoming an increasingly valuable 
resource, and the population and climate pressures being applied to areas of the world are causing new and 
reusable sources of water to be explored.  As a result, the usage of technologies such as water recycling and 
RO will become more commonly deployed.  Additionally, a blend of ethical, moral, legal, and business 
considerations will be crucial for helping to shape public opinion and legislative agendas in the face of new 
scientific discoveries.  
 From the perspective of the morality and ethics, the precautionary principle and concern for future 
generations will help to drive society’s views and demands for the regulation of PCPPs.  John F. Kennedy 
Jr. said, “Our most basic common link is that we all inhabit this small planet, we all breathe the same air, 
we all cherish our children’s futures, and we are all mortal” [175].  While this quote spoke to the arms race 
and threat of nuclear war between the Soviet Union and the United States, it is just applicable to 
environmental issues 50 years later.  Water is a fundamentality scarce resource, and it is being redistributed 
across the globe creating pressure.  Therefore, if humanity is able to adapt appropriately and provide fresh 
sources of water for future generations (giving them the same opportunities as our generation was 
afforded), then there is an ethical obligation to ensure that as a society, there is not a depletion of resources.  
As a result, society is called to investigate and implement emerging technologies like RO, water recycling, 
and aquifer recharge to ensure that future generations have access to safe water.  Without this, there will be 
an injustice that may threaten our children’s future.  Finally, the precautionary principle dictates that the 
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deployment of advanced, albeit expensive technologies like plasma arc waste disposal, should be 
undertaken to avoid the associated dangers of PCPPs.  For example, estrogenic compounds in the 
environment pose a threat to environmental and public health, and while at their current concentrations 
these compounds do not pose a risk to humans, there is the potential for adverse effects to occur.  
Therefore, a novel technology should be applied to remediate these water supplies.  While the potential 
application of ethical frameworks like the precautionary principle could help to motivate the public and 
employ action, there is still a lack of legal framework that could help to regulate PCPPs.    
The legal entity that is responsible for regulating PCPPs is the Federal Drug Administration 
(FDA), which with adaptation of the current legal framework, could be able to consider the environmental 
and potential public health consequences of accumulation of these compounds in the environment.  In its 
current form, the FDA prioritizes public health as the primary consideration of drug approval while 
completely disregarding environmental protection [176].  While this is the current state of affairs, it is 
conceivable that current statutes could be applied to the FDA and pharmaceutical companies to at a bare 
minimum consider the environmental impacts of PCPPs, or even to prevent their release into the 
environment.  The main laws that may be pivotal in this role would be the National Environmental Policy 
Act (NEPA), Clean Water Act (CWA), Safe Drinking Water Act (SWDA), Resource Conservation and 
Recovery Act (RCRA), and Toxic Substances Control Act (TSCA) [176, 177].  Potential mechanisms of 
regulation within the relevant laws are shown in Table 14.   
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Table 14: Summary of current statutes, which could be adapted to regulated PCPPs 
Law Potential Implications and Effects  
NEPA 
• Apply law to FDA and require Environmental Impact 
Assessment (EIS and EA) process  
• Do not categorically exclude pharmaceuticals (concentration at 
point of entry less than 1 bbp) 
CWA 
• Apply technology forcing mechanism under Section 
301(b)(2)(A)  
• Consider PCPPs as toxic pollutants by classifying them as such 
SWDA 
• Utilizes a health based rationale, and this law is not as useful 
since “little is known about the impacts of exposure at low 
concentrations of pharmaceuticals over long periods of time” 
• Still offers EPA a potential regulatory mechanism for EPA by 
promulgating standards 
RCRA 
• Governs land disposal of hazardous waste, but exempts 
domestic sewage or anything from domestic sources  
• Flushed PCPPs are outside the purview of the act  
• Hospitals and nursing homes are subject to RCRA’s provisions 
TSCA • Explicitly excluded pharmaceuticals from its coverage 
Source: [176, 177] 
 
While there are many environmental laws on the books, the most promise for regulating micropollutants is 
with RCRA, SWDA, SWA, and NEPA.  With that said, these laws would place a large strain on the 
pharmaceutical industry and WWTPs.  Further research would need to be conducted to ascertain which 
type of technology would qualify as the best available (BAT – under the CWA) without becoming so cost 
prohibitive as to make either of these industries overly burdened.  Additionally, the public health benefit 
must remain at the forefront of this decision process as laws and regulations potentially could become 
promulgated.      
It is likely that PCPPs will become regulated in some form or another over time and therefore, it 
will be necessary to utilize emerging and established technologies to remove these contaminants.  The 
implementation of different technologies will then generate new types of wastes that will need to be 
disposed of.  For example, the use of filtration processes results in membranes that must be disposed of; the 
use of ozone processes creates the potential for air pollution issues and regulation under the CAA; and the 
use of adsorption processes generate potentially hazardous waste from activated carbon that cannot be 
regenerated.  SDWA, RCRA, and CWA all become potentially become applicable with new treatment 
technologies and may place additional costs and concerns slowing enactment.  Therefore, the 
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implementation of new treatment methods will necessitate further application of existing statutes, causing 
an increase in costs and adding potentially new environmental harms to be concerned about.  With this said, 
the value of removing micropollutants from discharges to the environment may offset the concerns over 
new hazardous waste generation.   
Finally, new environmental regulation could be developed specifically aimed at preventing 
environmental impact and adverse public health impact from endocrine disrupting compounds and 
micropollutants.  This act like would take a form similar to the CWA and would set effluent limits from 
point sources to help protect human health and the environment.  While no such regulation or statute is 
being considered, it is highly probably that if the US were to adopt the Precautionary Principle as it applies 
to environmental issues, then this sort of act could come into fruition within the next few decades.  The 
implications of such an act would be tremendously favorable for the protection of health, but would likely 
increase the costs of treatment of water and wastewater.  Therefore, the enactment of such a statute would 
need to be carefully considered in the context of costs and benefits.   
This work recommends such a statute be enacted, not only due to the moral imperatives of the 
precautionary principle, and the moral imperatives of affording future generations the same opportunities 
that our generation was afforded, but also for the potential economic and technical stimulus that such a 
large scale implementation would spur.   
2. Paths forward  
 
Given the expense associated with each of the various tertiary treatment methods outlined above, 
it is highly unlikely that a combination of them would be employed and thus the optimal treatment method 
to move forward with would have the ability to remove biologically recalcitrant molecules, be energy 
efficient, and be acceptable from a cost and benefit analysis.  In terms of what effectively removes the most 
PCPPs, there are only a few contenders including, Wet Air Oxidation, Plasma Arc Waste Disposal, and 
UV/Ozone treatments.  With that said, each of these pieces of technologies each have their own pros and 
cons associated with them.  In terms of capital cost, Plasma Arc Waste Disposal is the most expensive, 
while biological treatment is the cheapest.  On the other hand, in terms of overall versatility and 
minimization of environmental impacts, Plasma Arc Waste Disposal does the most good.  Therefore, it is 
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recommended that Plasma Arc Waste Disposal be utilized for the final treatment of PCPPs after RO 
removes a majority of the contaminants of wastewater effluent.  A close second treatment option would be 
Wet Air Oxidation.  The recommended treatment methods in this thesis are shown in Figure 30 on page 
104.   
There are numerous benefits to treating the retentate of RO with Plasma Arc Waste Disposal.  
First, in the retentate stream, there are many different valuable metals that can be recovered with this 
technology which can be resold to help offset treatment costs [167, 166].  Additionally, the retentate 
contains many biologically recalcitrant PCPPs, which can be completely degraded along with other 
organics to form syngas.  Any other inorganic toxics will be vitrified and will be impermeable conferring a 
huge advantage over incineration where toxic ashes are still generated.  Furthermore, the 300:1 volume 
reduction that will not need to be disposed of in another fashion and the water will be vaporized for syngas 
production. Water will come back into the process during the combustion process primarily in the form of 
CO and H2 with some impurities.  This process may present problems, since Plasma Arc Waste Disposal 
was originally designed for the destruction of solid wastes and not liquid wastes so it is unclear whether 
this could actually be implemented.  Further research would be required to determine whether the syngas 
products that would come from a process that is occurring in water.    
On the other hand, Plasma Arc Waste Disposal can be utilized to generate electrical energy from 
MSW and used to power WAO to degrade micropollutants.  This would be the ultimate combination of 
technology since the input of MSW into 
the Plasma Arc Waste Disposal would 
produce electrical energy, keep MSW 
out of landfills preventing carbon 
emissions, and would provide a metal 
resale to help offset the huge capital that 
would be needed for this unique 
operation.  With the electrical energy 
requirements met, WAO could be 
conducted on the effluent from the 
 
Figure 30: Ideal treatment methods for the removal of PCPPs 
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WWTP.  This would not only decrease the COD of the effluent entering the environment, but also the 
water would be saturated with oxygen.  Finally, the oxidation of organics would help to keep 
micropollutants out of the environment.   
With the high promise of treatment with WAO and Plasma Arc Waste Disposal, further research and 
development must be conducted to allow for widespread implementation of this technology, which is 
believed to be one of the best solutions for removing PCPPs from wastewater.  The treatment scheme 
suggested for the removal of PCPPs is shown in Figure 30.  Unlike, WAO which is a liquid phase process, 
Plasma Arc Waste Disposal is a solid phase process, so the organics and metals amenable to treatment must 
be consolidated into a solid phase or research must be conducted on the feasibility of applying this 
treatment method to the liquid phase.  One potential mechanism of consolidating the liquid effluent is to 
utilize an evaporator, although this does create the need for further energy production.  On the other hand, it 
may be more cost effective to apply WAO and utilize only the energy from Plasma Arc Waste Disposal to 
run this process via the pyrolysis of waste products.  Either of these options present feasible alternatives to 
solving the issues associated with PCPPs being discharged into the environment and will decrease the 
burden on the environment in terms of landfill requirements.  In order to proceed with this kind of 
recommendation further research and development must be conducted in Plasma Arc Waste Disposal and 
its application to the liquid phase treatment, feasibility and characterization of end products from the liquid 
phase, and improvement on reactor materials (utilize research from fusion) to extend plant life.  
Additionally, financing will need to be extended to allow for plants to be built, but it is unlikely that banks 
will extend financing for these high capital cost plants.  Therefore, either federal or private equity firms are 
envisioned to finance the loans for these massive capital expenditures.  Furthermore, it is predicted that as 
climate change becomes a larger issue and carbon offsets become more of a reality, the application of 
Plasma Arc Waste Disposal will become a more and more attractive disposal methodology.   
3. Future Research and Approaches 
There are many different potential approaches that could be utilized to help treat biologically 
recalcitrant PCPPs that are not yet technologically or economically feasible.  This thesis has examined 
many different treatment methods, but there is still not a technology that can be easily applied at all scales 
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of WWTPs.  Therefore, continued research and development in conjunction with technological innovation 
and financing will be needed to help address the removal of micropollutants in the coming years.   
The first set of solutions to the micropollutant problem involves conditioning or engineering of 
algae or bacteria that could be added within the WWTP.  In the past, bioaugmentation was touted as a 
method for the removal of undesired compounds in a WWTP.  The implementation of bioaugmention 
requires that bacteria be grown and conditioned to the compounds that are desired to be removed, and thus 
high concentrations of the compounds are utilized to acclimatize these bacteria [178].  Once sufficient 
yields are obtained, the bacteria are freeze dried for transportation to their final implementation site, usually 
a WWTP [178].  These conditioned bacteria are then added to the biological treatment process during 
wastewater treatment [178].  The bacteria utilized for these treatment processes is usually a blend of species 
or strains that are proprietary and has been utilized for WWTP, cleaning of grease traps, biological 
treatment of industrial waste products, and degradation of hydrocarbons and petroleum distillates [178].  
Biotechnology and genetic engineering may prove useful in designing microbes for the degradation of 
selected compounds, and this is an area where genetic engineering may prove useful.  The application of 
these microbes to the removal of PCPPs would require the usage of advanced techniques in genetic 
engineering that have not previously been needed in wastewater treatment.  Naturally occurring or 
classically selected microbes have been able to treat many of the compounds of interest, but “there are, 
however, some situations where biotechnology offers potential advantages: for example, to engineer a 
naturally occurring derivative pathway so that it is continuously active in the bacteria, even in the absence 
of a molecule ordinarily needed to activate the pathway…” [179, pp. 271-275].  While past experience with 
many bioaugmentation strategies has not produced highly favorable results, observed increases in 
efficiency were actually due to improvements in plant operations and not due to the addition of the 
conditioned bacteria, there is still room for this technology to have an impact on the removal of 
micropollutants.  A related strategy that can be applied is algae treatment via biotransformation of organic 
chemicals like DDT, napthaline, and phenol into less toxic substances [180].  It should be noted that algae 
are rarely capable of complete degradation, although partial degradation can be expected with some 
biotransformation [180].  Therefore, there is a potential to modify algae utilizing genetic engineering to 
create natural pathways for the degradation of organic compounds including PCPPs.  Another potential 
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source of degradation of these compounds could be reverse engineering the bacteria that produce many of 
these pharmaceutical agents.  Further research should be conducted on algae and bacteria to effectively 
degrade PCPPs, as the addition of these compounds would provide a biologic method for their removal.  
Another potential method would be to isolate the enzymes that are responsible in bacteria or algae for 
degradation and mass produce them.  These enzymes could then be added during the wastewater treatment 
process to degrade micropollutants of concern that do not respond to conventional biological treatment.  It 
could also be imagined that algae or bioaugmentation would provide an excellent means of removing 
PCPPs.   
In terms of pros and cons, there are numerous different potential reasons for implementing 
bioaugmentation or algae to degrade micropollutants.  One of the largest drawbacks associated with the 
implementation of bioaugmentation or algae is the costs of developing these particular processes.  Genetic 
engineering processes are expensive and can be largely a trial and error process to get to the exact set of 
pathways necessary to allow for algae or bacteria to degrade substances of interest.  Additionally, the 
implementation of bioaugmentation requires that the bacteria be conditioned at high concentrations of the 
compounds to be degraded.  Pharmaceutical compounds are remarkably expensive, and conditioning 
bacteria with high concentrations will be extremely expensive.  Furthermore, considering the amount of 
bacteria needed to treat micropollutants for a single treatment plant, a substantial operation would need to 
be established in order to yield enough conditioned bacteria.  On the other hand, treatment with algae or 
bioaugmentation has the advantage of being easy to implement (freeze dried bacteria can be added to the 
WWTP), requires no additional capital expenditures for equipment at the WWTP, and in situ treatment has 
shown that bioaugmentation is an effective strategy for degrading organic compounds.  Therefore, algae 
and bioaugmentation should be further investigated for the removal of PCPPs, and if feasible, could be a 
viable method for removing these compounds.   
Another attractive set of solutions revolve around the usage of sorption processes by utilizing 
novel methods.  New materials could be utilize for sorption processes that address the expense associated 
with regenerating the sorbent and making the sorbent specific to the micropollutants of interest.  One 
possible means of removing micropollutants, comes from biomaterials research, where surfaces can be 
coated with different receptors, antigens, etc. to allow for molecules to bind or not bind to a surface [181].  
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In a similar fashion to medical devices, novel materials could be devised with the receptors that PCPPs 
bind to within the human body, thereby making the sorbents highly specific.  For example, if the removal 
of Esterone is desired, then placing an estrogen receptors or estrogen G protein-coupled receptors on the 
surface of the sorbent would be a means of selectively removing Esterone compounds [182].  While it is 
likely that these surfaces would not be easily regenerated, research could be done to address the possibility 
of these types of surfaces.  Additionally, to improve surface area, which improves sorption efficiency, 
nanoparticles coated with these receptors could be utilized to remove compounds of interest.  Another 
novel material that may prove to be useful for water treatment technology is graphene.  Membranes 
composed of graphene have already been proposed as an alternative to RO for desalting water, allowing for 
improved flux across the membrane [183].  Also, the role that functional groups play on a nanoporous 
graphene filter, demonstrate a degree of customizability while preserving that flow can still occur [183].  
These types of materials definitely have the potential to revolutionize water treatment and become the 
breakthrough that is needed to address sorption and filtration as a potential means of removing 
micropollutants.  Therefore, while not technologically developed yet, research and development should be 
directed at novel sorbents and membranes like graphene to aid in the removal of PCPPs.  It should be noted 
that a similar problem to RO will be encountered in the reject stream where there will be a concentrating 
effect and that will need to be treated.  Finally, a novel material for sorption could be discovered that is 
easily regenerated and has tight reversible binding.  Future research should be directed towards these novel 
adsorbents along with the fabrication of graphene, so that adsorption becomes a more viable treatment 
methodology for treating micropollutants.   
In terms of pros and cons, there are numerous different potential reasons for implementing 
graphene, nanotechnology, or developing a novel sorbent to remove micropollutants.  First, graphene is a 
high potential technology that in the future could be utilized to remove PCPPs.  Currently, graphene is still 
so new that fabrication costs are high and future uncertain, so it remains unclear how to mass-produce this 
material.  This is the largest drawback, in conjunction with it is a largely unproven technology, but with 
time will become more studied.  On the other hand, graphene has many positives: it provides higher flux 
than RO allowing for smaller modules and less energy needed to generate pressure differentials to drive 
filtration, and the surface is modifiable to improve flux rates.  Additionally, the structure of the graphene 
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without punching holes into it is impermeable to even helium, making the material extremely attractive as a 
filter that operates on the size exclusion principle [183].  While graphene holds great promise, another 
potential technology to be utilized is nanotechnology where the receptors of interest are covering 
nanoparticles.  Nanotechnology for water treatment has many disadvantages over other approaches 
including: receptors must be isolated and reproduced, which is an expensive process, high cost due to shear 
number of molecules that have to be manufactured, and large processing costs.  On the other hand, 
nanotechnology has many potential benefits including: high specificity for the compounds of interest, 
won’t remove minerals from the water like RO, and there is a wealth of knowledge that can be utilized in 
generating these types of particles from biomaterials research.  Finally, if society follows previous paths, 
depending on a novel material to be discovered to bail us out of the problems associated with PCPP is a 
potential option.  Waiting for a novel material to be developed has many shortcomings such as, basic 
research and development is slow and costly, research and development advances are sporadic, research 
and development costs are huge and there is no certainty in that a breakthrough will be found in a given 
timeframe.  Alternatively, a breakthrough could revolutionize the industry, and may allow for cost-effective 
and seamless removal.  Many of the compounds of interest do theoretically adsorb, so this method of 
removal holds promise.  Therefore, sorption processes hold promise especially with graphene processes, 
and as a result, continued research should be conducted in this area to increase the probability that a major 
breakthrough could occur.   
Additional methods also revolve around the application of currently available industrial and 
chemical processes to the treatment of PCPPs.  Multi-stage flash distillation (MSF) has been used as an 
alternative to RO for producing desalted water.  MSF works by flashing a small amount of water into steam 
in multiple stages, running past cold water resulting in a countercurrent heat exchanger [184].  The largest 
demand of this technology is energy; so many times the plant is coupled to a cogeneration facility where 
the heat can be used to heat the influent water of the MSF [184].  While desalting is the traditional usage 
for this particular technology, it could be imagined that the flash distillation process would be useful for the 
removal of PCPPs from wastewater.  The result of applying this technology would be a very high quality 
effluent which would be largely devoid of micropollutants, unless these compounds possessed large vapor 
pressures or were able to become volatilized.  Therefore, MSF may hold promise as a technology for the 
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removal of micropollutants from wastewater.  Another potential mechanism of removal of PCPPs is 
Chromatography.  The mobile phase is where compounds of interest are dissolved, while these compounds 
move through the stationary phase within an instrument [185].  Different compounds will move at different 
speeds, causing a separation of these compounds based off the compound’s partition coefficient [185].  As 
a result, given that there is a large degree of variation in partition coefficients of PCPPs; chromatography 
could be utilized hypothetically to separate these compounds.  Research and development would be needed 
to scale up these processes to the size of a WWTP, but the separation needed for this process would not be 
extremely high in resolution, which should help to drive down potential costs.  Finally, molecular 
differentiation could be utilized as another means of removing micropollutants from wastewater.  While not 
perfectly related, density overlap sorting recently has been utilized to separate plastics for recycling.  This 
process allows for mixed plastics to be separated on the basis of multiple variables (temperature, pressure, 
shear, and mass) [186].  This novel process allows for significant waste reduction by sorting by density.  
Therefore, if this process were applied to the removal of PCPPs, it may be possible to separate these 
particles based off shear, pressure, temperature, and mass difference.  While this application would require 
further research, it potentially would be very worth exploring considering the success that the plastics 
industry has experienced with this technology.   
In terms of pros and cons, there are numerous different potential reasons for implementing MSF, 
chromatography, or density overlap sorting for the removal of PCPPs.  MSF has numerous pros including 
being a straight forward process, has no reduced heat transfer due to scaling in the reactor, and the presence 
of suspended solids do not affect the process [184].  On the other hand, MSF is energy intensive, the steam 
is partially consumed during the process, has the recurring problem of having a left over substance to treat 
that is now highly concentrated in the liquid phase, and the output stream will not necessarily be 
completely devoid of PCPPs [184].  An alternative technology is the application of chromatography to 
remove micropollutants of interest.  One of the most promising technologies is density overlap sorting, 
which has the pros of utilizing pressure, temperature, and shear to differentiate materials, where most 
technologies only utilize one of these factors [186].  This technology also has a lower capital investment 
than other similar processes and allows for high quality final products to be produced [186].  Like many 
separation technologies, density overlap sorting is highly energy intensive and as a result, the recovered 
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products must be quite valuable to offset a part of this cost.  Finally, chromatography holds promise with its 
ability to separate out mixtures effectively, but it is ultimately not very cost effective and is somewhat slow 
depending on the complexity of the feed mixture [185].  Although, with further research, a fast system, 
much like the quick gas chromatography used in airports to screen for bomb materials, could be developed 
to remove PCPPs from wastewater [187].  Therefore, while these applications would require further 
research, there is the potential, especially with density overlap separation, to remove many of the PCPPs of 
interest.   
Finally, truly novel processes and treatment methods could be developed to treat micropollutants 
and will require  truly out of the box thinking to address these recalcitrant compounds.  Materials research 
will be necessary, along with processing engineering for any new process to be implemented to remove 
PCPPs.  There are three relatively new technologies that potentially could be utilized in the treatment of 
water to remove PCPPs including, fabric filtering with novel materials that could repel undesired organics, 
capsular perstraction (“enveloping of pre-selected organic solvents within a porous hydrogel membrane to 
form liquid-core microcapsules”) [188], and nanotechnology of some form.  To construct filters, a novel 
hydrophobic material is required.  One such material can repel water and adsorb oil, while another material 
has been discovered and considered for use in rain jackets that are both breathable and lightweight [189].  
There is the potential for these materials to be adapted for the removal of PCPPs by utilizing these 
compounds successful rejection of water and adsorption of hydrophobic compounds, to trap the PCPPs in 
the hydrophobic portion and thereby generate clean water.  Further research and development would be 
required in order to even demonstrate the potential for implementing this type of technology.  Additionally 
the usage of nanotechnology and capsular perstraction may hold promise as strategies for the removal of 
PCPPs from water [188, 190].  Whelehan et al. demonstrated the viability of capsular perstraction for 
rapidly removing seven PCPPs of interest, but these experiments would need to be repeated in the context 
of wastewater effluent to ascertain the role of competitive substrates amongst other factors.  Like any of the 
potential nanotechnology efforts, these methods will be expensive and will require large scale 
manufacturing to allow for the treatment of wastewater at the scale of a WWTP.  Therefore, further 
research should be undertaken to determine how nanotechnology could play a role in potentially removing 
micropollutants, as well as into methods for mass producing these particles.  Additionally, nanotechnology 
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in the form of nanoparticles may hold promise for the ability to remove PCPPs from water [190].  Again 
further research would need to be conducted as to the type of nanoparticles would be suitable for 
effectively, rapidly, and cost effectively removing micropollutants.  Therefore, truly novel processes and 
treatment methods may hold a plausible solution for the removal of PCPPs from water, but these techniques 
are so new that it is extremely difficult to predict if and when they could be available for usage in the field.   
If prioritization of research funding must occur, then the most promising technologies to remove 
PCPPs from water should preferentially be funded over those that are more of a stretch.  As a result of the 
analysis in this work, the funding potential should go to Plasma Arc waste disposal, Wet Air Oxidation, 
reverse osmosis, 
bioaugmentation, and 
grapheme filters.  The rest of 
the technologies that are 
outlined in this work still have 
the potential to be a part of the 
solution for removing 
micropollutants from water, 
but they will require heavy 
investment in research and 
development prior to 
becoming viable.  With that 
said, these solutions should 
not be discounted and should 
still be funded.    
4. Model plant design  
 
In order to effectively remove PCPPs from wastewater utilizing current technology, there a 
numerous different paths that could be taken to remove these compounds effectively.  It should be noted 
that while there are numerous treatment technology combinations that could accomplish this task, the costs 
 
Point in System 
Concentration 
(½¾/À) Volume (MGD) 
Mass 
Total 
(lbs) 
Biological WWTP Effluent 75 100 6245931 
RO retentate and Recycle 7.5 10 62459 
Combined Recycle and  
Retentate (1 pass) 68.86 110 6308390 
Effluent out of 2nd Pass of 
WWTP 0.69 110 63084 
Figure 31: With the addition of the recycle loop from the retentate, the 
concentration of the influent increases, thereby increasing the likelihood 
that biological degradation will occur.   
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are disregarded.  As part of a theoretical exercise, the plant design paths are meant to establish which 
technologies could accomplish the removal.  The various design paths are shown in Figure 32 (page 114).  
One optimal treatment path relies on tertiary treatment of WWTP effluent in the form of Wet Air Oxidation 
to ultimately degrade the PCPPs of interest.   This would require the Wet Air Oxidation module, likely a 
Zimpro® process, to be scaled to the size of the treatment plant (100-1000 MGD).  One of the advantages of 
this path is that utilizes established technology and that as the technology becomes more widely 
implemented, the capital cost is likely to decrease.   Another likely treatment path utilizes Reverse Osmosis 
as the first step in the treatment sequence of effluent.  From here Plasma Arc Waste Disposal can be used to 
generate energy for the RO process and the tertiary treatment process or with additional research could be 
directly applied to the retentate.   A final treatment scheme would be to recycle the retentate of RO to the 
biological WWTP.  This would increase the mass flow of PCPPs into the biological process, thereby 
potentially allowing for these substances to be degraded (see Figure 31, page 112).  By recycling the 
retentate stream into the treatment plant, an additional 10 MGD of water will flow into the plant at an 
average concentration of 7.54 µg/L.  The effect of treatment in this fashion is a 10 fold reduction in the 
mass load to the environment, which potentially avoids adverse environmental impacts.  Therefore, by 
selecting an optimal treatment scheme, there is the potential to avoid adverse effects and to remove many 
of these PCPPs of concern.   
[191] [192] [193] [194] [190] [195] [196] [197] [114] [198] [199] [200] [201] [202]  [203] [204]  [205] 
[206] [207] [208] [209] [210] [211] [212] [213] [214] [215] [216] [217] [218] [219] [220] [221] [222] 
[223] [224] [225] [226] [227] [228] [229] [230] [231] [232] [233] [234] [235] [236] [237] [238] [239] 
[240] [241] [242] [243] [244] [245] [246]
  
 
Figure 32: Potential treatment methods demonstrate that there are numerous paths for the removal of PCPPs.  Each of the different paths will have different costs 
and benefits associated with it and will achieve different levels of removal. The least expensive path will involve a recycle loop of the rententate for biological 
treatment, which could be powered by Plasma Arc Waste Disposal (produces energy from municipal and industrial wastes).  
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5. Final Thoughts 
 
Currently there are not any viable technologies to treat these recalcitrant compounds in terms of 
applicable technology, cost-effectiveness, or scalability to current WWTP volumes.  First off, biological 
treatment, either as plug-flow or CSTR, for many of the PCPPs is not going to occur due to the competitive 
effects associated with the many compounds present at higher concentrations in the WWTP.  Secondly, 
PCPP adsorption density will be a dose dependent process and with the costs associated with activated 
carbon, it is highly unlikely this technology will be able to be implemented in the field.  Additionally, the 
higher concentration species will be more competitive and be sorbed preferentially over PCPPs.   
Therefore, both sorption processes and biological treatment have similar shortcomings with respect to 
higher concentration species being preferentially removed due to competitive kinetics.   
 There are currently available technologies, that if scaled correctly, which could adequately remove 
PCPPs from water, but technological breakthroughs may make implementation more cost-effective and 
likely.   The current best available technology, barring a major technological breakthrough is Wet Air 
Oxidation in combination with Plasma Arc Waste Disposal.  In this treatment scheme, the addition of RO 
could be considered and then Plasma Arc Waste Disposal could be utilized to treat the retentate.   However, 
the addition of RO will still present the challenge of membrane fouling which must be solved in order for 
RO to be a viable technology.  Finally, technological breakthrough will be crucial to successfully removing 
micropollutants from WWTP’s effluent.   Technologies that hold the most promise include: Wet Air 
Oxidation, RO, bioaugmentation, and grapheme filters.  Specifically, there is optimism surrounding 
graphene filters as a breakthrough, which could drastically reduce the costs associated with RO and prevent 
membrane fowling.  As a result, then applying Wet Air Oxidation to the retentate might be a good method 
of removal.  Future research will be needed to advance technologies to the point of large scale 
implementations and to drive down the large capital costs associated with many of the potential treatment 
technologies.    
 As a society, we have a moral obligation to ensure that there are adequate sources of fresh water 
for future generations.  By implementing technologies such as Plasma Arc Waste Disposal, there is the 
ability to fulfill the obligation to future generations for water and to help impact climate change in a 
positive fashion by making sure that less trash is destined for landfills.  Additionally, by further purifying 
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the water destined for the environment, the negative consequences of PCPPs to the environment will be 
avoided and further degradation of water supplies will be avoided.  While there are many positives and 
cause for optimism, there should always be a cautionary undertone.  The lessons drawn from nuclear power 
plants, which like many of the proposed alternative technology implementations are capital intensive, 
demonstrated that there is resistance to funding such large upfront capital expenditures.  Generally, 
economics tend to drive policy, and thus, there will need to be further research to determine how to drive 
down the capital costs of alternative treatment methods that are able to effectively remove PCPPs from 
wastewater.  Therefore, while the economics may be prevailing most decision, hopefully society’s ethical 
and moral framework will prevail and chose to implement new technologies to remove PCPPs from 
wastewater; thereby, improving water quality for future generations and preventing additional 
environmental damage.  
  
Appendix I: Freundlich Literature Values  
 
Compound n Kf Original Kf units Converted Kf 
(mg/g)(mg/L)^n 
Carbon Author 
Phenol 0.69 0.22 (mg/g)(mg/L)^(n) 0.22 EFB 500 [130] 
 
0.3 2.79 (mg/g)(mg/L)^(n) 2.79 EFB 800 [130] 
 
0.616 6.193 (mg/g)(mg/L)^(n) 6.193 GAC, NS [131] 
 
2.525253 0.851 (mg/g)(mg/L)^(n) 0.851 RGM1 [132] 
 
2.267574 0.863 (mg/g)(mg/L)^(n) 0.863 RB2 [132] 
 
2.336449 1.452 (mg/g)(mg/L)^(n) 1.452 ROW0.8supra [132] 
 
2.380952 0.209 (mg/g)(mg/L)^(n) 0.209 Cgran [132] 
 
0.54 21 (mg/g)(mg/L)^(n) 21 Fitrasorb 300 [133] 
 
0.037 0.371 (mg/mg)(mg/L)^(1/n) 37 GAC [134] 
 
1.694915 2.11 (mg/g)(mg/L)^(n) 2.11 Modified Bentonite, ph 4 [135] 
 
2.272727 3.72 (mg/g)(mg/L)^(n) 3.72 Modified Bentonite, ph 7 [135] 
 
3.030303 8.35 (mg/g)(mg/L)^(n) 8.35 Modified Bentonite, ph 12 [135] 
 
2.47 0.04177 (mol/L)*(L/g)^n 38.097 PX-21 [202] 
 
0.1912 89.43 (mol/L)*(L/g)^n 89.43 Filtrasorb-400 [136] 
 
3.142 53.985 (mg^(1-1/n))*(L^1/n)/g 53.985 GAC [137] 
 
0.56 0.17 L/mg 0.17 GAC-70 [138] 
 
0.42 0.32 L/mg 0.32 Com GAC-70 [138] 
 
0.37 0.6 L/mg 0.6 GAC-80 [138] 
 
2.380952 37 (mg/g)(L/mg)^(1/n) 37 GAC [138] 
 
3.134796 36.3 (mg/g)(L/mg)^(1/n) 36.3 F-400 [138] 
 
0.4 0.046 (moles/g)*(L/mole)^n 44.355 Coconut shell Activated Carbon [247] 
 
0.38 0.021 (moles/g)*(L/mole)^n 25.461 Coconut shell Activated Carbon [138] 
 
0.167 0.008 (moles/g)*(L/mole)^n 111.207 Coconut shell Activated Carbon [138] 
 
0.117 0.011 (moles/g)*(L/mole)^n 271.093 Coconut shell Activated Carbon [138] 
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3.846154 50 mg/g 50 Filtrasorb-400 [119] 
2-CP 2.066116 2.512 (mg/g)(mg/L)^(n) 2.512 RGM1 [132] 
 
2.178649 2.518 (mg/g)(mg/L)^(n) 2.518 RB2 [132] 
 
2.439024 3.75 (mg/g)(mg/L)^(n) 3.75 ROW0.8supra [132] 
 
2.717391 0.667 (mg/g)(mg/L)^(n) 0.667 Cgran [132] 
 
28.57143 169.2 (mg/g)(L/mg)^(1/n) 169.2 SA4 [140] 
 
3.875969 39.3 (mg/g)(L/mg)^(1/n) 39.3 CA1 [140] 
 
31.25 155.4 (mg/g)(L/mg)^(1/n) 155.4 PKDA [140] 
 
0.286 35.4 (mg/g)(L/mg)^(1/n) 35.4 Cagran [140] 
 
2.841 0.916 (mg/g)(mg/L)^(n) 0.916 Modified Bentonite [141] 
 
2.302 0.566 (mg/g)(mg/L)^(n) 0.566 Modified Bentonite [141] 
 
2.793 57.795 (mg^(1-1/n))*(L^1/n)/g 57.795 GAC [137] 
4-CP 1.872659 3.034 (mg/g)(mg/L)^(n) 3.034 RGM1 [132] 
 
1.972387 3.076 (mg/g)(mg/L)^(n) 3.076 RB2 [132] 
 
2.040816 4.256 (mg/g)(mg/L)^(n) 4.256 ROW0.8supra [132] 
 
2 0.955 (mg/g)(mg/L)^(n) 0.955 Cgran [132] 
 
3.593 0.03458 (mol/L)*(L/g)^n 134.341 PX-21 [202] 
 
3.737 101.504 (mg^(1-1/n))*(L^1/n)/g 101.504 GAC [137] 
DCP 1.828154 6.934 (mg/g)(mg/L)^(n) 6.934 RGM1 [132] 
 
1.960784 5.794 (mg/g)(mg/L)^(n) 5.794 RB2 [132] 
 
2.293578 9.333 (mg/g)(mg/L)^(n) 9.333 ROW0.8supra [132] 
 
1.858736 1.75 (mg/g)(mg/L)^(n) 1.75 Cgran [132] 
 
0.144033 220.9557 ??? 220.956 Filtrasorb-400 [136] 
 
3.925 128.728 (mg^(1-1/n))*(L^1/n)/g 128.728 GAC [137] 
TCP 1.934236 13.37 (mg/g)(mg/L)^(n) 13.37 RGM1 [132] 
 
2.159827 9.55 (mg/g)(mg/L)^(n) 9.55 RB2 [132] 
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2.109705 13.8 (mg/g)(mg/L)^(n) 13.8 ROW0.8supra [132] 
 
1.620746 2.965 (mg/g)(mg/L)^(n) 2.965 Cgran [132] 
 
1.25 22.04 (mg/g)(L/mg)^(1/n) 22.04  [143] 
 
1.219512 31.48 (mg/g)(L/mg)^(1/n) 31.48  [143] 
 
1.190476 35.42 (mg/g)(L/mg)^(1/n) 35.42  [143] 
 
0.1512 588.7 ??? 588.7 Filtrasorb-400 [136] 
 
6.821 284.41 (mg^(1-1/n))*(L^1/n)/g 284.41 GAC [137] 
PCP 3.236246 28.84 (mg/g)(mg/L)^(n) 28.84 RGM1 [132] 
 
2.688172 26 (mg/g)(mg/L)^(n) 26 RB2 [132] 
 
3.134796 31.33 (mg/g)(mg/L)^(n) 31.33 ROW0.8supra [132] 
 
2.132196 14.12 (mg/g)(mg/L)^(n) 14.12 Cgran [132] 
p-Nitrophenol 2.358 1.1824 (mg/g)(mg/L)^(n) 1.1824 Modified Bentonite [141] 
 
4.235 0.0302 (mol/g)(mol/L)^n 190.211 PX-21 [202] 
 
0.1494 166.5 - 166.5 Filtrasorb-400 [136] 
 
 
  
  
Appendix II: EasyFitXL Distributions 
 
Bernoulli Error Function Geometric Levy Pareto Reciprocal 
Beta Exponential Gumbel Max Logarithmic Pareto 2 
(Lomax) 
Rice 
Binomial F Gumbel Min Logistic Pearson 5 Student's t 
Burr Fatigue Life Hyperbolic 
Secant 
Log-Gamma Pearson 6 Triangular 
Cauchy Frechet Hypergeometric Log-Logistic Pert Uniform 
Chi-
Squared 
Gamma Inverse Gaussian Log-Pearson 3 
(LP3) 
Poisson Wakeby 
Dagum Generalized Extreme 
Value 
Johnson SB Lognormal Phased Bi-
Exponential 
Weibull 
Discrete 
Uniform 
Generalized Gamma Johnson SU Negative 
Binomial 
Phased Bi-
Weibull 
 
Erlang Generalized Logistic Kumaraswamy Nakagami Power Function  
Error Generalized Pareto Laplace Normal Rayleigh  
Source: http://www.mathwave.com/products/easyfit_desc.html#dist  
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Appendix III: Final Data Distributions 
33%, Ce = 0.01mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
1 Beta 0.36315 1 34.211 28 N/A 
22 Gen. Pareto 0.36563 2 14.499 6 N/A 
15 Frechet  0.36991 3 23.69 14 15.153 42 
40 Pearson 5 0.37237 4 46.465 29 17.717 43 
41 Pearson 5 0.37238 5 46.465 30 17.717 44 
33 Log-Logistic 0.38241 6 22.829 12 6.4607 24 
35 Lognormal 0.38301 7 26.776 17 5.9629 19 
36 Lognormal 0.38301 8 26.776 16 5.9629 18 
14 Fatigue Life 0.38385 9 31.866 24 1.9923 7 
 
…
 
 
…
 
 
…
 
 
…
 
19 Gen. Extreme Value 0.45275 24 13.442 3 2.7576 9 
 
 
# Distribution Parameters 
19 Gen. Extreme Value k=-1.456  σ=0.003  µ=0.00694 
20 Gen. Gamma k=19.379  α=0.01887  β=0.01044 
21 Gen. Gamma k=0.33402  α=1.1094  β=0.00225 
22 Gen. Pareto k=-4.8204  σ=0.06708  µ=-0.00518 
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33%, Ce = 0.1 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
40 Pearson 5 0.3742 1 39.388 28 8.9734 39 
39 Pearson 5 0.37422 2 39.388 29 8.9742 40 
35 Lognormal 0.37432 3 27.454 17 6.2157 31 
34 Lognormal 0.37432 4 27.454 16 6.2157 30 
21 Gen. Pareto 0.38013 5 14.338 5 N/A 
15 Frechet  0.38285 6 24.604 13 16.494 43 
12 Fatigue Life 0.38619 7 32.231 22 2.0282 6 
13 Fatigue Life 0.38619 8 32.231 21 2.0282 5 
 
…
 
 
…
 
 
…
 
 
…
 
18 Gen. Extreme Value 0.44318 23 12.643 2 2.9572 8 
 
…
 
 
…
 
 
…
 
 
…
 
20 Gen. Gamma 0.47845 31 33.335 27 3.6362 15 
 
 
# Distribution Parameters 
18 Gen. Extreme Value k=-1.5454  σ=2.7898E-4  µ=7.1357E-4 
19 Gen. Gamma k=20.628  α=0.02092  β=0.00103 
20 Gen. Gamma k=0.35502  α=1.2229  β=2.0507E-4 
21 Gen. Pareto k=-5.2424  σ=0.00737  µ=-5.3399E-4 
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33%, Ce = 0.2 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
35 Lognormal 0.37176 1 27.634 16 4.4225 23 
34 Lognormal 0.37176 2 27.634 15 4.4225 22 
39 Pearson 5 0.38489 3 40.759 29 9.3973 40 
40 Pearson 5 0.3849 4 40.759 28 9.3977 41 
15 Frechet  0.38641 5 24.935 13 28.027 44 
13 Fatigue Life 0.38692 6 32.35 22 2.0395 7 
12 Fatigue Life 0.38692 7 32.35 21 2.0395 8 
21 Gen. Pareto 0.38721 8 14.369 5 N/A 
 
…
 
 
…
 
 
…
 
 
…
 
18 Gen. Extreme Value 0.43852 22 12.346 2 2.008 6 
 
…
 
 
…
 
 
…
 
 
…
 
19 Gen. Gamma 0.66962 47 72.096 40 1.8318 3 
 
 
# Distribution Parameters 
18 Gen. Extreme Value k=-1.5871  σ=1.3466E-4  µ=3.6093E-4 
19 Gen. Gamma k=21.02  α =0.02161  β=5.1074E-4 
20 Gen. Gamma k=0.361  α =1.2616  β=9.9428E-5 
21 Gen. Pareto k=-5.4476  σ=0.00385  µ=-2.7125E-4 
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33%, Ce = 0.5 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
47 Rice 0.36863 1 71.713 42 N/A 
35 Lognormal 0.37275 2 27.843 16 4.4976 23 
34 Lognormal 0.37275 3 27.843 15 4.4976 22 
25 Inv. Gaussian 0.37739 4 42.476 31 7.9263 36 
12 Fatigue Life 0.38779 5 32.494 21 2.053 8 
13 Fatigue Life 0.38779 6 32.494 22 2.053 9 
3 Burr 0.38837 7 32.556 23 5.7467 32 
15 Frechet  0.39078 8 25.403 13 25.974 43 
21 Gen. Pareto 0.39707 9 14.5 6 N/A 
 
…
 
 
…
 
 
…
 
 
…
 
18 Gen. Extreme Value 0.43204 21 12.024 2 1.239 4 
 
…
 
 
…
 
 
…
 
 
…
 
20 Gen. Gamma 0.46896 30 33.604 26 3.8207 17 
 
 
# Distribution Parameters 
18 Gen. Extreme Value k=-1.6444  σ=5.1268E-5  µ=1.4651E-4 
19 Gen. Gamma k=21.666  α=0.02247  β=2.0288E-4 
20 Gen. Gamma k=0.37063  α=1.3129  β=3.8531E-5 
21 Gen. Pareto k=-5.7383  σ=0.00163  µ=-1.1106E-4 
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33%, Ce = 1 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
25 Inv. Gaussian 0.37257 1 42.231 27 8.8598 36 
34 Lognormal 0.38573 2 28.079 14 4.484 24 
35 Lognormal 0.38573 3 28.079 15 4.4839 23 
13 Fatigue Life 0.38837 4 32.599 19 2.0621 10 
12 Fatigue Life 0.38837 5 32.599 20 2.0621 9 
15 Frechet  0.39409 6 25.722 12 25.555 41 
48 Uniform 0.39491 7 54.794 35 N/A 
45 Rayleigh  0.39881 8 65.302 36 7.1163 34 
 
…
 
…
 
…
 
…
21 Gen. Pareto 0.40511 11 14.655 5 N/A 
 
…
 
 
…
 
 
…
 
 
…
 
18 Gen. Extreme Value 0.42726 19 11.844 1 0.60012 1 
 
…
 
 
…
 
 
…
 
 
…
 
20 Gen. Gamma 0.46405 28 33.667 22 3.9154 19 
 
# Distribution Parameters 
18 Gen. Extreme Value k=-1.6861  σ=2.4691E-5  µ=7.3957E-5 
19 Gen. Gamma k=24.261  α=0.02185  β=9.9738E-5 
20 Gen. Gamma k=0.38489  α=1.3683  β=1.8894E-5 
21 Gen. Pareto k=-5.9569  σ=8.5356E-4  µ=-5.6464E-5 
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33%, Ce = 2 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
25 Inv. Gaussian 0.38518 1 42.518 28 9.0684 37 
13 Fatigue Life 0.38893 2 32.685 19 2.071 11 
12 Fatigue Life 0.38893 3 32.685 20 2.071 12 
49 Uniform 0.39237 4 54.545 35 N/A 
35 Lognormal 0.39316 5 28.179 14 4.5579 28 
34 Lognormal 0.39316 6 28.179 15 4.5579 27 
46 Rayleigh  0.39443 7 62.282 36 7.2828 35 
 
…
 
 
…
 
 
…
 
 
…
 
21 Gen. Pareto 0.41933 13 14.876 5 N/A 
 
…
 
 
…
 
 
…
 
 
…
 
18 Gen. Extreme Value 0.42368 18 11.857 1 0.6536 1 
 
…
 
 
…
 
 
…
 
 
…
 
20 Gen. Gamma 0.46377 30 33.719 22 3.9862 21 
 
 
# Distribution Parameters 
18 Gen. Extreme Value k=-1.7254  σ=1.1934E-5  µ=3.7339E-5 
19 Gen. Gamma k=24.316  α=0.02288  β=4.9812E-5 
20 Gen. Gamma k=0.39304  α=1.4051  β=9.3181E-6 
21 Gen. Pareto k=-6.1683  σ=4.4541E-4  µ=-2.8784E-5 
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33%, Ce = 4 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
25 Inv. Gaussian 0.38243 1 31.41 18 7.6824 36 
13 Fatigue Life 0.38937 2 32.761 21 2.0779 11 
12 Fatigue Life 0.38937 3 32.761 22 2.0779 10 
49 Uniform 0.39014 4 54.562 36 N/A 
46 Rayleigh  0.39052 5 59.33 38 7.4093 35 
34 Lognormal 0.39686 6 28.264 15 4.6312 28 
35 Lognormal 0.39686 7 28.264 14 4.6312 27 
 
…
 
 
…
 
 
…
 
 
…
 
18 Gen. Extreme Value 0.41979 12 11.875 1 0.65068 2 
 
…
 
 
…
 
 
…
 
 
…
 
21 Gen. Pareto 0.4257 17 15.08 5 N/A 
 
…
 
 
…
 
 
…
 
 
…
 
20 Gen. Gamma 0.4752 32 33.733 25 4.0515 22 
 
# Distribution Parameters 
18 Gen. Extreme Value k=-1.7596  σ=5.7831E-6  µ=1.8806E-5 
19 Gen. Gamma k=24.409  α=0.02396  β=2.4848E-5 
20 Gen. Gamma k=0.40183  α=1.4437  β=4.5936E-6 
21 Gen. Pareto k=-6.3559  σ=2.3076E-4  µ=-1.4606E-5 
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33%, Ce = 6 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
46 Rayleigh  0.38821 1 57.651 38 7.4291 35 
49 Uniform 0.38877 2 54.661 37 N/A 
13 Fatigue Life 0.38949 3 32.804 21 2.0798 10 
12 Fatigue Life 0.38949 4 32.804 20 2.0798 11 
34 Lognormal 0.39859 5 28.326 14 4.6539 28 
35 Lognormal 0.3986 6 28.326 15 4.6539 27 
25 Inv. Gaussian 0.40015 7 30.873 18 7.1864 34 
15 Frechet  0.40044 8 26.902 12 30.323 42 
 
…
 
 
…
 
 
…
 
 
…
 
18 Gen. Extreme Value 0.41687 12 11.869 1 0.49355 1 
 
…
 
 
…
 
 
…
 
 
…
 
21 Gen. Pareto 0.4303 17 15.252 5 N/A 
 
…
 
 
…
 
 
…
 
 
…
 
20 Gen. Gamma 0.47946 33 33.724 23 4.0869 22 
 
# Distribution Parameters 
18 Gen. Extreme Value k=-1.7787  σ=3.7776E-6  µ=1.2560E-5 
19 Gen. Gamma k=24.964  α=0.02432  β=1.6468E-5 
20 Gen. Gamma k=0.40871  α=1.4716  β=3.0310E-6 
21 Gen. Pareto k=-6.463  σ=1.5653E-4  µ=-9.7883E-6 
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33%, Ce = 8 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
46 Rayleigh  0.38641 1 56.443 38 5.5147 37 
49 Uniform 0.38761 2 54.738 37 N/A 
12 Fatigue Life 0.38981 3 32.83 25 2.0847 13 
13 Fatigue Life 0.38981 4 32.83 24 2.0847 14 
40 Pearson 5 0.39432 5 43.44 33 9.5284 39 
39 Pearson 5 0.39432 6 43.44 34 9.5284 40 
25 Inv. Gaussian 0.39858 7 30.842 20 5.2938 36 
34 Lognormal 0.39905 8 28.361 17 4.681 31 
 
…
 
 
…
 
 
…
 
 
…
 
21 Gen. Pareto 0.40638 13 14.527 4 N/A 
 
…
 
 
…
 
 
…
 
 
…
 
18 Gen. Extreme Value 0.41154 15 11.652 1 0.70955 2 
 
…
 
 
…
 
 
…
 
 
…
 
20 Gen. Gamma 0.48099 37 33.702 27 4.1271 25 
 
# Distribution Parameters 
18 Gen. Extreme Value k=-1.7847  σ=2.8060E-6  µ=9.4204E-6 
19 Gen. Gamma k=25.312  α=0.02461  β=1.2299E-5 
20 Gen. Gamma k=0.41365  α=1.4915  β=2.2566E-6 
21 Gen. Pareto k=-6.4969  σ=1.1766E-4  µ=-7.3042E-6 
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33%, Ce = 10 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
46 Rayleigh  0.38579 1 55.565 38 5.5099 36 
49 Uniform 0.3874 2 54.786 37 N/A 
12 Fatigue Life 0.38982 3 32.851 21 2.085 13 
13 Fatigue Life 0.38982 4 32.851 22 2.085 14 
25 Inv. Gaussian 0.39795 5 114.07 45 5.2948 35 
34 Lognormal 0.39884 6 28.383 15 4.7022 30 
35 Lognormal 0.39884 7 28.383 16 4.7022 29 
15 Frechet  0.40183 8 27.245 14 0.0252 1 
 
…
 
 
…
 
 
…
 
 
…
 
18 Gen. Extreme Value 0.41412 14 11.922 1 0.56352 3 
 
…
 
 
…
 
 
…
 
 
…
 
21 Gen. Pareto 0.42521 16 15.356 5 N/A 
 
…
 
 
…
 
 
…
 
 
…
 
20 Gen. Gamma 0.48169 34 33.69 25 4.1403 26 
 
# Distribution Parameters 
18 Gen. Extreme Value k=-1.7999  σ=2.2241E-6  µ=7.5771E-6 
19 Gen. Gamma k=25.344  α=0.02498  β=9.8626E-6 
20 Gen. Gamma k=0.4169  α=1.5048  β=1.8041E-6 
21 Gen. Pareto k=-6.5827  σ=9.6090E-5  µ=-5.9309E-6 
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50%, Ce = 0.01 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
41 Pearson 5 0.37273 1 39.363 27 11.524 42 
40 Pearson 5 0.37274 2 39.363 28 11.524 43 
33 Log-Logistic 0.37655 3 19.023 11 13.416 45 
22 Gen. Pareto 0.38202 4 14.351 6 N/A 
36 Lognormal 0.38888 5 20.735 14 0.64475 6 
35 Lognormal 0.38888 6 20.736 15 0.64475 7 
15 Frechet  0.38921 7 20.467 13 19.286 48 
32 Log-Logistic 0.39288 8 22.071 16 7.3125 37 
50 Uniform 0.40373 9 58.017 38 N/A 
 
…
 
 
…
 
 
…
 
 
…
 
19 Gen. Extreme Value 0.44349 17 12.835 3 3.0677 15 
 
…
 
 
…
 
 
…
 
 
…
 
21 Gen. Gamma 0.5031 38 26.604 22 3.1923 18 
 
 
# Distribution Parameters 
19 Gen. Extreme Value k=-1.5287  σ=0.05349  µ=0.13415 
20 Gen. Gamma k=19.882  α=0.01481  β=0.19817 
21 Gen. Gamma k=0.29072  α=1.0316  β=0.03943 
22 Gen. Pareto k=-5.1617  σ=1.3689  µ=-0.10049 
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50%, Ce = 0.1 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
33 Log-Logistic 0.38575 1 17.97 11 17.094 44 
32 Log-Logistic 0.39655 2 19.914 16 3.5967 24 
50 Uniform 0.39673 3 54.511 37 N/A 
1 Beta 0.39798 4 10.925 1 16.815 43 
41 Pearson 5 0.40041 5 42.87 30 12.861 40 
40 Pearson 5 0.40042 6 42.87 31 12.862 41 
22 Gen. Pareto 0.4038 7 14.57 6 N/A 
16 Frechet  0.4039 8 19.047 12 15.13 42 
35 Lognormal 0.40391 9 19.398 13 7.5495 37 
 
…
 
 
…
 
 
…
 
 
…
 
19 Gen. Extreme Value 0.43065 15 12.009 2 1.3211 12 
 
…
 
 
…
 
 
…
 
 
…
 
21 Gen. Gamma 0.50119 36 25.169 22 1.1065 11 
 
 
# Distribution Parameters 
19 Gen. Extreme Value k=-1.6631  σ=0.00477  µ=0.0139 
20 Gen. Gamma k=19.286  α=0.01514  β=0.0199 
21 Gen. Gamma k=0.28185  α=1.0541  β=0.00361 
22 Gen. Pareto k=-5.8356  σ=0.15762  µ=-0.01059 
 
 
  
133 
 
50%, Ce = 0.2 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
27 Kumaraswamy 0.36706 1 11.539 1 25.292 41 
25 Inv. Gaussian 0.37014 2 113.3 43 8.1505 34 
40 Pearson 5 0.38284 3 32.206 25 9.3147 35 
39 Pearson 5 0.38285 4 32.206 26 9.3149 36 
31 Log-Logistic 0.38969 5 18.278 11 16.809 40 
49 Uniform 0.39408 6 54.284 36 N/A 
32 Log-Logistic 0.39983 7 20.227 16 3.6698 23 
14 Frechet  0.40507 8 19.435 12 25.74 42 
15 Frechet  0.40637 9 19.703 13 32.327 43 
 
…
 
 
…
 
 
…
 
 
…
 
18 Gen. Extreme Value 0.42592 15 11.875 2 0.69251 7 
 
…
 
 
…
 
 
…
 
 
…
 
20 Gen. Gamma 0.50777 37 25.47 21 1.1294 10 
 
 
# Distribution Parameters 
18 Gen. Extreme Value k=-1.7051  σ=0.0023  µ=0.00702 
19 Gen. Gamma k=19.884  α=0.01516  β=0.00989 
20 Gen. Gamma k=0.28495  α=1.0734  β=0.00177 
21 Gen. Pareto k=-6.0585  σ=0.08233  µ=-0.00539 
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50%, Ce = 0.5 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
43 Pert  0.37477 1 43.276 34 N/A 
25 Inv. Gaussian 0.38141 2 59.369 39 7.78 30 
39 Pearson 5 0.38461 3 31.97 28 9.3859 31 
40 Pearson 5 0.38464 4 31.97 29 9.3873 32 
49 Uniform 0.39075 5 54.377 38 N/A 
13 Fatigue Life 0.39368 6 26.251 26 31.248 38 
12 Fatigue Life 0.39368 7 26.251 27 31.248 39 
31 Log-Logistic 0.39371 8 18.435 11 25.603 37 
 
…
 
 
…
 
 
…
 
 
…
 
18 Gen. Extreme Value 0.41993 16 11.807 2 0.69775 7 
 
…
 
 
…
 
 
…
 
 
…
 
21 Gen. Pareto 0.42048 17 15.001 6 N/A 
 
…
 
 
…
 
 
…
 
 
…
 
20 Gen. Gamma 0.50862 39 25.332 22 53.156 43 
 
 
# Distribution Parameters 
18 Gen. Extreme Value k=-1.7582  σ=8.7415E-4  µ=0.00284 
19 Gen. Gamma k=20.282  α=0.01669  β=0.00392 
20 Gen. Gamma k=0.30337  α=1.1339  β=6.8854E-4 
21 Gen. Pareto k=-6.3483  σ=0.03479  µ=-0.0022 
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50%, Ce = 1 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
39 Pearson 5 0.36384 1 30.485 26 8.5794 28 
40 Pearson 5 0.36661 2 30.501 27 8.6832 29 
49 Uniform 0.38844 3 54.598 38 N/A 
31 Log-Logistic 0.3986 4 18.869 10 27.713 34 
23 Gumbel Min 0.40589 5 12.872 2 1.2257 10 
32 Log-Logistic 0.40646 6 20.764 16 1.2486 11 
15 Frechet  0.40702 7 20.203 13 34.317 35 
14 Frechet  0.41184 8 19.994 12 27.672 33 
 
…
 
 
…
 
 
…
 
 
…
 
18 Gen. Extreme Value 0.41566 11 11.83 1 0.69009 9 
 
…
 
 
…
 
 
…
 
 
…
 
21 Gen. Pareto 0.42718 12 15.234 5 N/A 
 
…
 
 
…
 
 
…
 
 
…
 
20 Gen. Gamma 0.51844 39 25.801 23 0.11747 6 
 
 
# Distribution Parameters 
18 Gen. Extreme Value k=-1.796  σ=4.2162E-4  µ=0.00143 
19 Gen. Gamma k=20.642  α=0.0164  β=0.00196 
20 Gen. Gamma k=0.30106  α=1.1395  β=3.3800E-4 
21 Gen. Pareto k=-6.561  σ=0.01808  µ=-0.00112 
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50%, Ce = 2 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
40 Pearson 5 0.37183 1 30.436 27 5.9 32 
39 Pearson 5 0.37184 2 30.436 28 5.8997 31 
49 Uniform 0.38634 3 54.87 39 N/A 
25 Inv. Gaussian 0.39097 4 122.15 46 5.4626 30 
23 Gumbel Min 0.40246 5 13.061 2 1.3189 13 
31 Log-Logistic 0.40258 6 19.121 11 27.2 36 
15 Frechet  0.40877 7 20.409 13 33.844 43 
32 Log-Logistic 0.40925 8 21.002 16 1.282 12 
18 Gen. Extreme Value 0.41162 9 11.901 1 0.67146 9 
 
…
 
 
…
 
 
…
 
 
…
 
21 Gen. Pareto 0.43352 13 15.487 5 N/A 
 
…
 
 
…
 
 
…
 
 
…
 
20 Gen. Gamma 0.52129 39 25.895 22 26.786 35 
 
 
# Distribution Parameters 
18 Gen. Extreme Value k=-1.8319  σ=2.0354E-4  µ=7.2075E-4 
19 Gen. Gamma k=21.098  α=0.01712  β=9.7295E-4 
20 Gen. Gamma k=0.311  α=1.1768  β=1.6592E-4 
21 Gen. Pareto k=-6.7675  σ=0.00937  µ=-5.6610E-4 
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50%, Ce = 4 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
50 Uniform 0.3859 1 52.771 38 N/A 
24 Gumbel Min 0.39939 2 13.228 2 1.4167 14 
33 Log-Logistic 0.40669 3 19.428 10 29.489 41 
19 Gen. Extreme Value 0.40773 4 11.997 1 0.63963 11 
15 Frechet  0.40937 5 20.662 13 0.06595 3 
32 Log-Logistic 0.41278 6 21.337 16 14.334 38 
46 Rayleigh  0.41283 7 40.904 35 4.8615 31 
36 Lognormal 0.41373 8 21.094 14 31.15 42 
35 Lognormal 0.41373 9 21.094 15 31.15 43 
 
…
 
 
…
 
 
…
 
 
…
 
22 Gen. Pareto 0.43964 16 15.751 5 N/A 
 
…
 
 
…
 
 
…
 
 
…
 
21 Gen. Gamma 0.52265 39 26.17 23 11.363 34 
 
 
# Distribution Parameters 
19 Gen. Extreme Value k=-1.8668  σ=9.8243E-5  µ=3.6273E-4 
20 Gen. Gamma k=21.533  α=0.01756  β=4.8431E-4 
21 Gen. Gamma k=0.3171  α=1.2068  β=8.1283E-5 
22 Gen. Pareto k=-6.9728  σ=0.00485  µ=-2.8641E-4 
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50%, Ce = 6 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
46 Rayleigh  0.38535 1 38.791 35 5.8209 33 
49 Uniform 0.39412 2 52.439 39 N/A 
23 Gumbel Min 0.39775 3 13.311 2 1.479 14 
18 Gen. Extreme Value 0.40545 4 12.053 1 0.20987 6 
31 Log-Logistic 0.40891 5 19.577 10 29.198 40 
15 Frechet  0.40927 6 20.782 12 0.43605 10 
35 Lognormal 0.41297 7 21.282 13 33.944 41 
34 Lognormal 0.41297 8 21.282 14 33.944 42 
32 Log-Logistic 0.41471 9 21.528 15 5.5804 32 
 
…
 
 
…
 
 
…
 
 
…
 
21 Gen. Pareto 0.44321 17 15.911 5 N/A 
 
…
 
 
…
 
 
…
 
 
…
 
20 Gen. Gamma 0.52236 39 26.303 23 27.631 38 
 
 
 
# Distribution Parameters 
18 Gen. Extreme Value k=-1.8874  σ=6.4108E-5  µ=2.4272E-4 
19 Gen. Gamma k=21.809  α=0.01787  β=3.2201E-4 
20 Gen. Gamma k=0.32101  α=1.2272  β=5.3442E-5 
21 Gen. Pareto k=-7.0961  σ=0.0033  µ=-1.9213E-4 
 
  
139 
 
50%, Ce = 8 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
46 Rayleigh  0.39034 1 37.748 36 5.8692 27 
23 Gumbel Min 0.39664 2 13.362 2 1.5271 9 
49 Uniform 0.39964 3 52.339 40 N/A 
18 Gen. Extreme Value 0.4038 4 12.088 1 0.19605 4 
15 Frechet  0.40902 5 20.87 12 0.42972 5 
31 Log-Logistic 0.41048 6 19.686 10 28.993 39 
35 Lognormal 0.41429 7 21.425 14 33.778 41 
34 Lognormal 0.41429 8 21.425 13 33.778 42 
32 Log-Logistic 0.41618 9 21.679 15 14.38 32 
 
…
 
 
…
 
 
…
 
 
…
 
21 Gen. Pareto 0.44581 16 16.027 5 N/A 
 
…
 
 
…
 
 
…
 
 
…
 
20 Gen. Gamma 0.52188 40 26.415 24 27.476 37 
 
 
 
# Distribution Parameters 
18 Gen. Extreme Value k=-1.9024  σ=4.7319E-5  µ=1.8253E-4 
19 Gen. Gamma k=22.0  α=0.01808  β=2.4104E-4 
20 Gen. Gamma k=0.32342  α=1.2418  β=3.9636E-5 
21 Gen. Pareto k=-7.1873  σ=0.00251  µ=-1.4469E-4 
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50%, Ce = 10 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
46 Rayleigh  0.39335 1 36.957 35 5.908 27 
23 Gumbel Min 0.40035 2 13.397 2 1.5669 10 
27 Kumaraswamy 0.40179 3 15.849 4 N/A 
18 Gen. Extreme Value 0.4025 4 12.112 1 0.1833 5 
49 Uniform 0.4032 5 52.305 40 N/A 
15 Frechet  0.40868 6 20.901 13 0.42507 6 
31 Log-Logistic 0.41163 7 19.735 11 28.844 38 
35 Lognormal 0.41528 8 21.509 15 33.719 39 
34 Lognormal 0.41528 9 21.509 14 33.719 40 
 
…
 
 
…
 
 
…
 
 
…
 
21 Gen. Pareto 0.44786 17 16.119 6 N/A 
 
…
 
 
…
 
 
…
 
 
…
 
20 Gen. Gamma 0.52069 39 26.417 24 27.295 36 
 
 
# Distribution Parameters 
18 Gen. Extreme Value k=-1.9144  σ=3.7370E-5  µ=1.4633E-4 
19 Gen. Gamma k=22.158  α=0.01851  β=1.9241E-4 
20 Gen. Gamma k=0.32813  α=1.2617  β=3.1410E-5 
21 Gen. Pareto k=-7.2605  σ=0.00203  µ=-1.1610E-4 
 
  
141 
 
67%, Ce = 0.01 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
53 Uniform 0.3797 1 54.341 42 N/A 
34 Log-Logistic 0.38913 2 16.378 11 24.05 37 
35 Log-Logistic 0.38938 3 16.066 10 15.597 32 
30 Kumaraswamy 0.39196 4 15.859 9 N/A 
18 Frechet  0.39477 5 18.469 19 30.575 39 
37 Lognormal 0.39492 6 16.525 12 17.354 33 
38 Lognormal 0.39492 7 16.525 13 17.354 34 
21 Gen. Extreme Value 0.39666 8 11.611 1 1.5644 1 
24 Gen. Pareto 0.40067 9 14.033 5 N/A 
26 Gumbel Min 0.40142 10 12.113 2 2.6737 4 
 
…
 
 
…
 
 
…
 
 
…
 
22 Gen. Gamma 0.48613 39 20.586 23 26.198 38 
 
 
# Distribution Parameters 
21 Gen. Extreme Value k=-1.6378  σ=0.91861  µ=2.6116 
22 Gen. Gamma k=0.35941  α=1.2162  β=0.68286 
23 Gen. Gamma k=20.493  α=0.02034  β=3.6565 
24 Gen. Pareto k=-5.7044  σ=28.928  µ=-1.9675 
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67%, Ce = 0.1 mg/L 
 
 
 
# Distribution Parameters 
19 Gen. Extreme Value k=-1.829  σ=0.07608  µ=0.27269 
20 Gen. Gamma k=21.949  α=0.0247  β=0.35872 
21 Gen. Gamma k=0.39471  α=1.4392  β=0.05852 
22 Gen. Pareto k=-6.7504  σ=3.4828  µ=-0.20656 
 
  
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
36 Lognormal 0.38954 1 17.803 12 28.878 31 
35 Lognormal 0.38955 2 17.803 13 28.878 32 
50 Uniform 0.38956 3 48.396 41 N/A 
30 Levy 0.39525 4 30.653 32 2.1718 7 
31 Levy 0.39526 5 30.653 33 2.1719 8 
15 Frechet 0.39826 6 19.982 19 16.241 24 
32 Log-Logistic 0.40317 7 17.035 9 14.859 23 
24 Gumbel Min 0.40771 8 12.394 3 1.4564 4 
 
…
  
…
 
 
…
 
 
…
 
19 Gen. Extreme Value 0.41233 10 11.482 1 0.71351 3 
 
…
 
 
…
 
 
…
 
 
…
 
22 Gen. Pareto 0.43325 12 15.153 6 N/A 
 
…
 
 
…
 
 
…
 
 
…
 
21 Gen. Gamma 0.49119 38 21.125 23 25.544 27 
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67%, Ce = 0.2 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
51 Uniform 0.38667 1 45.346 40 N/A 
36 Lognormal 0.38891 2 18.159 12 30.947 34 
37 Lognormal 0.38891 3 18.159 13 30.947 35 
24 Gumbel Min 0.40301 4 12.437 2 1.6986 5 
19 Gen. Extreme Value 0.40572 5 11.285 1 0.60534 1 
34 Log-Logistic 0.40695 6 17.333 8 14.65 25 
15 Frechet  0.40792 7 20.493 23 15.972 26 
33 Log-Logistic 0.41506 8 18.396 14 12.213 24 
39 Normal 0.43548 9 14.403 3 2.6393 10 
 
…
 
 
…
 
 
…
 
 
…
 
22 Gen. Pareto 0.44406 13 15.512 6 N/A 
 
…
 
 
…
 
 
…
 
 
…
 
21 Gen. Gamma 0.4876 37 21.225 24 49.837 40 
 
 
 
# Distribution Parameters 
19 Gen. Extreme Value k=-1.8979  σ=0.03529  µ=0.13812 
20 Gen. Gamma k=22.435  α=0.02663  β=0.17822 
21 Gen. Gamma k=0.4077  α=1.5357  β=0.02753 
22 Gen. Pareto k=-7.1596  σ=1.8547  µ=-0.1045 
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67%, Ce = 0.5 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
51 Uniform 0.38773 1 42.45 40 N/A 
36 Lognormal 0.38967 2 18.768 13 34.845 27 
37 Lognormal 0.38967 3 18.768 14 34.845 28 
19 Gen. Extreme Value 0.39535 4 15.091 4 N/A 
24 Gumbel Min 0.39612 5 12.504 2 2.067 11 
1 Beta 0.40222 6 17.093 9 N/A 
42 Pearson 5 0.40756 7 30.445 35 1.4059 5 
41 Pearson 5 0.40758 8 30.446 36 1.4057 4 
34 Log-Logistic 0.41294 9 17.867 11 26.784 23 
 
…
 
 
…
 
 
…
 
 
…
 
22 Gen. Pareto 0.45992 26 16.128 8 N/A 
 
…
 
 
…
 
 
…
 
 
…
 
21 Gen. Gamma 0.48263 37 21.617 28 46.485 37 
 
 
 
# Distribution Parameters 
19 Gen. Extreme Value k=-1.997  σ=0.01261  µ=0.05616 
20 Gen. Gamma k=23.111  α=0.02845  β=0.0708 
21 Gen. Gamma k=0.41586  α=1.6504  β=0.01008 
22 Gen. Pareto k=-7.7803  σ=0.81024  µ=-0.04239 
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67%, Ce = 1 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
19 Gen. Extreme Value 0.3869 1 15.031 4 N/A 
36 Lognormal 0.38843 2 19.215 12 34.17 28 
37 Lognormal 0.38843 3 19.215 13 34.17 29 
24 Gumbel Min 0.39157 4 12.566 2 0.66243 3 
51 Uniform 0.39177 5 42.107 40 N/A 
41 Pearson 5 0.40324 6 30.119 37 1.4399 14 
42 Pearson 5 0.40324 7 30.119 38 1.4399 13 
34 Log-Logistic 0.41727 8 18.274 10 24.338 26 
 
…
  
…
 
 
…
 
 
…
 
22 Gen. Pareto 0.47282 30 16.71 8 N/A 
 
…
  
…
 
 
…
 
 
…
 
21 Gen. Gamma 0.48349 35 21.915 27 43.886 34 
 
 
# Distribution Parameters 
19 Gen. Extreme Value k=-2.077  σ=0.00573  µ=0.02841 
20 Gen. Gamma k=23.649  α=0.02989  β=0.03522 
21 Gen. Gamma k=0.42149  α=1.7443  β=0.0047 
22 Gen. Pareto k=-8.3111  σ=0.43423  µ=-0.0214 
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67%, Ce = 2 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
18 Gen. Extreme Value 0.378 1 14.996 3 N/A 
36 Lognormal 0.39026 2 19.646 12 0.39047 7 
35 Lognormal 0.39026 3 19.646 13 0.39047 8 
50 Uniform 0.39349 4 39.653 39 N/A 
23 Gumbel Min 0.39438 5 12.64 1 0.29232 5 
41 Pearson 5 0.40127 6 29.878 36 1.4324 15 
40 Pearson 5 0.40127 7 29.878 37 1.4324 14 
25 Inv. Gaussian 0.40985 8 39.938 40 2.272 16 
32 Log-Logistic 0.4214 9 18.679 10 23.879 21 
 
…
 
 
…
 
 
…
 
 
…
 
20 Gen. Gamma 0.48177 33 22.21 27 46.126 35 
 
…
 
 
…
 
 
…
 
 
…
 
21 Gen. Pareto 0.48641 36 17.403 8 N/A 
 
 
 
# Distribution Parameters 
18 Gen. Extreme Value k=-2.1612  σ=0.00258  µ=0.01436 
19 Gen. Gamma k=24.213  α=0.03137  β=0.01753 
20 Gen. Gamma k=0.42678  α=1.844  β=0.00219 
21 Gen. Pareto k=-8.8997  σ=0.2333  µ=-0.0108 
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67%, Ce = 4 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
19 Gen. Extreme Value 0.36869 1 14.988 3 N/A 
24 Gumbel Min 0.39441 2 12.739 1 0.39529 4 
51 Uniform 0.39527 3 39.285 40 N/A 
37 Lognormal 0.39902 4 20.056 13 4.6627 15 
36 Lognormal 0.39903 5 20.056 14 4.6628 16 
42 Pearson 5 0.40269 6 29.771 36 1.3762 13 
41 Pearson 5 0.4027 7 29.771 37 1.3762 12 
1 Beta 0.40306 8 17.964 9 N/A 
34 Log-Logistic 0.4253 9 19.078 11 24.422 23 
 
…
 
 
…
 
 
…
 
 
…
 
21 Gen. Gamma 0.47843 31 22.496 28 48.455 35 
 
…
 
 
…
 
 
…
 
 
…
 
22 Gen. Pareto 0.50053 41 18.212 10 N/A 
 
 
 
# Distribution Parameters 
19 Gen. Extreme Value k=-2.2488  σ=0.00115  µ=0.00725 
20 Gen. Gamma k=24.805  α=0.03289  β=0.00872 
21 Gen. Gamma k=0.43187  α=1.9489  β=0.00102 
22 Gen. Pareto k=-9.5472  σ=0.12558  µ=-0.00545 
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67%, Ce = 6 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
18 Gen. Extreme Value 0.36308 1 14.996 3 N/A 
23 Gumbel Min 0.39344 2 12.812 1 35.241 22 
50 Uniform 0.39825 3 39.398 40 N/A 
35 Lognormal 0.40308 4 20.286 12 4.612 12 
36 Lognormal 0.40308 5 20.286 13 4.6121 13 
40 Pearson 5 0.40769 6 26.638 34 34.312 21 
41 Pearson 5 0.41641 7 26.821 37 35.571 23 
25 Inv. Gaussian 0.42465 8 55.189 45 0.53249 8 
32 Log-Logistic 0.42743 9 19.306 9 24.173 19 
 
…
 
 
…
 
 
…
 
 
…
 
20 Gen. Gamma 0.47602 30 22.656 28 0.34121 6 
 
…
 
 
…
 
 
…
 
 
…
 
21 Gen. Pareto 0.50899 41 18.741 8 N/A 
 
 
# Distribution Parameters 
18 Gen. Extreme Value k=-2.3014  σ=7.1777E-4  µ=0.00486 
19 Gen. Gamma k=25.165  α=0.03379  β=0.0058 
20 Gen. Gamma k=0.43487  α=2.0122  β=6.5091E-4 
21 Gen. Pareto k=-9.9538  σ=0.08748  µ=-0.00366 
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67%, Ce = 8 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
18 Gen. Extreme Value 0.35902 1 15.007 3 N/A 
28 Kumaraswamy 0.38749 2 16.926 7 N/A 
23 Gumbel Min 0.39447 3 12.873 1 34.913 19 
50 Uniform 0.3996 4 39.518 40 N/A 
35 Lognormal 0.40545 5 20.287 15 0.37563 8 
36 Lognormal 0.40545 6 20.287 14 0.37563 9 
40 Pearson 5 0.40789 7 26.705 37 34.443 17 
41 Pearson 5 0.4079 8 26.705 38 34.444 18 
25 Inv. Gaussian 0.42285 9 55.773 45 0.53755 10 
 
…
 
 
…
 
 
…
 
 
…
 
20 Gen. Gamma 0.47198 29 22.506 28 0.32248 7 
 
…
 
 
…
 
 
…
 
 
…
 
21 Gen. Pareto 0.51506 41 19.143 9 N/A 
 
 
# Distribution Parameters 
18 Gen. Extreme Value k=-2.3392  σ=5.1205E-4  µ=0.00366 
19 Gen. Gamma k=29.943  α=0.03142  β=0.00427 
20 Gen. Gamma k=0.4523  α=2.1337  β=4.7434E-4 
21 Gen. Pareto k=-10.255  σ=0.06771  µ=-0.00275 
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67%, Ce = 10 mg/L 
# Distribution 
Kolmogorov 
Smirnov 
Anderson 
Darling Chi-Squared 
Statistic Rank Statistic Rank Statistic Rank 
18 Gen. Extreme Value 0.35584 1 15.019 2 N/A 
1 Beta 0.36408 2 16.992 6 N/A 
23 Gumbel Min 0.39559 3 12.926 1 34.656 24 
49 Uniform 0.40029 4 39.625 38 N/A 
35 Lognormal 0.40712 5 20.564 13 5.9801 15 
36 Lognormal 0.40712 6 20.564 14 5.9802 16 
40 Pearson 5 0.40816 7 26.761 34 34.576 22 
41 Pearson 5 0.40837 8 26.764 35 34.605 23 
28 Kumaraswamy 0.41451 9 17.929 9 N/A 
 
…
 
 
…
 
 
…
 
 
…
 
20 Gen. Gamma 0.47485 30 22.845 27 0.32169 9 
 
…
 
 
…
 
 
…
 
 
…
 
21 Gen. Pareto 0.5198 42 19.469 10 N/A 
 
 
# Distribution Parameters 
18 Gen. Extreme Value k=-2.3688  σ=3.9380E-4  µ=0.00293 
19 Gen. Gamma k=25.633  α=0.03495  β=0.00347 
20 Gen. Gamma k=0.43885  α=2.0939  β=3.7130E-4 
21 Gen. Pareto k=-10.495  σ=0.05552  µ=-0.00221 
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Appendix IV:  Matlab Code for Adsorption Processes  
 
function [Ce, kvec, nvec, C0vec, FinalCe, FinalQe] = CeGeneratorFinal(z) 
%% UNTITLED Summary of this function goes here 
%   Detailed explanation goes here 
  
%%Initialize variables  
load kandm.mat 
Ce = zeros(size(kandm,1),1); 
kvec = zeros(size(kandm,1),1); 
nvec = zeros(size(kandm,1),1); 
C0vec = zeros(size(kandm,1),1); 
Qe=zeros(size(kandm,1),1); 
options=optimset('Display','off'); 
  
%% Find a given Se for all values  
for j=1:length(z) 
     
    m=z(j) 
     
    for i=1:size(kandm,1) 
        Kf=kandm(i,2); 
        n=kandm(i,1); 
  
                C0 = 0.000004547; %(5%: 0.000004547, 33%: 0.000085941, 50%: 0.001624175, 67%: 
0.030695007, 95%: 0.580099709) 
                C0vec(i)=C0; 
                 
            Ce(i) = real(1000*fsolve(@(x) (C0-x-(Kf*m*x^(1/n))), C0/2, options)); 
       Qe(i)=(C0*1000-Ce(i))/m; 
    end 
    FinalCe(:,j)=Ce(:,1); 
    Ce = zeros(size(kandm,1),1); 
    FinalQe(:,j)=Qe(:,1); 
    Qe=zeros(size(kandm,1),1); 
end 
  
end 
  
  
 
Running the program for each percentile influent concentration:  
 
clear all 
z=[0.0001,0.001,0.01, 0.1, 0.2, 0.5, 1, 2, 4, 6, 8, 10];  
z=z*1000; 
[Ce, kvec, nvec, C0vec, FinalCe, FinalQe] = CeGeneratorFinal(z); 
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